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An estimated 300,000 people in the U.S. are living with Chagas Disease (CD), many 
of whom may not yet know they are infected. Approximately 20% to 30% of individuals with 
CD are expected to develop clinical symptoms that may manifest as heart disease and result 
in death if left untreated. The prevalence of CD in humans is not well understood. Given its 
asymptomatic manifestation and the rarity in cases seen by physicians in general, CD may be 
under-recognized by physicians. 
The purpose of this research was to explore the understanding and knowledge of CD 
in Texas HCP populations (cardiologists, infectious disease specialists, and general/ family 
practice providers) and identify provider-based education and practice recommendations to 
reduce the prevalence of undiagnosed CD.  
Texas quarterly Inpatient Public Use Data Files (IPUDF) for 2013 to 2016 were used 
to identify ICD heart-related missed CD diagnosis and CD diagnosis and map the cases. 
Counties with a high burden of heart-related diagnosis were indicative areas with CD 
diagnosis, as shown by the ICD codes and by the TDSHS CD-reported cases. Heart-related 
diagnosis and age demographics indicate the possibility of missed CD diagnosis throughout 
the state.  
 Self- administered online knowledge, attitudes, and practice (KAP) questionnaires 
were used to quantify knowledge deficits by physician specialty (n= 43): family or general 
practice (n= 21); infectious disease (n= 19); and cardiology (n= 3). ID specialists had a 
greater grasp on the nuances of CD and were more confident than family providers in 
recognizing risk factors and the vector and were more knowledgeable overall. 
Key informant (KI) telephone interviews were conducted (n= 13) among infectious 
disease specialists (n= 8), cardiologists (n= 4), and one family physician to explore barriers 
and recommendations to improve awareness and knowledge. Training and experience, 
according to the KI, were essential in shaping physicians’ understanding of CD in Texas. 
Specific physician recommendations to enhance awareness and improve knowledge on CD in 
Texas include: 1) engage patients and physician leadership; 2) increase surveillance to better 
understand prevalence; 3) improve access to physician resources and how materials on CD 
are disseminated; and 4) improving and updating physician resources. 
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BACKGROUND 
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be fatal if 
not diagnosed and treated in its early stages. CD was first discovered in 1909 by Carlos Chagas 
in Brazil and is endemic in Latin America.2 The World Health Organization (WHO) recognizes 
CD as a neglected tropical disease3 that continues to widen its global reach beyond the American 
tropics. Its impact and burden 4-7 are beginning to be seen in non-endemic regions from imported 
cases, including Europe and Asia. American trypanosmiasis,8 infection from the hemoflagellate 
protozoan parasite Trypanosoma cruzi (T. cruzi), causes CD.1,9 CD accounts for the highest 
burden of any parasitic disease in the 22 Latin American countries where it is endemic (Figure 
1). T. cruzi is endemic throughout Central and South America and is found in North America, 
including in Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in 
Latin America have CD.11 Over 28,000 people are infected each year in Mexico, Central 
America and South America, accounting for at least 12,000 deaths per year.12  
Kissing Bugs and Trypanosoma cruzi 
Trypanosoma cruzi, infects invertebrate and vertebrate hosts during its various life 
cycles. The complex life cycle of T. cruzi is described in Figure 2.8 Reduviids, also known as 
triatomines or kissing bugs, are blood-feeding insects that transmit the parasite (mainly through 
their feces) that causes CD. The kissing bugs are unaffected by T. cruzi but act as the vector for 
the parasite. Kissing bugs transmit the parasite to mammals including humans,1 but can also 
infect reservoir hosts such as canines, opossums, raccoons, and other domestic8,13 and sylvatic 
animals.14 Although CD is a zoonotic disease, the focus of this dissertation will be on the human 
health aspect.   
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Figure 1: World-wide prevalence of Chagas Disease1 
 
 
Figure 2: Lifecycle and transmission of Trypanosoma cruzi in human hosts2 
 
                                                 
1 Source: Drugs for Neglected Disease initiative (DNDi) - https://T. cruzi.dndi.org/diseases-
projects/chagas/  
2 Source: Rassi et al. (2010). Chagas disease. The Lancet, 375: 402 
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Geography of Vectorial Transmission to Humans 
Vectorial transmission is most common among children and adolescents in endemic 
countries.8 In Latin American communities, transmission usually occurs during childhood as a 
result of limited or nonexistent vector control eradication and screening interventions coupled 
with poor housing conditions.15 The U.S. is not considered an endemic area, however kissing 
bugs infected with T. cruzi have been found throughout the South (i.e., from California to 
Georgia) and local transmission have been reported (Figure 3) in these states.10 However, the 
burden of T. cruzi infections from triatomine exposure in the states where the vector has been 
reported (Figure 3) has not been assessed. In Texas alone, eleven different species (from the 
genus Triatoma, Rhodnius, and Panstrogylus ) of the vectors are able to transmit the parasite and 
are found throughout the state.16 Other routes of transmission include: vertical or congenital; 
blood-borne; organ-derived; and oral.10 Kissing bugs can be found indoors and outdoors, 
including the following: “beneath porches; between rocky structures; under cement; in rock, 
wood, brush piles, or beneath bark; in rodent nests or animal burrows; in outdoor dog houses or 
kennels; and in chicken coops or houses”.17 
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Figure 3: Triatomine prevalence in the U.S., by state3 
 
Congenital Transmission 
Congenital transmission occurs in both endemic and non-endemic countries.8 Pregnant 
women are a specific concern since they may transmit the parasite to their children unknowingly. 
Even in Mexico, Central America and South America where CD is prevalent, residents may not 
be aware of their infection status nor know how or where to seek and access treatment if they 
believe they are infected.18 In Latin America, over 14,000 congenital CD cases occur each year.19 
An estimated 20 to 183 congenital CD cases per year are expected in Europe.20 According to 
Centers for Disease Control and Prevention (CDC), 63 to 315 congenital infections occur in the 
U.S. each year.21 With an estimated 40,000 women of childbearing age infected with T. cruzi, the 
risk of transmission from an infected mother to child in the U.S. is between 1% to 5%.22 In the 
U.S., there are no requirements, similar blood screening, or recommended guides to prompt 
healthcare providers (HCP’s) to screen all pregnant women at risk for T. cruzi infection. 
                                                 
3 Source: Centers for Disease Control and Prevention (https://T. 
cruzi.cdc.gov/parasites/chagas/gen_info/vectors/index.html)  
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Transmission from Blood Transfusions  
In contrast to the lack of compulsory screening and testing in the general population or 
with pregnant women, the blood supply in the U.S. has been screened for CD antibodies since 
2007.1 Blood donation screening is the most common means by which individuals learn about 
their CD diagnosis in the U.S.23 From 2007 to 2017, a total of 2,269 confirmed serological 
positive donations have been identified throughout the U.S.24 As shown in Figure 4, California, 
Texas, Georgia, North Carolina, Virginia, Florida, and New York had the highest prevalence. 
Nationwide, 1 in 27,500 blood donations tested positive for T. cruzi from 2008 to 2012.25 For 
that same period, 1 in 6,500 blood donations in Texas were T. cruzi positive.26 Approximately 
11% of suspected cases will follow-up with a HCP to receive treatment.25 In general, blood 
donors testing positive for T. cruzi will receive a letter notifying them of their potential CD 
serostatus. However, most infected persons (both globally and in the U.S.) are unaware of their 
status.1  
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Figure 4: Lab-confirmed Chagas cases in blood donations, 2007 – Aug. 20174 
 
Chagas as a Global Threat 
As a result of globalization, human migration has changed the distribution of CD in 
endemic and non-endemic countries: CD is both a re-emerging and a neglected tropical disease.4 
Figure 1 shows the impact to European countries, Japan, and Australia. For example, a recent 
literature review notes that while Japan’s prevalence may reach up to 4,000 CD cases yet only 7 
have been reported in medical literature.27 In the U.S., both autochthonous (or locally-acquired) 
infections and imported cases from Latin America have been recorded and reported.23,28,29 Two 
case studies presented by Hsu and colleagues describes how both CD patients were Central 
American immigrants identified in a New Orleans hospital. 30 Reports from locally-acquired 
infections are rare in Texas,29 yet documented reports from autochthonous cases date back to the 
                                                 
4 Source (formerly known as) the American Association of Blood Banks (AABB): http://T. 
cruzi.aabb.org/research/hemovigilance/Pages/chagas.aspx 
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1930’s.23 Nonetheless, most infections are due to imported cases from areas of endemicity in 
Latin America given the prevalence of the vector.21  
Phases and Clinical Manifestations 
Acute infection 
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the first 
two months of the initial infection, which may manifest with mild flu-like symptoms or febrile 
illness31. Other symptoms may include: malaise, enlarged spleen, liver, and lymph nodes; 
localized or generalized edema; chagomas or breaks in the skin; and result in abnormal 
electrocardiogram (ECG).8 The hallmark characteristic, though not always present, is the 
swelling of the eyelids, or Romaña’s sign, the site where the kissing bug feces was deposited or 
rubbed into the eye.11 Acute infection may manifest as early as one week after  exposure and 
may be self-limiting in most individuals.8 The patient may not seek medical attention since the 
symptoms are mild and not unique to CD. Figure 5 shows the acute and chronic phases of a T. 
cruzi infection and the onset of the immunological response. 
Chronic infection 
During the chronic stage, two presentations are possible: the indeterminate form, which is 
commonly asymptomatic; and the determinate which include cardiac (e.g., cardiomyopathy, 
heart failure, altered heart rate or rhythm) and intestinal complications2.  The majority of infected 
individuals (70%-80%) 2,15 will advance from the acute phase and remain in a latent or 
indeterminate chronic form of the disease (mostly asymptomatic), which may persist as a 
lifelong infection. The danger of this asymptomatic status is that once symptoms do manifest, 
eliminating the parasite becomes more difficult or impossible and often results in death.  
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Chronic determinate phase 
Conversely, only 20-30% of infected individuals will progress from the indeterminate 
chronic phase to a “clinically evident disease” or chronic determinate phase, months to decades 
after becoming infected.15 Chronic determinate CD often corresponds to the organ involved 
(heart; esophagus; and/or colon): cardiac, digestive, or both.8 The digestive manifestation is 
typically found manly in South America or in persons infected in that region.8 Heart failure 
occurs usually towards the latter phase of Chagasic heart disease.8 Sudden death due to cardiac 
complications can occur.11 The parasite is classified into six types with Strain I being wild, Strain 
II being domestic; both of which are “pure”, while Strains III through VI are considered 
hybrids.32 TcI has a “wide distribution”—from the Southern U.S. to Northern Argentina and 
Chile.33 The strain classification relates to the pathogenicity and distribution of the parasite and 
its association to sudden death in infected persons.  
Figure 5: Acute and chronic phases of Chagas disease infection5 
 
                                                 
5 Source: Susan Montgomery, DVM, MPH 
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Cardiomyopathy 
For the scope of this study, heart-related symptoms were the primary focus, given that the 
digestive manifestation is a hallmark of South American infections. In the Southern Cone of 
South America (i.e., Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil) 
gastrointestinal CD is more common than CD cardiomyopathy, as the latter is more commonly 
seen in Central America and North America.34 According to the National Institutes of Health 
(NIH), cardiomyopathy, “refers to diseases of the heart muscle…as it becomes enlarged, thick, 
or rigid…the heart thus becomes weaker pumping less blood and beating irregularly”.35 Chagasic 
cardiomyopathy includes “cardiac arrhythmias, heart failure, and risk of sudden death from 
ventricular fibrillation or tachycardia or thromboembolic events”8 and an estimated 5.4 million 
people will develop these symptoms.36 Cardiovascular disease in CD patients is believed to be 
the result of “parasite persistence in cardiac tissue and immune-mediated myocardial injury.”37 
CD may present as idiopathic cardiomyopathy and be overlooked by many or most HCPs as a 
diagnosis. Some estimates considering that the Latino immigrant population is younger than the 
current U.S. population, suggest that, 10 – 15% of the total U.S. population (or 30,000 to 45,000 
individuals) is living with undiagnosed CD cardiomyopathy.21  
Epidemiology and Surveillance 
In the U.S., currently there is no federal mandate requiring each state to report human CD 
cases,38 though currently it is a reportable disease in Arizona, Arkansas, Louisiana, Mississippi, 
Tennessee, and Texas.1,39 As such, no national registry or database of confirmed human CD 
cases exists in the U.S., except through the case tracking and reporting by the CDC. In turn, the 
CDC tracking is limited by the reports they receive directly from the state health departments 
and individual HCP’s.  
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Excluding blood donor screening, no active surveillance for T. cruzi infections in the U.S. 
exists at this time.40 Though reportable since 2013,2 the Texas Department of State Health 
Services (TDSHS) currently does not actively surveil for CD, T. cruzi infections, or CD-related 
symptoms (i.e., syndromic surveillance).23,41 In the absence of systematic national and State-
level surveillance,1 the disease burden, distribution, and populations at higher risk cannot be 
accurately quantified or described.10,23 The lack of epidemiological data also highlights the gaps 
in detecting chronic Chagas cases. 
The CDC estimates that 300,000 infected individuals are living in the U.S., however this 
is only based off of a formula using the number of Latin American immigrants in the U.S. and 
average prevalence found in Latin America. 42 Since becoming reportable in 2013, there have 
been 91 confirmed cases of CD in Texas. Of those cases, 20 were locally acquired, 61 were 
imported and 10 were from unknown origins.43 In Texas, between 2013 and 2015, a total of 439 
canine Chagas cases were reported.44 
Screening and Diagnosing 
For the scope of this dissertation, screening refers to the process by which HCP’s 
determine if further laboratory diagnostics are required. During the initial screening, the HCP 
discusses the patient’s medical history, “including questions about travel and living conditions,” 
and performs a physical examination and possibly an ECG.15,31 The diagnosing of CD represents 
the clinical and serological testing required to confirm the presence of T. cruzi. In the U.S., the 
CDC requires confirmatory laboratory diagnosis for T. cruzi using at least two different 
immunoassay procedures (i.e., enzyme-linked immunosorbent assay [ELISA] and 
immunofluorescent antibody test) prior to treatment.15 At least two different serological tests are 
required given the lack of specificity and sensitivity obtained from one single procedure. Such 
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laboratory assays are used to detect IgG or IgM antibodies to the parasite are available from 
major commercial laboratories (e.g., Mayo Medical Lab, ARUP, and Quest Diagnostics).45 
Nonetheless, no standardized protocol (at the national, State, or local/county level) is available 
for physicians to reference when attempting to request the laboratory codes. Recent statistical 
modeling demonstrates the value of screening Latin American immigrants in non-endemic 
countries.46 Women are recognized as a target population for community screening programs in 
non-endemic countries in Europe (e.g., Spain and Italy) due to the risk of transmitting the 
parasite to their children.47,48 No commercially-available rapid screening kit is available for 
HCP’s to routinely use that provide an immediate confirmatory results for T. cruzi. In contrast to 
other chronic diseases49 (i.e., type II diabetes, heart disease, cancer, etc.), screening and 
diagnosing for CD is not routinely performed.    
Drug Treatment 
Antiparasitics (antitrypanosomal drugs) are currently not commercially available to the 
public in the U.S. and are only released by the CDC through investigational protocols. These 
drugs have been extensively used in Latin America. Nifurtimox and benznidazole are the two 
antiparastics used to eliminate T. cruzi.11 The drugs are generally better tolerated by younger 
individuals because side-effects are less frequent and severe.15,31 Benznidazole is the first line 
treatment because it has less side-effects.15 Each drug has specific side-effects that tend to 
increase as the patient becomes older. As of 2017, benznidazole has been FDA-approved in the 
U.S. for use in children aged 2-12 years.38 
Prevention Programs 
For over a century, Latin American countries have been trying to understand CD, the 
prevalence, and how to prevent and mitigate the adverse health outcomes. Currently, education 
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campaigns in Latin America primarily target rural and low-income communities and provide 
prevention messages. Most interventions in these regions  have focused on vector control and 
improving housing conditions,50 as highlighted in Figure 6. The known prevalence of CD in 
Latin America is likely higher than in the U.S. due to poorer housing conditions, pathogenicity of 
vector, and higher quantities of the vectors in large urban areas. Although CD diagnostics and 
eventual treatment in Latin America can be challenging due to limited resources and access to 
health care,51,52 physicians in Latin America are more aware of CD screening and recommended 
guidelines for diagnosis and treatment than those in the U.S. Furthermore, international 
cooperation has made vector surveillance possible. The southern Cone Initiative, for example, 
was one of the first collaborative programs in the 1990’s that focused on vector control and 
educating the community about kissing bugs.50 Similar international efforts to the southern Cone 
Initiative have been sustain by Central and South American countries and have resulted in 
reducing the rate of new (acute) infections in some regions.  
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Figure 6: Example of Campaigns in Latin America6 
 
 
Role of Healthcare Providers 
Due to the number of cases, its asymptomatic nature, urgency for early diagnosis and 
treatment and unknown prevalence in the U.S., CD should be a concern for HCP’s. Many 
physicians currently practice medicine within their subspecialty and in isolation from other HCP 
specialties.53 Even fewer communication exchanges occur with other scientists (i.e., 
veterinarians, entomologists, ecologists, policy scientists, etc.). The lack of collaboration and 
engagement may prevent the exchange of new ideas and innovations. In turn, this is a barrier for 
an accurate and timely diagnosis for a patient.53 Recent epidemiological trends in the vector, or 
in zoonotic populations, for example, can shed light about the potential threat to human health. 
As we move towards a healthcare model in which the patient, as the consumer, is more informed 
and encouraged to participate in decision-making process, he or she may be a stronger advocate 
                                                 
6 Source: http://T. cruzi.taringa.net/posts/salud-bienestar/12344378/Que-es-la-Vinchuca.html  
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to improve the likelihood of testing and diagnosis, rather than rely solely on the physician as the 
gatekeeper for information. It is unclear how medical training and continuing education among 
the various specialties and sub-specialties shape how individual physicians receive, synthesize, 
and apply information regarding emerging or rare diseases like CD. 
Health System Barriers 
According to the WHO, an effective health system “delivers quality services to all 
people, when and where they need them.”54 Although their configuration is diverse and specific 
to meet the needs of each individual country, it still “requires a robust financing mechanism; a 
well-trained and adequately paid workforce; reliable information on which to base decisions and 
policies; well-maintained facilities and logistics to deliver quality medicines and technologies.”54 
The emerging literature frames health system barriers to diagnosing and treatment of CD at the 
national, community, and individual levels, specific to the countries and population 
described.42,55-58 Nonetheless, elements regarding the patient, provider, and health system 
barriers are applicable in understanding the screening, diagnosing, and treatment barriers of CD 
in Texas.  
Patient level 
The first challenge is that CD is rarely diagnosed during the acute phase of the 
infection.23 The latency and asymptomatic nature of the disease may not prompt individuals to 
seek immediate medical consultation or treatment. Cultural beliefs and systemic barriers may 
also prevent or delay a patient from seeking medical care, particularly as documented in Central 
and South American groups.55,58 For instance, an individual distrusts the medical system, while a 
systemic barrier may include the lack of drugs or HCP’s.32,48,55,56 Individuals in impoverished 
communities in Latin America and in the U.S. lack health insurance or the means to access 
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medical care, even if they wanted to get diagnosed and treated.57 These challenges are also 
reflected in the Latin American immigrants in the U.S. and other non-endemic countries. In rare 
occasions, individuals recognize the exposure to a kissing bug or develop clinical manifestations 
(i.e., a chagoma) that may prompt medical attention. Figure 7 summarizes some of the 
individual-level barriers. 
Figure 7: Patient barriers and strategies for coping with Chagas disease7 
 
System and provider level  
Due to the rarity in reporting autochthonous cases, there is still a lack of overall 
awareness among HCP’s in the U.S., including in Texas.23 HCP’s may consider CD only as a 
                                                 
7 Source: Forsyth, C.J. (2017) “I Cannot Be Worried”: Living with Chagas in Tropical Bolivia. 
PLoS Neglected Tropical Disease, 11:1 
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neglected tropical disease and not recognize the risk factors for local and acquired infections in 
Texas. They also may not consider their patients from Latin America or from mothers from Latin 
America at risk if they have never encountered the disease before and know very little about it.  
According to the 2015 American Community Survey, Hispanics/ Latinos represent 38.4% 
(which represent 10,196,367 persons) of the total population for the State.59 Furthermore, in 
2010, the Hispanic/ Latino population made up 37.6% of the total State population (an increase 
of 735,446 from 2010 to 2015).59 In 2010, Hispanics/ Latinos in Texas from Mexico accounted 
for 31.6% (or 7,951,193 individuals) of the population, while persons from Central America 
accounted for 1.7% (or 420,683 individuals), and persons from South American represented 
0.5% (or 133,808 individuals).59 These data indicate the increase in Hispanic/ Latino immigrants 
in the State and also highlight the opportunities for missed screening and diagnosis for this 
specific population. 
There are few comprehensive resources targeting HCP’s that illustrate the clinical criteria 
used to evaluate and diagnose CD.8,15 The TDSHS and the CDC have outlined general 
recommendations for the clinical diagnosis and treatment of CD.2,15 However, there are no 
specific recommendations in Texas for HCP’s to target screening to Latin American immigrants 
or women of child bearing age. A patient profile could help frame the risks of exposure to guide 
HCP’s in deciding if further screening or serological testing is needed. No patient profile 
currently exists that identifies populations in Texas (or the U.S.) with a higher risk of exposure or 
transmission. Without such guidance, HCP’s may not perform a thorough medical history (i.e., 
discuss potential exposure to the vector and parasite).60-62 For example, the HCP’s may not ask 
the patient about travel history or previous place of residence. Thus, even if a HCP is more 
familiar or aware of CD, s/he may have limited experience in identifying infected individuals 
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with the indeterminate form; performing clinical evaluations; ordering appropriate laboratory 
tests; or coordinating with health officials. Consequently, lack of awareness or experience may 
delay a patient from receiving adequate treatment. 
Public Health Significance 
The WHO ranks Chagas as the top global neglected parasitic disease, five times greater 
than the number of disability adjusted life years (DALY) when compared to malaria. Although 
generally regarded as a rare neglected tropical disease1, current vector surveillance,28,29 the 
increased frequency of Chagas positive blood donors, 26,40,63 and population migration,3,4 
demonstrate why more Chagas cases may be on the rise in the U.S., including Texas. It is 
estimated that at least 300,000 people in the U.S. are living with CD, many of whom may not yet 
know they are infected. Approximately 20% to 30% of individuals with CD are expected to 
develop clinical symptoms that may manifest as heart disease and result in death if left untreated.  
With more than 60 cases of Chagas reported in Texas between 2013 and 2015 alone, it is 
becoming clear that HCP’s must be aware of CD and not dismiss the accumulating body of 
evidence. HCP’s may not be familiar or prepared to correctly and timely screen and diagnose 
suspected cases. In turn, the lack of awareness and skill may lead to underdiagnosing and under-
reporting. Chagas-related deaths can be prevented if more CD cases are diagnosed and treated at 
the early onset of the disease. 
Reducing the morbidity and mortality associated with CD is the impetus for the CDC to 
recognize CD as public health concern in the U.S. The CDC created a funding mechanism to 
support multi-site projects aimed to inform and educate HCP’s about CD as well as to encourage 
collaboration and facilitate access to information and resources. Through community based 
participatory research (CBPR) and community engagement activities, the Texas Chagas 
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Taskforce was created in late 2015 with funding from the CDC. Various stakeholders were 
recruited throughout the State of Texas representing a variety of sectors, local and state health 
departments, organizations, and expertise. 
Understanding the level of knowledge and awareness of CD among the HCP’s 
throughout the State, specifically physicians who may routinely come in contact with those 
patients at higher risk, will help identify learning gaps in the medical curriculum and provide 
insight into how best to target HCP’s serving high-risk populations. The overall objectives of this 
study were to: 1) examine the level of knowledge and awareness of HCP’s in Texas regarding 
screening, diagnosis and treatment of CD; 2) describe the prevalence of reported cases in Texas; 
and 3) illustrate the potential missed cases for CD diagnosis in Texas. 
The research expands on the knowledge of U.S. physician awareness and attitudes 
regarding Chagas and contribute to the literature on the frequency of diagnosis and possible 
missed diagnosis of Chagas. To the best of our knowledge, no other study has examined ICD-9 
CD and ICD-10 CD data for both Chagas and other possibly undiagnosed forms of chronic 
determinant forms of Chagas (e.g., cardiomyopathy, idiopathic myocarditis). The data was 
mapped together to identify possible regions within the state where missed diagnoses are more 
likely to occur. The level of awareness of Chagas throughout the State of Texas has not been 
assessed previously to be able to make meaningful recommendations (i.e., convenience 
sampling). 
Statement of the Problem 
Strategies and decisions derived from high-quality1 and up-to date data are needed to 
minimize the threat of CD. However, there has been limited research on U.S. physicians’ 
knowledge and awareness of CD despite evidence CD presence in the U.S. patient population 
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and blood supply. This poses the following questions: 1) what do physicians know about and 
understand regarding the screening, diagnosis and treatment of CD and 2) how many missed 
diagnoses of CD may be occurring in patients, both asymptomatic and symptomatic.  
Frameworks 
Diffusion of Innovations  
In an effort to better understand why some physicians may serve as early adopters of the 
idea of screening for a neglected disease such as CD, the Theory of Diffusion of Innovations 
may help to frame the issue.64 In this model, diffusion is the “process by which an innovation or 
“new” practice is communicated through certain channels over time, among members of a social 
system,” and is then maintained or becomes accepted as practice over time.64 CD is often 
overlooked as a possible diagnosis in part due to its asymptomatic nature, but also because of the 
lack of knowledge surrounding the testing and treatment, the innovation. Innovation, in this 
context, reflects the ideas and practices related to CD testing, screening, and diagnosing and the 
skills and experience needed to ensure timely diagnosis and treatment. Better understanding of 
how to diffuse the practice of screening patients for CD could be helpful for shaping practices 
and policies that prevent under or missed diagnoses of not only CD but other neglected tropical 
diseases that may be present on our ever-changing global environment.  
Reducing or eliminating diagnostic errors 
A diagnostic error is the “failure to: a) establish an accurate and timely explanation of the 
patient’s health problems; or b) communicate that explanation to the patient.”53 The Institute of 
Medicine’s (IOM) recommends that in order to reduce diagnostic errors and improve diagnosis 
in healthcare it is important to “consider a patient-centered perspective.”53 According to the 
IOM, the diagnostic process must start with the patient engaging in the health system. In turn, the 
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HCP engages in a decision process that includes gathering information to synthesize what is 
observed through physical examinations and discussed between provider and patient to develop a 
working diagnosis. 
Engaging with patients is key in screening and diagnosing CD given the nature of the 
disease and the limited awareness by HCP’s. Failure to obtain a complete medical history, for 
example, will yield incomplete information. Conversely, even if a complete medical history is 
performed, but the HCP is unable to synthesize the information, then a missed diagnosis may 
occur. Figure 8 illustrates the conditions necessary for a CD patient to receive treatment. 
However, most physicians lack the training or have never considered risk factors specific 
to Texas because they have never tested a patient for CD before. These scenarios present missed 
opportunities in which the HCP’s may not be screening patients and following up with the 
corresponding testing to ensure a timely diagnosis of CD. Death and morbidity from CD can be 
prevented if more cases are screened during the initial phases of the disease, when the drug 
treatment is more effective. Thus, it is crucial for infected patients (i.e., those recently exposed or 
with a letter from the blood-bank stating a positive screen) to get tested immediately to confirm 
diagnosis and receive treatment.  
Furthermore, HCP’s may fail to accurately describe a Chagas diagnosis using the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM).65 
ICD-9-CM  is “the official system of assigning codes to diagnoses and procedures associated 
with hospital utilization in the United States.”66 Effective October 1, 2015 the tenth version, 
ICD-10-CM, replaced ICD-9-CM.65 The ICD coding system may allow for estimates of 
incidence of diseases. The ICD-9 and ICD-10 codes can be used to specify diagnosis based on 
physician reimbursement coding. 
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Systems-level perspective 
The previously discussed health system models and a conceptual model used by Yang et 
al frame the barriers to screening and diagnosis to CD in the continuum of treatment through a 
socioecological perspective. Figure 9 illustrates recurring themes at both provider and the patient 
levels. The figure is an adaptation of a conceptual model for delayed tuberculosis (TB) diagnosis. 
Both TB and CD have asymptomatic/ latent phases that as shown in the figure, and have a salient 
effect on the health outcome. If no symptoms overtly manifest, then the patient may not seek 
medical consultation in a timely manner. For CD, delayed medical consultation has deleterious 
impact since treatment may not be as effective once cardiac-related complications manifest. The 
model also illustrates how the lack of HCP awareness plays a key role in CD screening and 
diagnosis.67 Similar to TB, HCP’s lack of suspicion for the CD will delay confirmatory diagnosis 
and treatment. 
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Figure 8: Patient Engagement in the Medical Health System to Receive a Chagas Diagnosis and Treatment 
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Figure 9: Systems-level Conceptual Model for Barriers to Chagas Screening, Diagnosis, and Treatment  
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Specific Aims 
I posited that HCP’s in Texas are generally unaware of CD as a diagnosis and 
therefore may miss crucial opportunities to screen and diagnose the disease amongst their 
patients. This remains true despite current initiatives to educate HCP’s (i.e., Texas Chagas 
Taskforce), vector surveillance, and mainstream media attention (e.g., local media and 
national news coverage on kissing bugs). Because of the potential longevity of the disease 
and its asymptomatic (chronic indeterminate form) nature, persons with CD are more likely 
to remain undiagnosed by their HCP than patients with other infectious diseases that may 
present with clinical symptoms. Also, because only 20 – 30% of CD positive patients will 
ever present with symptoms (e.g., cardiomyopathy, megacolon, etc.), it can often be a missed 
diagnosis or go under-reported.  The extent of CD knowledge deficits throughout the State of 
Texas remains unstudied. How, when, and if providers screen and diagnose for CD in Texas 
is important to understand so that missed diagnoses are prevented and prevalence of the 
disease is better understood. This is especially important since treatment is only available for 
patients who are positive for CD but are not yet symptomatic and can potentially be a life-
saving treatment.  
The overall objective of the study was to explore the understanding and knowledge of 
CD in Texas HCP populations and identify provider-based education and practice 
recommendations to reduce the prevalence of undiagnosed CD. 
The aims of the proposed study are as follows: 
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1. To better estimate prevalence and possible missed diagnoses of CD, map CD cases in 
Texas using DSHS and ICD coding data and compare with non-CD cardiomyopathy 
cases using ICD diagnosis 
a. Map all DSHS and ICD code reported cases of CD  
b. Map non-CD cardiomyopathy ICD code reported cases in Texas along with 
additional risk factors (e.g. age, ethnicity) 
2. Used a mixed methods design to identify and describe gaps related to knowledge, 
attitudes, and practices in the screening, diagnosis and treatment of CD among 
practicing physicians in Texas 
a. Used an online questionnaire to quantify and describe knowledge among 
specialists, including: cardiologists, infectious disease specialists and family 
practice physicians 
b. Conducted key informant interviews to explore the barriers to screening, 
diagnosis and treatment amongst physicians who have treated CD and those 
who have not treated CD 
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METHODS 
Overall Study Design 
Overall, this study included elements of a concurrent (embedded) and sequential 
explanatory study design. The mapping aim was embedded within the overall explanatory 
mixed methodology in establishing a baseline for the knowledge, attitudes, and practices 
among physicians. In the explanatory design, data collected from the knowledge, attitudes, 
and practices questionnaires were collected and analyzed first, followed by the collection and 
analysis of qualitative data from the key informant interviews to “help explain the initial 
quantitative results.”68 The purpose was to identify themes related to barriers in diagnosing 
CD and discuss potential statewide recommendations. Also, maps were created to show the 
potential burden of CD in the state by comparing the overall frequency in ICD-9/10-CM 
reporting of idiopathic and ischemic heart disease to the confirmed TDSHS reported Chagas 
cases.  
Human Subjects Protection 
There were no direct risks associated with this study. The research was reviewed by 
the Committee for the Protection of Human Subjects (CPHS) at the University of Texas 
Health Science Center (UTHealth) and approved on February 5, 2018 (HSC-SPH-17-1039). 
The key informant script and the online questionnaires were revised and resubmitted for IRB 
approval.  Final approval was received on July 2, 2018. 
Informed consent was obtained verbally for key informant participants prior to 
conducting the interview. A prompt was included in the online questionnaire to obtain 
informed consent electronically (i.e. a specific item with the answer choices of “Yes, I agree 
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to participate” “No, I do not agree to participate” was included). Administrative data from the 
hospital inpatient public use file were de-identified.  
Methodology for Aim 1: Mapping 
Data sources 
The Inpatient Public Use Data File (IPUDF), maintained by the TDSHS, and the 
number of Chagas confirmed cases data were used to create maps for this aim. The Texas 
Health Care Information Council (THCIC) is responsible for collecting and maintaining 
updates to the PUDF.69 Information is collected from every licensed hospital in the state 
other than hospitals in a county with a population of fewer than 35,000, or those in a county 
with a population greater than 35,000 and with fewer than 100 licensed hospital beds and not 
in an area designated as an urbanized area by the U.S. Bureau of Census, or those that do not 
seek insurance payment or government reimbursement. Updates to the PUDF are quarterly; 
the third quarter for 2016 is the most recently available dataset and the earliest is 1999. 
Datasets contain patient demographics, hospital information and length of stay, principal and 
secondary diagnosis, hospital charges. However, no personable identifiable information is 
recorded in the reports (e.g., no dates of birth, address, social security number). CD became 
reportable in 2013. Thus, the hospital inpatient PUDF for 2013 to 2016 was requested. 
Confirmed and reported CD cases (local, imported, and unknown source of transmission) 
were mapped using data from TDSHS Zoonotic Control division for that same time period.44 
Census data (i.e., American Fact Finder web application) was used to download the 
American Community Survey (ACS) 5-year Texas population estimates for 2016.70 This 
included Texas demographic data on age and Hispanic status by county. A basemap was 
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created by downloading the shapefile for the Texas counties from the U.S. Census Bureau 
(i.e., TIGER/Line Web interface).71 
Variables 
The following patient demographics from the raw quarterly base inpatient data files 
were kept: patient’s age group (i.e., <18; 18 to 44; 45 to 66; 65 to 74; and ≥75); ethnicity 
(Hispanic or non-Hispanic); race (American Indian/ Eskimo; Asian or Pacific Islander; 
Black; White; or Other); and sex code (male or female). All of the principle diagnostic codes 
(i.e., 1—24) were coded to determine if that particular patient record contained any of the 
ICD-9 or 10 diagnostic codes of interest. Additional variables that were kept from the initial 
raw IPUDF included: record identification number for each hospital admission; patient’s 
county and zip code of residence; provider ID; and type of admission.  
Case definitions 
A cardiologist was consulted to identify and review the diagnostic codes. Dummy 
variables were created using the Chagas diagnosis in the IPUDF for: ICD-9-CM (i.e., 086.0, 
086.1, and 086.2) for 2013 through 2015 (third quarter); and for ICD-10-CM codes (B57.0, 
B57.1, B57.2, and B57.5) for the last quarter of 2015 and for 2016. These seven ICD9/10 CD 
diagnosis codes were collapsed as either CD-heart, or CD-non-heart related diagnosis. One 
additional variable for the total of all CD diagnosis was created and was used in the maps. 
Eight ICD-9/10 diagnostic codes were used to create the heart-related diagnosis (i.e., the 
proxy for potentially missed CD). Table 1 shows the diagnostic code utilized from each 
version.  
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Table 1: Chagas and cardiomyopathy-related ICD-9 CM and ICD-10 CM codes 
 
Case  ICD Version Diagnostic 
Code 
Description 
Chagas-related ICD-9-CM 086.0 Chagas with heart involvement 
 ICD-9-CM 086.1 Chagas with other organ 
involvement 
 ICD-9-CM 086.2 Chagas without mention of organ 
involvement 
 ICD-10-CM B57.0 Acute CD, heart 
 ICD-10-CM B57.1 Acute CD, without heart 
 ICD-10-CM B57.2 Chronic CD, with heart 
 ICD-10-CM B57.5 Chronic CD with other organ 
involvement 
Heart-related ICD-9-CM 414.8 Other forms of chronic ischemic 
heart disease 
 ICD-9-CM 422.91 Idiopathic myocarditis 
 ICD-9-CM 425.8 Cardiomyopathy, excludes Chagas 
 ICD-9-CM 425.4 Cardiomyopathy, includes idiopathic 
 ICD-10-CM I42.5 Other restrictive cardiomyopathy 
 ICD-10-CM I42.8 Other cardiomyopathies 
 ICD-10-CM I25.5 Ischemic cardiomyopathy 
 ICD-10-CM I42.9 Cardiomyopathy, unspecified 
 
Data collection and management 
Initially, each of the quarterly IPDUF were exported as a comma separated value file 
(CSV) to Excel. Stata was used to create the indicator or dummy variables (i.e., flag the case 
definitions), drop variables that were not of interest for this study, denote the steps performed 
and run quality checks, and merge quarterly datasets to corresponding years. “If statements” 
were used on Stata to flag each of the admitting, principal, and other diagnosis codes for any 
Chagas or heart-related ICD 9/10 codes prior to merging quarterly datasets into the 
corresponding yearly datasets. Patient records that did not contain the case definitions were 
eliminated from the dataset. The combined raw IPUDF contained over 12 million hospital 
admissions, yet 3.1% were eligible for the geospatial analysis (i.e., contained a heart related 
 30 
and or Chagas disease diagnosis code). Appendix D shows the frequency for each code, by 
year. 
Four datasets (for 2013, 2014, 2015, and 2016) and the corresponding codebooks 
were created on Stata and Excel, respectively. Additionally, demographic indicator variables 
were created for age, race, ethnicity, and sex code. For age, the categories were collapsed 
from 22 groups to create 5 age group variables: children (individuals under 18); 18 to 44; 45 
to 64; 65 to 74; and 75 and over. This re-grouping allowed for inclusion of the patient 
populations with HIV, alcohol, and drug use populations given their categorization into these 
5 age groups. Five race indicator variables were created for: American Indian/ Eskimo; Asian 
or Pacific Islander; Black; White; and Other. Two indicator variables were coded for 
Hispanic origin and for those of non-Hispanic origin. Male and female indicator variables 
were created.  
The tabulations by county and case definition, and by county, case definition, and 
demographic characteristic (i.e., age group, ethnicity, race, and sex) were inputted to an 
Excel spreadsheet for each corresponding year. The counties were listed as rows and the 
variables as numbers. An additional spreadsheet was created to summarize the sub-totals for 
the corresponding ICD 9/10 Chagas disease diagnostic codes (both heart and other organ 
involvement) and for the heart-related diagnostic codes for all four years. Thus, there were 
multiple iterations of data management to create a final dataset and ultimately a table with 
the counties by enumerating the totals for each of the cases, as shown in the Appendix E. A 
total of 78 heart-related Chagas codes was identified and 29 that were not related to heart-
complications that could be mapped to a county. There were 366,575 heart-related diagnostic 
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codes that were mapped to a county. The Federal Information Processing Standard (FIPS) 
code was listed for each county in the final table to link up to the county shape file. 
Demographic data for the state was downloaded using the American Fact Finder web 
application as CSV files. The five year 2016 estimates were chosen for the Hispanic 
population and age categories. Excel was used to import the CSV files, clean up the variables 
(i.e., rename columns for ArcMap usability; remove extraneous data). An Excel workbook 
was created for each variable. To calculate the Hispanic proportion, the number of Hispanics 
was divide by the total population for each county. To create the table for age groups, only 
the population estimates for males, females, and all, aged 20 to 59 were summed for each 
respective group (i.e., a column for each: males, females, and total). 
Mapping 
ArcMap GIS (Version 10.6.0), a software application used to map and analyze a 
geographic information system (GIS), was used to visualize the ICD 9/10 inpatient hospital 
diagnostic codes and illustrate the salience of potentially missed Chagas disease diagnoses 
(e.g., cardiomyopathic diagnoses).72 GIS maps are useful in illustrating issues or particular 
situations and contextualize environmental factors.73  Given that the vector is found 
throughout the state as demonstrated from emerging animal and entomological surveillance74 
this study aim can help visualize where the potential for missed diagnoses is the most 
prevalent throughout the state and serve as exploratory for further research to map the vector 
ecology with findings from this research.  
A total of 5 maps were created.  First, the table of Chagas disease counts reported to 
TDSHS (by local, imported, or unknown transmission). Each value was set to represent one 
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count. Next, the table with the heart-related ICD (9 and 10) total counts for each county was 
added in order to output a choropleth map, that is as each range of values increased so did the 
corresponding color intensity. The natural breaks (or Jenks) classification was initially used 
in order to minimize variance within groups but maximize it between them, followed by 
manual adjustments to categorize the data into 5 groups. The demographic tables from the 
ACS estimates were then loaded to ArcMap. For each map, the heart-related ICD diagnoses 
were represented as graduated symbols (i.e., red triangles) using the same group 
classification as before (e.g., Jenks). Graduated colors were used to show the proportion of 
Hispanics and the proportion of the county population aged 20 to 59. A final map was 
developed, which adjusted for the county populations and used a Jenks classification for the 
categories, which were per 10,000 persons. All tables were linked to the county shapefile 
(i.e., the basemap) using the FIPS county code. 
Methodology for Aim 2a: Questionnaire 
Study design and population 
The study design for Aim 2a was cross-sectional, in which data was collected from 
three online questionnaires from July 5, 2018 through October 1, 2018. Having a baseline to 
quantify general knowledge on CD, as well as specific diagnostic procedures, practices, and 
overall attitudes on CD is crucial for the development of targeted HCP educational efforts 
and the dissemination of resources. 
Infectious disease HCP’s were hypothesized to be the most aware of CD compared to 
cardiologists and family/ general practice physicians given their experience in diagnosing 
related parasitic diseases. Infectious disease HCP’s were thus a focal group since other 
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general practice HCP’s may refer patients to them. Cardiologists were hypothesized to also 
be aware and knowledgeable of CD since the chronic phase of the disease involves heart-
related complications. However, in general, cardiologists may lack the awareness to 
recognize the acute or chronic asymptomatic CD cases and understand the importance or 
value of screening high risk populations. Cardiologists may facilitate the communication 
between other provider specialties, since they may be somewhat more familiar and aware of 
CD than other general practitioners.  
In previous CD awareness questionnaires aimed at HCP’s, the response rate has been 
between: 40.1% and 41.7%.60,61,75 Finally, family practice physicians were chosen as a target 
population given the lack of research and thus the inability to establish a baseline knowledge 
among this population. Moreover, this specialty is more likely to engage with patients 
worried about the risk of triatomine exposure or be the first points of contact for recipients of 
blood donation letters, prior to consulting with ID specialists.  
Thus, similar to the recent study assessing CD awareness among Ohio HCP, the 
questionnaires focused on cardiologists, infectious disease specialists, and family care 
physicians. The rationale was that these providers as are more likely to provide medical care 
to most patients. Although primary care physicians and other primary healthcare workers 
such as physician assistant and nurse practitioners act as gate keepers in referring their 
patients to specialized care, due to time constraints and limited resources the scope of this 
research was only on licensed practicing physicians in Texas who were listed with a primary 
specialty in cardiology, family medicine/ general practice, or infectious disease medicine.  I 
expected the sample will be representative and reflect the knowledge, attitudes, and beliefs of 
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the targeted population, but findings may not be necessarily generalizable to all HCP’s in 
Texas. However, given, the design of this research, the findings will guide future research 
and outreach efforts for specific HCP populations and specific Texas geographical locations. 
In turn, this target population will engage with patients seeking primary care as a result of 
vector exposure, blood donation letters, or from exhibiting clinical symptoms.  
Instrument development 
A questionnaire was developed to describe: 1) the overall awareness of CD; 2) 
screening, diagnosis, and reporting procedures; 3) and risk and exposure factors specific to 
Texas. Questionnaires used to collect information related to knowledge, attitudes, and 
practices (KAP) have been used by the WHO, particularly in developing countries to better 
understand the community members’ perceptions about specific health concerns.76 Multiple 
choice items and ordered-category items (i.e., Likert scales) are ways to objectively assess 
the knowledge.77 
Prior to this research, no tool was available to assess Chagas KAP among physicians 
to measure specific domains (e.g., recognizing risk factors, performing screening and 
diagnostic practices, frequency of CD-related resources). Thus, specific questions were 
formulated to ensure physician attitudes about CD as well as their experience and self-
efficacy in making a CD diagnosis were captured. The questionnaire was tailored to the three 
clinically-focused specialties. Survey questions from published research62 as well as from an 
online continuing education course from the CDC78 were used to create the items.  
Questionnaire items included: physician demographics (i.e., practice type and years 
since graduation); clinical manifestation; risk of transmission; and whether a Latin American 
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immigrant population is served/ proportion served. The questionnaire will include both right/ 
wrong items as well as self-reported level of confidence scales.  
The three instruments were piloted among Texas Chagas Taskforce members, and 
practicing physicians (cardiologist, infectious disease specialist, and general practice 
provider), and non-CD experts to ensure reliability, validity of questions, and address any 
issues including completion time and ease of use across various platforms including smart 
phones. Follow-up meetings were conducted to discuss issues and revisions to questions and 
responses. For instance, after discussing with the physicians and other individuals who 
piloted the questionnaire, the response choices for various knowledge items were revised to 
eliminate similar or confusing answers, and thus make it easier to assess whether or not the 
concept was known to the physician.  
Sampling and recruitment 
First, the Texas Medical Association (TMA) leadership was engaged. The TMA is a 
professional medical society that includes over 50,000 physicians and medical students.79 I 
will contact TMA staff and leadership about collaborating in this project to recruit 
questionnaire participants while pending feedback from the taskforce and from other HCP’s 
to improve the questionnaire tool.  
Two TMA staff members who were active Chagas Taskforce members served as 
points of contact to facilitate coordination with TMA leadership. After meeting, discussing, 
and reviewing the questionnaires, they agreed to forward my request via email to their 
respective chairs. The email provided the rationale, aims, and my contact information. A link 
to each specific online questionnaire was included. I did not receive access to the sampling 
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frame or was I copied in the direct communication to be able to follow-up with physicians. 
After two weeks, no new responses were initiated. I reached out to additional professional 
medical networks, societies and groups with access to physicians throughout San Antonio 
and the state (e.g., the Bexar County Medical Society, Harris County Health, Metropolitan 
Health District, and TDSHS, the Bexar County Health Collaborative, UT Health in San 
Antonio, UTHealth Tyler Population Health at the UT System). I also disseminated my 
request to professional colleagues who had access or worked with physicians. Finally, I 
reached out to physicians who participated in the Texas Chagas Taskforce webinar or 
workshop. A total of 5 followed up with me replying their ineligibility to participate in the 
research (i.e., practiced in other states; had a primary specialty that was outside the scope of 
this research). 
Sample size 
In the past, TMA conducted two annual questionnaires that supported state and 
legislative advocacy efforts. A 2015 Questionnaire on meaningful use program for the Center 
for Medicare and Medicaid Services (CMS) had a 4.96% (n= 543) response rate based on 
10,943 eligible participants.80 However, a 2016 questionnaire on electronic health record 
(EHR) usage and experiences with a sampling frame of 39,165 (Texas physicians with email 
address in the TMA database) had a lower response rate of 2.77% (n=1,084).81 Initially, 
response rate between 2.0 and 5.0% was expected. If the response rate within this range is 
not achieved, other professional medical societies will be contacted (i.e., Texas Infectious 
Disease Society; Texas Chapter of the American College of Cardiology).  
 37 
Moreover, a 2015 physician workforce study in Texas indicated that there were 
63,000 licensed physicians in Texas but only 46,953 were active in patient care.82 From this 
research 453 practicing infectious disease specialists, 1,027 cardiologists, and 6,367 general/ 
family practice physicians were identified for 2015.82 Taking into account the number of 
each provider in the respective specialties and the collective TMA questionnaire response 
rate (between 2.0 and 5.0%), I expected the following response rate if all eligible physicians 
were emailed the link: 9 to 23 among infectious disease specialists; 20 to 51 among 
cardiologists; and 127 to 318 for family/ general practice physicians. This was a particular 
challenge given that a research study like this has not been previously done before to guide 
the decisions in statistical sampling and power. Using sample size calculations with a margin 
error of 10% and a confidence level of 90% resulted in a sample size of 59 for infectious 
disease, 64 cardiologists, and 67 general/ family practitioners.83 The low threshold was to 
collect at least 30 participants from each group (for a total of n= 90). The reasons for the low 
power was that this research was explanatory in that findings would guide the development 
of grounded theory. In turn, specific hypotheses could be generated and tested, and the 
experiences of working with this challenging population could also improve sampling and 
response rate. No other study has demonstrated the response rate throughout the state, 
especially as it relates to an infectious disease specialists and cardiologists.  
Data collection and management 
Qualtrics (Research Core), an online application, was used to design, manage, and 
implement the questionnaire.84 The questionnaires were anonymous and self-administered. 
Participants had a month to complete the questionnaire. The response rate was monitored 
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weekly. The recorded responses from the Qualtrics repository were exported as a CSV file 
for each questionnaire. The raw dataset was managed using Microsoft Excel with each 
question response that was initially coded as text numerically recoded to dichotomous or 
categorical values. Individual data dictionaries were created for each questionnaire. Copies of 
the original data files were saved in order to facilitate corresponding changes. A Do file 
(using Stata) was created for each questionnaire to denote changes made to the original 
dataset. 
The participants’ eligibility was checked. Table 2 summarizes the number of 
physicians sampled, the number who consented, and the number excluded. Among the 27 
sampled ID specialists, 4 did not consent to participate and 3 additional participants were not 
licensed by the TMB. One participant indicated that s/he was a cardiologist, so the responses 
were grouped in the cardiology group. A total of 34 physicians were sampled for the family/ 
general practice questionnaire. Nine did not consent, three additional participants were not 
licensed by the TMB, and one did not complete any questionnaire items other than the 
specialty. Thus a total of 11 ID specialists was excluded from the analysis. There were 11 
sampled cardiologists (including the response from captured in the ID questionnaire), 6 of 
which did not consent and only 4 were licensed by the TMB. Only three were included in the 
analysis. 
Table 2: Sampling and Participation, by Specialty 
 
Stage Total Infectious Disease 
Family or 
General 
Practice 
Cardiology 
Sampled 71 26 34 11 
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Consented and agreed to 
participate 52 22 25 5 
Licensed by TMB 45 19 22 4 
Included for analysis* 43 19 21 3 
*Not all of the participants answered each question, hence the missing data in the analysis. 
Data analysis 
Descriptive statistics were calculated as frequencies and proportions using Stata 
(14.2).85 Pearson’s Chi square tests were used to compare differences in the response choice 
proportions (e.g., knowledge and attitude items), by physician group. Fisher’s exact test was 
used in cells with 5 or fewer counts. A p-value less than 0.05 was considered statistically 
significant. A summed index score77 for the correct knowledge items was created that ranged 
from 0 to 13. No partial credit was assigned for partially correct responses, rather a “1” was 
assigned for identifying the correct choice. 
Methodology for Aim 2b: Key Informant Interviews 
Study design and sampling 
The purpose of the semi-structured interviews was to explore specific domains 
quantified from the questionnaires, specifically regarding screening practices, as well barriers 
and recommendations to improve physician awareness. Initially a list of physicians (n= 24) 
that had treated CD patients was requested by the CDC. However, the CDC did not allow 
access to directly contact the physicians. Instead assistance was requested from the Texas 
Chagas Taskforce to identify and recruit physicians to participate as key informants. Four of 
the physicians listed were already part of the Taskforce and agreed to participate. An 
additional set of physicians (n= 10) were identified by taskforce member. Only half agreed to 
participate and confirmed a date and time for the call. In total, 13 physicians were identified 
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and recruited to participate using purposive, convenience, and snowball sampling, four of 
which indicated that they had not previously managed any type of care for a patient with CD. 
Interview questions  
As summarized by Padgett, the purpose of qualitative interviews is “to reveal key 
domains in which the experts add a top-down insider perspective that would otherwise be 
missed without their participation”.86 Physicians were asked about their practice: the number 
of years in their specialty; whether they practice in a rural or urban area; type of medical 
practice (i.e., hospital, private, teaching). They were asked to describe their medical 
education and if they had training or medical experience in any country that is endemic to 
CD. Physicians were prompted to discuss their experience(s) in managing the care to CD 
patients (as defined by the continuum from screening and diagnosis, to treatment, to follow-
up care) and elaborate on take-home messages, perceived barriers, and resources that helped 
them better understand CD. The script and guiding questions are shown in Appendix C. 
Recruitment 
Physicians listed in the sampling frame were emailed a brief description of the study. 
Once a physician agreed to participate, a follow-up email was sent to confirm the telephone 
interview. The informed consent and a summary of the key questions were attached in the 
email. A study identification number (Study ID) was assigned to each participant for each 
corresponding group.  The Study ID consisted of 4 digits. The first digit starting from the left 
referred to the physician specialty: 0 if unknown at the time (i.e., if HCP provided contact 
information at a workshop or from online questionnaire); 1 for infectious disease; or 2 for 
cardiology. The next digit indicated whether the physician had treated for Chagas disease: 0 
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if it was not known at the time the Study ID was described; 1 if they had treated CD patients; 
2 if they had not treated CD patients. Finally, the two out-right digits denoted the total 
sampling frame from 01 to 99.  
A Study Participant List was created that linked the study ID to the names and contact 
information of the participants. A copy of the KI tracking table is shown in Appendix G. The 
purpose was to ensure confidentiality but be able to link physicians to their form and follow-
up if needed. Initially, data collection was expected to conclude once saturation (i.e., “when 
additional analyses of the data bring redundancy and reveal no new information”86) was 
reached.87 Given the challenges in recruiting physicians especially those with no knowledge 
of CD, or experience in managing the care of a CD patient the resulting domains and 
sampling strategies were homogenous. Thus, saturation was reached faster than anticipated. 
Interviews were conducted from late June through the end of August of 2018. 
Data collection and management 
Interviews ranged from 12 to 45 minutes in duration. All twelve were digitally 
recorded and securely stored. The script was used to guide the discussion. Notes were written 
down notes during the interview on the form, which were then scanned and securely stored 
electronically and managed via NVivo for Mac, 88 which is a qualitative data analysis (QDA) 
software used “to store data and facilitate coding and analysis.”86 All of the twelve KI audio 
recordings were transcribed by Adept Word Management Inc. 
(https://adeptwordmanagement.com/). The audio transcripts were emailed back as Word files 
and stored to NVivo. Inaudible sections were reviewed by the PI to ensure the KI’s message 
was accurately reflected. 
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Data analysis 
A grounded theory (GT) approach was used to guide the thematic analysis of the 
participant’s feedback. GT is an approach that was first described by Glaser and Strauss86,89 
in 1967 for qualitative research with the goal of developing “new, contextualized theories”90 
that explain a “process, an action, or an interaction shaped by the views of a large number of 
participants.”91 A GT approach was relevant for this research given the lack of existing 
frameworks or models to explain the uptake of information among physicians regarding CD 
risk factors in the U.S. and its screening and diagnostic procedures.  
GT involves “inductive coding from the data, memo writing to document analytic 
decisions, and weaving of theoretical ideas and concepts without permitting them to drive or 
constrain the study’s emergent findings.”86 The salient feature with this approach is that the 
data drives the emergence of themes (i.e. inductive) rather than relying on other research to 
describe the phenomenon or use “prefigured codes or themes” from the existing literature.91 
Themes or categories are “broad units of information that consist of several codes aggregated 
to form a common idea.”91 
Using NVivo, field notes, guides/ scripts, and the audio transcriptions were reviewed. 
Cases were defined as the KI participants and coded accordingly. Descriptive themes were 
developed initially as primary nodes. The nodes were reviewed and compared to identify 
patterns. Axial coding was performed after the interviews were open-coded. Emerging 
themes were identified to describe the experiences in participating physicians that lead to 
screening and diagnosing CD and thus having an increased awareness (i.e., the identification 
of the core phenomenon denoted in GT). Finally, selective coding was used to weave in the 
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codes and propose hypotheses to describe the links between strategies (i.e., the actions taken 
in response to the core phenomenon); the causal conditions (i.e., the factors leading to the 
core phenomenon); the contextual and intervening factors (i.e., the broad and specific factors 
that influenced the strategies); and the outcomes. 
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LITERATURE REVIEW 
Quantifying the Global Threat 
Intercontinental migration (i.e., from Central and South America to North America, 
Europe, and Japan) has facilitated the spread of CD into previously non-endemic 
countries.47,92-94 This globalization has resulted in CD as an emerging global disease. In 
countries where the vector is not present, blood transfusion, blood/ organ donations, and 
vertical transmission are of concern. Through computational simulation modeling, the global 
economic burden of CD is $627.5 million in health-care costs and 806,170 disability-adjusted 
life-years (DALYs) annually.95 The total net costs for infected individuals $24.73 billion in 
healthcare costs, which exceeds cervical cancer costs. Bern and Montgomery estimated the 
possible prevalence of T. cruzi infections in Latin American- born individuals living in the 
U.S. using 2005 data. They showed there to be an estimated 22.8 million immigrants from 
Latin American living in the U.S. at that time and accounted for 1.31% of T. cruzi 
infections.21 While Mexico accounted for the largest immigrant population, it only 
represented 1.03% of infections or an estimated 174,388 cases. In contrast, Bolivia 
represented the highest proportion (6.75%) but only represents about 4,149 cases. Thus, these 
estimates are likely to increase as the number of immigrants from Central and South America 
continue to increase. 
Awareness of Chagas Disease 
Among Healthcare Providers 
Given the emerging global concern, HCP’s, including those in non-endemic countries 
in Europe must be familiar with CD etiology, screening, management, and treatment. In a 
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2013 study by Muñoz et al., physicians (pediatricians and obstetricians/gynecologists) and 
nurses in Spain were surveyed regarding their knowledge on Chagas. Eight basic questions 
were asked regarding the distribution, transmission in endemic countries, all routes of 
transmission, clinical manifestations, diagnosis, blood donation, and treatment. Physicians 
(n= 47) knew the least when it came to treatment and disease distribution (i.e., 57% and 60% 
only answered correctly) but in general answered more questions correctly compared to 
nursing professionals.61 When compared to findings from other HCP CD knowledge studies 
from the U.S., this study suggests that HCP’s in European countries that are seeing large 
waves of Latin American immigrants (i.e., Spain) are more aware than HCP’s in other 
countries where screening and interventions are more limited, such as in the U.S. However, it 
is important to recognize that this study was conducted in a hospital (Poniente de Almería) 
that had already began screening interventions to prevent vertical transmission. 
A small study done in the U.S. demonstrated a limited awareness of CD among 
various sub-specialty providers. Stimpert and Montgomery showed that the knowledge, 
attitudes, and practices about CD were limited among a U.S. convenience sample of 
physicians in primary care, infectious disease (ID), cardiology, obstetrics/ gynecology 
(OBGYN), and transplantation medicine.62 Forty-seven percent of OBGYN doctors had 
never heard of CD compared to 14% in primary care, 23% in cardiology, and 19% in 
infectious disease. Moreover, 68% of OBGYN physicians reported lack of confidence in CD 
knowledge being up to date, compared to infectious disease specialists who had the lowest at 
27%. Additionally, 33% of OBGYN physicians did not know the cause of CD, and another 
big proportion (30%) of OBGYN HCP’s did not know about the clinical manifestations of 
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disease. When asked how often the risk for CD in their patient population is considered: 34% 
of cardiologists, 29% of ID specialists 60% of OBGYN, 43% primary care, and 39% 
transplantation medicine doctors indicated that they never consider risk for CD in patients. 
HCP’s were then asked to correctly identify the percentage of patients with chronic infection 
for which clinical disease develops. OBGYN (56%) had the most incorrect responses and the 
ID specialists the least (28%). Finally, when asked about CD symptom etiology, 48% of 
OBGYN answered incorrectly while ID specialists had the least incorrect responses (14%). 
All in all, OBGYN had the least amount of CD knowledge, while ID specialists had the most 
awareness regarding CD.A total of 1,142 HCP’s through a national sample were surveyed. 
This was one of the earlier efforts to assess and quantify differences in knowledge levels by 
provider specialties. 
Similar findings were observed in a 2010 Chagas awareness study from Verani et al. 
Questions were related to etiology, clinical manifestations, diagnosis, and risk for congenital 
transmission and represented a national sample of practicing OBGYN (n= 421). The online 
questionnaire was more comprehensive and focused specifically on congenital transmission 
risks and etiology. Over 68% of respondents self-reported a “very limited” level of 
knowledge regarding CD and 9% had never heard of CD.75 Over a third of the participants 
did not know the causative agent for CD and 32% correctly identified the clinical 
manifestations for chronic CD. Next, an item was included about the proportion of patients 
seen that are immigrants from Mexico, Central America or South America. About 41% of 
HCP’s indicated that they see 1-10% of immigrants from Latin America. Moreover, 78% and 
20% never and rarely, respectively consider a CD diagnosis for immigrant patients. This 
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study helps to illustrate the differences in provider awareness and the need for tailored 
messaging that is relevant to the specialty (i.e., how to mitigate or prevent congenital 
transmission). 
Knowledge of CD was evaluated in HCP’s in six Appalachian Ohio counties with a 
higher proportion of Hispanic population compared to the rest of the state.60 HCP specialties 
for this survey included cardiologists, internists, emergency department physicians, and 
primary care/ family physicians. Most of the HCP’s (83%) had a very limited or limited level 
of CD knowledge. Regarding the consideration for CD in diagnosis, 46% never considered 
while 35% rarely did. Finally, 69% did not know the correct percentage of patients with 
chronic infection for which clinical disease develops. These findings contrast somewhat to 
the national results from Stimpert in that in general these Ohio HCP’s knew less than the 
nationally surveyed physicians. Despite the limitations in estimating the prevalence, perhaps 
the disease is not as rare as perceived, thus presenting a barrier for correctly and efficiently 
diagnosing and treating patients. In the U.S., the CDC and health department have released 
educational resources aimed at healthcare providers as well as the general public31. However, 
the value and impact remains unseen. This study did not categorize the responses by 
physician specialty, and while similar questions were asked, they were not comparable to 
work from previous research. 
A recent case report by Dolhoun and Antes illustrates the opportunity for missed 
diagnosis from HCP with limited experience in screening and diagnosing Chagas.96 A 
healthy individual with no travel history to Central or South America, in a suburban 
residence in San Francisco, California presented with insect bites throughout a 6-week 
 48 
period. He initially attempted to self-treat with over the counter medication, then contacted 
his primary care physician, and tried to avoid specific behaviors (i.e. not sleeping in his own 
bed, using a different means of transportation). His physician prescribed him 
sulfamethoxzazole-trimethoroim and naproxen. He continued to receive new bites until he 
contacted a local pest management company that was able to identify triatomines in his 
room. This then prompted coordination with his physician and the CDC for confirmatory 
testing. It is surmised that the triatomines were found in the corrugated cardboard boxes that 
were occasionally received and stored in his room. 
Assessing knowledge, attitudes, and practices (KAP) is useful in identifying 
“knowledge gaps and cultural barriers;”97 as well as “exploring changes in the community,” 
including among “medical practicioners.”98 Unlike the latter resource, much of the KAP 
guides focuses on the community-at-large in order to understand specific challenges to the 
uptake of a health behavior, current needs, or any other barriers to adapting or implementing 
interventions.97  
Among the Population 
Several recent studies have examined the level of CD awareness among Latin 
American immigrants, particularly from Bolivia. A 2014 study by Sanchez et al. assessed CD 
awareness among Latin American immigrants living in Los Angeles, California. Countries of 
birth included Mexico, El Salvador, Guatemala, or other. A total of 62% remembered seeing 
triatomines in their home country, yet 86% had never heard of CD. From those who had 
heard of CD, 81% believed that it was not a serious medical condition.  This presents a 
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challenge in persuading high risk exposure patients to seek and follow-up with medical 
treatment, assuming it is accessible and available to begin with. 
Bolivian immigrants in Spain were surveyed and blood samples were screened in a 
study by Salvador-Gil et al.47 Questions related to symptoms, complications, means of 
transmission, and places to seek medical assistance. Out of the 96 participants, over 35% 
were serological positive for T. cruzi, but nearly one quarter did not know about CD and 71% 
did not know about the symptoms for CD. This suggests that not only is there high level of 
knowledge deficits among high risk population, but they may not now to seek medical 
assistance given that they may be already infected. 
A similar study was conducted in Germany among Bolivian-origin residents.94 CD 
awareness and serology was performed in 43 participants in one specific community in 
Munich. Less than 10% tested positive for T. cruzi. Nearly 70% had heard about CD, 56% 
were unware of the symptoms, 30% had not knowledge on CD transmission, and 93% had 
never undergone testing. This research shows that even among high-risk exposure groups, 
there is room to better educate and inform individuals and empower them to seek medical 
resources. 
Qualitative research further supports the quantitative results from surveys. Work form 
Blasco-Hernández et al., highlights how Bolivian women living in Spain perceive CD with a 
low-risk and may thus contribute to under diagnosis of disease.93 Through key informant 
interviews and focus group sessions, women were aware of CD—the vector, the clinical 
manifestations, but were indifferent to the risk of contracting the disease and getting testing. 
In a different study with Bolivian women who had tested positive for CD, they 
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acknowledged emotional distress when diagnosed with CD but were unable to find medical 
treatment.56 
A study aimed to identify barriers to access and treatment among Latin American 
immigrants in Georgia revealed consistent finding through qualitative research.58 In this 
sample of immigrants, the majority of participants were unaware of CD but were somewhat 
familiar with the triatomes or chinches. However, they confused the vector with other 
diseases not associated with Chagas. They recognized the potential to delay formal medical 
care, but that they trusted these remedies, especially if they consulted with family or friends 
still in their country. They also described “stoically waiting” for the illness to resolve on its 
own. This research helps to frame underlying cultural barriers that may delay medical 
consultation and engagement with the health system. If a patient does not have symptoms or 
does not trust doctors, then they may not be as likely to seek medical attention to get 
diagnosed or receive treatment.  
In Honduras, a community-based surveillance pilot program that also assessed the 
risk awareness among children resulted in a decline in seroprevalence from 3.4% to 0.4% and 
improved awareness.99 The success of this program indicates the feasibility and rationale for 
integrating vector surveillance with health education and screening.  
Although, local transmission in North America is rare, specific populations who are 
exposed to the outdoors more frequently than other groups has been recently studied in 
Texas. For example, 36% of individuals enrolled in a Chagas study acquired the parasite 
locally via a sylvatic transmission.100 Two-thirds from that proportion had reported a long 
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history (10 or more years) of outdoor/ recreational rural activities, thus placing this 
population of outdoor enthusiasts at an increased risk for infection. 
Physiology and Biomarkers for Chagas Cardiomyopathy 
One-third to 40% of CD patients will present with cardiomyopathy with various 
levels of cardiac involvement.101 Biomarkers are used to assess the severity of Chagas 
cardiomyopathy. Although Chagas cardiomyopathy and hear failure may have similar 
pathophysiological characteristics, the former is unique in that there are frequent ventricular 
arrhythmias, as well as “conduction disturbances, including sinus bradycardia, complete 
atrioventricular block, and right bundle block.”101 High sensitive cardiac troponin is known 
biomarker for the diagnosis of acute myocardial infarction.101 In a pilot study of T. cruzi 
positive donors in southeastern Texas, 41% had ECG consistent with Chagas 
cardiomyopathy and 36% were acquired through local transmission. In this study, high-
sensitivity troponin serum levels increased with cardiac severity. A recent from Echeverria et 
al. (2017) examined the association of T. cruzi infected individuals with Chagas 
cardiomyopathy and other biomarkers in a Colombian sample.101 Findings indicated that N-
terminal pro B-type natriuretic peptide (NT-proBNP) was similar to high sensitivity cardiac 
troponin in predicting the severity of Chagas cardiomyopathy. The clinical applications from 
the results of these studies thus shows the value of biomarkers in improving screening, 
particularly among the population with a high prevalence of CD. A recent literature review 
by Milei et al. concludes that chagasic cardiomypathies can be misdiagnosed.102 
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Surveillance 
Although there is a lack of human surveillance, entomological and vector research 
and estimates from blood donor screening are used to estimate the prevalence.16,29,63,74,103-107 
Work from Capuani et al. demonstrated an association between seropositive status and 
mortality in blood donors in Brazil using death certificates.108 A total of 159 deaths among 
the seropositive donors were identified, 16% of which contained an ICD-10-CM CD cause of 
death (i.e., B57.0 and B57.5). In all, deaths due to CD was 17.9 times greater in seropositive 
donors compared to the seronegative donors.  
United States 
In the U.S., “relatively few resources have been devoted to surveillance, prevention, 
and treatment”.109 Various studies throughout the last two decades have examined the 
potential for T. cuzi infection from blood donors here in the U.S. One of the earlier studies 
from Leiby et al., examined the prevalence of T. cruzi from blood donors in 1994 through 
1998 in Los Angeles and Miami.110 One in 7,500 and 1 in 9,000 tested serologically positive 
in Los Angeles and Miami donors, respectively. In a 2012 study, 41% (n=15) of the 
participants in Mississippi who were blood donor eligible had serologically tested positive 
for T. cruzi; out of those, 3 had reported visiting a rural area of an endemic country for less 
than 2 weeks, but all had previously lived where a vector has been documented.63 
Additionally, 87% reported outdoor leisure or work activity. Research on T. cruzi infections 
among organ recipients from 2001 to 2011 indicated that 32 recipients received organs from 
14 seropositive donors; transmission occurred in 9 recipients.111 In New York, 204 donors 
tested positive out of 1.07 million donors between 2007 through 2011.112 
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Texas 
Public health state surveillance for CD began in 2013 in Texas. The reasons for CD 
surveillance includes: 1) to identify the source of infection; 2) monitor acute and chronic 
disease burden.39 Non-human (i.e., canine cases) CD data were collected and reported 
between 2013 and 2016. Five locally acquired cases in southeastern Texas are described in 
Garcia et al. from a pilot study of positive blood donors.28 Four were infected near their 
residence; four blood donors had a moderate to high risk of transmission from birthplace. A 
literature review from Garcia and colleagues indicates the first case reported of Chagas in 
Texas was in 1935.23 Figure 10 shows a total of 51 confirmed of suspected cases that were 
reported in the literature between 1935 and 2015 in Texas.  
Figure 10: Counties in Texas with confirmed and suspected Chagas infection from 
the 8literature, 1935 to 2015 
 
 
                                                 
8 Source: Garcia et al. (2015). Historical perspectives on the epidemiology of human Chagas Disease 
in Texas and recommendations for enhanced understanding of clinical Chagas Disease in the 
Southern United States. PLoS Neglected Tropical Disease, 9:11. 
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Introduction 
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be 
fatal if not diagnosed and treated in its early stages. CD accounts for the highest burden of 
any parasitic disease in the 22 Latin American countries where it is endemic. T. cruzi is 
endemic throughout Central and South America and is found in North America, including in 
Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in Latin 
America have CD.11 Over 28,000 people are infected each year in Mexico, Central America 
and South America, accounting for at least 12,000 deaths per year.12 
Reduviids, also known as triatomines or kissing bugs, are blood-feeding insects that 
transmit the parasite (mainly through their feces) that causes CD. The kissing bugs are 
unaffected by T. cruzi but act as the vector for the parasite. Kissing bugs transmit the parasite 
to mammals including humans,1 but can also infect reservoir hosts such as canines, 
opossums, raccoons, and other domestic8,13 and sylvatic animals.14 Vectorial transmission is 
most common among children and adolescents in endemic countries.8 In contrast to the lack 
of compulsory screening and testing in the general population or with pregnant women, the 
blood supply in the U.S. has been screened for CD antibodies since 2007.1 Blood donation 
screening is the most common means by which individuals learn about their CD diagnosis in 
the U.S.23 
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the 
first two months of the initial infection, which may manifest with mild flu-like symptoms or 
febrile illness.31 Other symptoms may include: malaise, enlarged spleen, liver, and lymph 
nodes; localized or generalized edema; chagomas or breaks in the skin; and result in 
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abnormal electrocardiogram (ECG).8 Acute infection may manifest as early as one week after  
exposure and may be self-limiting in most individuals.8 The patient may not seek medical 
attention since the symptoms are mild and not unique to CD. During the chronic stage, two 
presentations are possible: the indeterminate form, which is commonly asymptomatic; and 
the determinate which include cardiac (e.g., cardiomyopathy, heart failure, altered heart rate 
or rhythm) and intestinal complications2.  The majority of infected individuals (70%-80%)2,15 
will advance from the acute phase and remain in a latent or indeterminate chronic form of the 
disease (mostly asymptomatic), which may persist as a lifelong infection. The danger of this 
asymptomatic status is that once symptoms do manifest, eliminating the parasite becomes 
more difficult or impossible and often results in death. Conversely, only 20-30% of infected 
individuals will progress from the indeterminate chronic phase to a “clinically evident 
disease” or chronic determinate phase, months to decades after becoming infected.15 Chronic 
determinate CD often corresponds to the organ involved (heart; esophagus; and/or colon): 
cardiac, digestive, or both.8 The digestive manifestation is typically found manly in South 
America or in persons infected in that region.8 Heart failure occurs usually towards the latter 
phase of Chagasic heart disease.8 Sudden death due to cardiac complications can occur.11 
For the scope of this study, heart-related symptoms were the primary focus, given that 
the digestive manifestation is a hallmark of South American infections. In the Southern Cone 
of South America (i.e., Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil) 
gastrointestinal CD is more common than CD cardiomyopathy, as the latter is more 
commonly seen in Central America and North America.34 According to the National 
Institutes of Health (NIH), cardiomyopathy, “refers to diseases of the heart muscle…as it 
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becomes enlarged, thick, or rigid…the heart thus becomes weaker pumping less blood and 
beating irregularly”.35 Chagasic cardiomyopathy includes “cardiac arrhythmias, heart failure, 
and risk of sudden death from ventricular fibrillation or tachycardia or thromboembolic 
events”8 and an estimated 5.4 million people will develop these symptoms.36 Cardiovascular 
disease in CD patients is believed to be the result of “parasite persistence in cardiac tissue 
and immune-mediated myocardial injury.”37 CD may present as idiopathic cardiomyopathy 
and be overlooked by many or most HCPs as a diagnosis. Some estimates considering that 
the Latino immigrant population is younger than the current U.S. population, suggest that, 10 
– 15% of the total U.S. population (or 30,000 to 45,000 individuals) is living with 
undiagnosed CD cardiomyopathy.21  
This study aims to illustrate the missed diagnosis for CD in Texas using geographical 
information system (GIS) mapping. 
Methods 
Data sources 
The Inpatient Public Use Data File (IPUDF), maintained by the Texas Department of 
State Health Services (TDSHS), and the number of Chagas confirmed cases data were used 
to create maps for this aim. Chagas disease (CD) became reportable in 2013. Thus, the 
hospital inpatient PUDF for 2013 to 2016 was requested. Census data (i.e., American Fact 
Finder web application) was used to download the American Community Survey (ACS) 5-
year Texas population estimates for 2016.70 This included Texas demographic data on age 
and Hispanic status by county. A basemap was created by downloading the shapefile for the 
Texas counties from the U.S. Census Bureau (i.e., TIGER/Line Web interface).71 
 58 
Variables and case definitions 
Patient demographics from the raw quarterly base inpatient data files included: 
patient’s age group (i.e., <18; 18 to 44; 45 to 66; 65 to 74; and ≥75); ethnicity (Hispanic or 
non-Hispanic); race (American Indian/ Eskimo; Asian or Pacific Islander; Black; White; or 
Other); and sex code (male or female). All of the principle diagnostic codes (i.e., 1—24) 
were coded to determine if that particular patient record contained any of the ICD-9 or 10 
diagnostic codes of interest. Additional variables that were kept from the initial raw IPUDF 
included: record identification number for each hospital admission; patient’s county and zip 
code of residence; provider ID; and type of admission.  
A cardiologist was consulted to identify and review the diagnostic codes. Dummy 
variables were created using the Chagas diagnosis in the IPUDF for: ICD-9-CM (i.e., 086.0, 
086.1, and 086.2) for 2013 through 2015 (third quarter); and the ICD-10-CM codes (B57.0, 
B57.1, and B57.2) for the last quarter of 2015 and all of 2016. These variables were the 
Chagas-related cases that were mapped. Heart-related diagnosis, a proxy for potentially 
missed diagnosis, in the IPUDF included the following codes: 414.8, 422.91, 425.8, 425.4 
(ICD-9); and I25.5 and I42.9 (ICD-10). Table 1 summarizes the ICD codes used to identify 
the cases.  
Data collection and management 
Each of the quarterly IPDUF were exported as a comma separated value file (CSV) to 
Excel. Stata was used to create the indicator or dummy variables (i.e., flag the case 
definitions), drop variables that were not of interest for this study, denote the steps performed 
and run quality checks, and merge quarterly datasets to corresponding years. “If statements” 
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were used on Stata to flag each of the admitting, principal, and other diagnosis codes for any 
Chagas or heart-related ICD 9/10 codes prior to merging quarterly datasets into the 
corresponding yearly datasets. Patient records that did not contain the case definitions were 
eliminated from the dataset. The combined raw IPUDF contained over 12 million hospital 
admissions, yet 3.1% were eligible for the geospatial analysis (i.e., contained a heart related 
and or Chagas disease diagnosis code).  
The results from tabulations by county and case definition, and by county, case 
definition, and demographic characteristic (i.e., age group, ethnicity, race, and sex) were 
inputted to an Excel spreadsheet for each corresponding year. The counties were listed as 
rows and the variables as numbers. An additional spreadsheet was created to summarize the 
sub-totals for the corresponding ICD 9/10 Chagas disease diagnostic codes (both heart and 
other organ involvement) and for the heart-related diagnostic codes for all four years. Thus, 
there were multiple iterations of data management to create a final dataset and ultimately a 
table with the counties by enumerating the totals for each of the cases, as shown in the 
Appendix. The Federal Information Processing Standard (FIPS) code was listed for each 
county in the final table to link up to the county shape file. 
Demographic data for the state was downloaded using the American Fact Finder web 
application as CSV files. The five year 2016 estimates were chosen for the Hispanic 
population and age categories. Excel was used to import the CSV files, clean up the variables 
(i.e., rename columns for ArcMap usability; remove extraneous data). An Excel workbook 
was created for each variable. To calculate the Hispanic proportion, the number of Hispanics 
was divide by the total population for each county. To create the table for age groups, only 
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the population estimates for males, females, and all, aged 20 to 59 were summed for each 
respective group (i.e., a column for each: males, females, and total). 
Mapping 
ArcMap GIS (Version 10.6.0), a software application used to map and analyze a 
geographic information system (GIS), was used to visualize the ICD 9/10 inpatient hospital 
diagnostic codes and illustrate the salience of potentially missed Chagas disease diagnoses 
(e.g., cardiomyopathic diagnoses).72 GIS maps are useful in illustrating issues or particular 
situations and contextualize environmental factors.73  Given that the vector is found 
throughout the state as demonstrated from emerging animal and entomological surveillance74 
this study aim can help visualize where the potential for missed diagnoses is the most 
prevalent throughout the state and serve as exploratory for further research to map the vector 
ecology with findings from this research.  
Results 
There frequency of each ICD code by year and by diagnostic code are described in 
detail in Appendix D. In total, 101 CD diagnoses between 2013 and 2016 were identified. 
The majority of CD diagnoses were identified for 2014 (n= 22, Chagas with heart 
involvement) and for 2016 (n= 27, chronic Chagas with heart involvement). In contrast, only 
1 acute Chagas without heart involvement was identified within the IPDF. A total of 21 
occurrences of Chagas without mention of organ involvement were identified. A total of 
378,592 cases of heart-related diagnoses were identified. “Cardiomyopathy, including 
idiopathic” and “other chronic ischemic heart disease diagnoses” accounted for the most 
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instances, 118,206 and 150,207, respectively. The least occurring diagnostic code was for 
idiopathic cardiomyopathy (n= 384). 
A total of 4 maps were created.  First, the table of Chagas disease counts reported to 
TDSHS (by local, imported, or unknown transmission). Each value was set to represent one 
count. Next, the table with the heart-related ICD (9 and 10) total counts for each county was 
added in order to output a choropleth map, that is as each range of values increased so did the 
corresponding color intensity. The natural breaks (or Jenks) classification was initially used 
in order to minimize variance within groups but maximize it between them, followed by 
manual adjustments to categorize the data into 5 groups. The demographic tables from the 
ACS estimates were then loaded to ArcMap. For each map, the heart-related ICD diagnoses 
were represented as graduated symbols (i.e., red triangles) using the same group 
classification as before (e.g., Jenks). Graduated colors were used to show the proportion of 
Hispanics and the proportion of the county population aged 20 to 59, given that we expected 
a larger proportion of the younger population with heart-related diagnosis could potentially 
be indicative of missed CD cases All tables were linked to the county shapefile (i.e., the 
basemap) using the FIPS county code. Appendix D details the frequency for each case. In 
total, 366,575 heart-related diagnostic cases were created from the IPUDF and categorized 
into five groups: 2 to 100; 101 to 500; 501 to 1,000; 1,001 to 20,000; and 20,001 to 60,000. 
Figure 1 illustrates the number of CD cases reported to DSHS between 2013 and 
2016 in Texas, by transmission type. A total of 91individual cases were reported between 
that time range, with each corresponding symbol representing a case. Based on the data 
presented in this figure, the largest clusters of imported cases were in Harris and Dallas. 
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Individual imported cases were reported in Potter and Wilbarger in the north, El Paso in the 
far west; and Shelby and Anderson towards the east. Locally-acquired cases were reported in 
Bexar and some in South Texas counties of Hidalgo, Brooks and Cameron. 
Figure 2, a choropleth map, shows the county unweighted burden of heart-related 
diagnostic codes from the IPDUF. The lighter pink-colored counties represent fewer counts 
of heart-related counts in contrast to the darker red-colored counties that represent 1,000 or 
more counts of heart-related diagnosis between 2013 and 2016. Bexar, Dallas, Tarrant, and 
Harris, had the highest number of heart-related codes (between 1,000 and 20,000). The 
following counties were in the second highest category for heart-related codes: El Paso; 
Midland, Ector, Lubbock, and Potter moving up the panhandle; Wichita, Grayson, and Lamar 
along the Oklahoma border; and Zavala, Wells, Hidalgo, Cameron, and Victoria to the south. 
Additionally, counties surrounding Dallas and Tarrant, counties to the north of Bexar, and 
counties around Harris also had a high number of heart-related codes.  
Figures 3a and 3b represent the ACS estimate of the Hispanic population and the 
proportion within that county between 20 and 59 years of age, respectively. A graduated 
symbology (i.e., red triangles) is shown in both maps to illustrate the potential for missed CD 
disease diagnosis given that a younger population might be experiencing heart complications. 
Counties with a high Hispanic population (75% to 99%) had a range of heart-related 
frequency, though the highest numbers were in El Paso, Maverick, Webb, Hidalgo, and 
Cameron. Counties with a lower proportion of a Hispanic population like Randall or 
Montgomery had large (but not the highest) numbers of heart-related diagnostic codes. The 
increase in the triangle symbology in the population map (Figure 3b) can be seen in some 
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counties with a large proportion of the population aged 20 to 59. In six counties with the 
largest proportion 55% to 65% in this age group (i.e., Hartley, Childress, King, Garza, 
Sterling, and Concho) had 100 or less heart-related diagnostic codes.  
Figure 4 shows the comparison between the CD diagnostic codes (blue) and the red 
triangles for the number of heart-related codes. Harris and Dallas/ Tarrant, Travis, Bexar, and 
Cameron counties show clusters of both ICD-coded CD and higher proportions of heart-
related diagnostic codes. Wilbarger had 6 CD diagnostic and only 345 heart-related codes.  
Figure 5 shows the prevalence of missed diagnosis per 10,000 as adjusted by the 
county population. Counties with the highest adjusted prevalence included Howard, 
Wilbarger, Callahan, McMullen, Maverick, Fayette, Colorado, Burleson, Grimes, Robertson, 
Leon, Wood, Camp, Red River, and Lamar. 
Discussion 
First and foremost, the maps demonstrate the need for statewide surveillance data in 
the human population to better determine populations at risk and whom to screen. However, 
in broad strokes, these maps begin to illustrate the systems-level and patient-level barriers 
and challenges to accessing and receiving care for CD. The CD cases reported to TDSHS are 
not homogenously dispersed throughout the state. Instead, clusters are depicted primarily in 
urban areas, where presumably there is increased access to physician care. Nonetheless, even 
with limited evidence, this dataset from TDSHS does show the potential for acquiring the 
infection through a vector: pockets of these locally-acquired cases were reported specifically 
in Bexar, Hidalgo, Brooks, and Cameron. However, no other areas, (i.e., the panhandle; 
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counties bordering Mexico; western Texas including the El Paso region; and the eastern 
parts) show locally-acquired infections. 
Some counties with a high burden of heart-related diagnosis also are indicative areas 
with CD diagnosis, as shown by the ICD codes and by the TDSHS CD-reported cases. The 
reasons for the congruence in these urban hubs—Bexar, Dallas, and Harris counties—are not 
only due to their respective overall populations, but also reflect the availability and ability of 
physicians in those counties to recognize the screen factors and move through the continuum 
of care in screening, diagnosing, and providing treatment to CD patients. However, as 
indicated from the findings of an upcoming manuscript, a physician’s awareness about CD, 
their inclination to consider risks in their patient population, and their knowledge on specific 
screening and diagnostic processes is limited, even in these urban geographies in which CD 
cases have been reported. 
Collectively, the heart-related diagnosis and age demographics indicate the possibility 
of missed CD diagnosis throughout the state. That is, a younger adult population with heart-
related complications is indicative various chronic conditions, including chronic Chagas 
cardiomyopathy (CCC). The fact that there are potentially missed diagnoses in counties that 
do not have a major Hispanic proportion of the total population—affects everyone and 
should be relegated to a disease of just immigrants. It also illustrates the potential challenge 
in certain populations not seeking access to medical care or having a physician available to 
correctly and timely diagnose CD. It also highlights the significance of imported CD cases 
that might go undiagnosed and untreated. Ultimately, the issue remains as to whether or not 
the individuals with heart-related were a missed diagnosis. That is, we cannot rule out with 
 65 
any level of confidence that any of those heart-related diagnoses were due to undiagnosed 
Chagas cardiomyopathy. 
CD is currently found throughout Texas, and there is a potential for local 
transmission.28 Five newly diagnosed CD patients are described in this 2015 case report.28 
All of these patients acquired CD locally and resided in rural Southeast Texas counties and 
were blood screened. This thus cements the possibility of persons currently not knowing that 
they have CD because not all cases are diagnosed. Thus physicians should not only be 
concerned about screening patients that come from countries where CD is endemic, but 
should consider local transmission in situations in which vector exposure is possible.  
Limitations 
This research has several limitations. This research is the first to examine statewide 
hospital records in order to qualify the potential for missed CD diagnosis in Texas. However, 
this research focused on potentially missed diagnosed cases of chronic Chagas, rather than 
including acute and indeterminate chronic forms of CD. Moreover, in examining chronic CD, 
the scope of this research was limited to CCC, rather than looking at other sequelae (i.e., 
gastrointestinal complications). Furthermore, establishing the criteria for missed diagnoses of 
CD was the greatest challenge, given the lack of research to inform specific risk factors that 
account for CCC. Thus the risk of misclassification is a concern. 
The data sources were another limitation. ICD-9 and ICD-10 heart-related and 
Chagasic diagnostic codes were not completely comparable given differences in their 
definitions. While ICD-10 denotes the disease progression (i.e., acute or chronic), there is no 
code specifying the indeterminate form of CD. In ICD-9 there is a code (086.2) that alludes 
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to the asymptomatic, indeterminate form (i.e., Chagas without mention or organ 
involvement). Similarly, among the heart-related diagnostics, there is a cardiomyopathy, 
excluding Chagas in ICD-9 code but not one for ICD-10. Between 2013 and August of 2015, 
a total of 21 records indicated Chagas without mention of organ involvement.  
Additionally, the Texas IPUDF was intended for administrative purposes and not 
intended for clinical or population health research. That is, there may be coding errors. For 
example, the difference in totals in Appendix D and E can be attributed to the hospitals not 
directly collecting the patient’s county of residence or suppressing the value if a county has 
fewer than five discharges for that quarter. The county of residence is assigned based on the 
patient’s zip code. For 2016, 45,008 ischemic cardiomyopathies were diagnosed but only 
43,597 patient records coded a county. Thus, the statewide patterns in reported and non-
diagnosed cases of CD from 2013 to 2016 are difficult to illustrate.  
Recommendations 
Future research can further explore the patterns of missed diagnoses within specific 
geographical targets (i.e., by examining and comparing urban and rural counties only in 
contrast to examining patterns throughout the state; or by examining differences in census 
tracts or zip codes). Furthermore, the case definitions for the missed CD diagnostic codes can 
be re-evaluated. For example, additional geospatial and statistical analyses can be performed 
on specific counties using only idiopathic cardiomyopathy diagnoses and comparing to other 
codes that accounted for the large number of heart-related diagnoses (e.g., other ischemic 
heart disease, ischemic cardiomyopathy, unspecified cardiomyopathy). Recent research, for 
example, show the promise of evaluating myocardial fibrosis using cardiac magnetic 
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resonance (CMR) as a predictor for CCC.113,114 As such, the ICD code for unspecified 
myocarditis (e.g., I51.4) from the Texas IPDF can be mapped alongside specific age intervals 
and other patient characteristics. Additional research can map the county demographics and 
more specific risk factors for CCC (i.e., by narrowing the age group).  
Secondly, the findings support the need for a surveillance system in the human 
population that would facilitate and increase the accuracy, validity, and generalizability of 
geospatial analysis. That is, maps that are created to illustrate the magnitude of CD cases in 
Texas would greatly benefit from epidemiological data that is specific to CD, rather than 
relying on administrative data such as the Texas PUDF.  
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Figures 
 
Results Figure 1: Reported Cases of Chagas Disease and County of Transmission, 2013 
to 2016. 
 
  
 69 
Results Figure 2: ICD Codes for Heart-Related Diagnosis, 2013 to 2016* 
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Results Figure 3a: Heart-Related ICD Diagnosis for 2013 
to 2016, * Hispanic Population** 
 
 
 
 
 
 
 
Results Figure 3b: Heart-Related ICD Diagnosis for 2013 
to 2016*, Population Aged 20 to 59 Years of 
Age 
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Results Figure 4: Chagas Disease and Heart-Related ICD Diagnostics Codes for 2013 to 
2016 
 
  
 72 
Results Figure 5: Heart-Related ICD Diagnostics Codes for 2013 to 2016, Adjusted by 
County Population 
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Introduction 
Chagas Disease (CD) is a neglected zoonotic disease1 of the Americas that can be 
fatal if not diagnosed and treated in its early stages. CD accounts for the highest burden of 
any parasitic disease in the 22 Latin American countries where it is endemic. T. cruzi is 
endemic throughout Central and South America and is found in North America, including in 
Mexico and in the Southern United States (U.S.).10 An estimated 8 million people in Latin 
America have CD.11 Over 28,000 people are infected each year in Mexico, Central America 
and South America, accounting for at least 12,000 deaths per year.12 
CD includes two main phases: acute and chronic.1,2 Acute infections occur up to the 
first two months of the initial infection, which may manifest with mild flu-like symptoms or 
febrile illness.31 Other symptoms may include: malaise, enlarged spleen, liver, and lymph 
nodes; localized or generalized edema; chagomas or breaks in the skin; and result in 
abnormal electrocardiogram (ECG).8 Acute infection may manifest as early as one week after  
exposure and may be self-limiting in most individuals.8 During the chronic stage, two 
presentations are possible: the indeterminate form, which is commonly asymptomatic; and 
the determinate which include cardiac (e.g., cardiomyopathy, heart failure, altered heart rate 
or rhythm) and intestinal complications2.  The majority of infected individuals (70%-80%)2,15 
will advance from the acute phase and remain in a latent or indeterminate chronic form of the 
disease (mostly asymptomatic), which may persist as a lifelong infection. The danger of this 
asymptomatic status is that once symptoms do manifest, eliminating the parasite becomes 
more difficult or impossible and often results in death. Conversely, only 20-30% of infected 
individuals will progress from the indeterminate chronic phase to a “clinically evident 
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disease” or chronic determinate phase, months to decades after becoming infected.15 Chronic 
determinate CD often corresponds to the organ involved (heart; esophagus; and/or colon): 
cardiac, digestive, or both.8 The digestive manifestation is typically found manly in South 
America or in persons infected in that region.8 Heart failure occurs usually towards the latter 
phase of Chagasic heart disease.8 Sudden death due to cardiac complications can occur.11 
For the scope of this study, heart-related symptoms were the primary focus, given that 
the digestive manifestation is a hallmark of South American infections. Some estimates 
considering that the Latino immigrant population is younger than the current U.S. population, 
suggest that, 10 – 15% of the total U.S. population (or 30,000 to 45,000 individuals) is living 
with undiagnosed CD cardiomyopathy.21 For the scope of this research, screening refers to 
the process by which HCP’s determine if further laboratory diagnostics are required. During 
the initial screening, the HCP discusses the patient’s medical history, “including questions 
about travel and living conditions,” and performs a physical examination and possibly an 
ECG.15,31 The diagnosing of CD represents the clinical and serological testing required to 
confirm the presence of T. cruzi. In the U.S., the CDC requires confirmatory laboratory 
diagnosis for T. cruzi using at least two different immunoassay procedures (i.e., enzyme-
linked immunosorbent assay [ELISA] and immunofluorescent antibody test) prior to 
treatment.15 At least two different serological tests are required given the lack of specificity 
and sensitivity obtained from one single procedure. Such laboratory assays are used to detect 
IgG or IgM antibodies to the parasite are available from major commercial laboratories (e.g., 
Mayo Medical Lab, ARUP, and Quest Diagnostics).45 Nonetheless, no standardized protocol 
(at the national, State, or local/county level) is available for physicians to reference when 
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attempting to request the laboratory codes. Recent statistical modeling demonstrates the 
value of screening Latin American immigrants in non-endemic countries.46 Women are 
recognized as a target population for community screening programs in non-endemic 
countries in Europe (e.g., Spain and Italy) due to the risk of transmitting the parasite to their 
children.47,48 No commercially-available rapid screening kit is available for HCP’s to 
routinely use that provide an immediate confirmatory results for T. cruzi. In contrast to other 
chronic diseases49 (i.e., type II diabetes, heart disease, cancer, etc.), screening and diagnosing 
for CD is not routinely performed.    
Due to the number of cases, its asymptomatic nature, urgency for early diagnosis and 
treatment and unknown prevalence in the U.S., CD should be a concern for HCP’s. Many 
physicians currently practice medicine within their subspecialty and in isolation from other 
HCP specialties.53 Even fewer communication exchanges occur with other scientists (i.e., 
veterinarians, entomologists, ecologists, policy scientists, etc.). The lack of collaboration and 
engagement may prevent the exchange of new ideas and innovations. In turn, this is a barrier 
for an accurate and timely diagnosis for a patient.53 Recent epidemiological trends in the 
vector, or in zoonotic populations, for example, can shed light about the potential threat to 
human health. As we move towards a healthcare model in which the patient, as the consumer, 
is more informed and encouraged to participate in decision-making process, he or she may be 
a stronger advocate to improve the likelihood of testing and diagnosis, rather than rely solely 
on the physician as the gatekeeper for information. It is unclear how medical training and 
continuing education among the various specialties and sub-specialties shape how individual 
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physicians receive, synthesize, and apply information regarding emerging or rare diseases 
like CD. 
CD is rarely diagnosed during the acute phase of the infection.23 The latency and 
asymptomatic nature of the disease may not prompt individuals to seek immediate medical 
consultation or treatment. Cultural beliefs and systemic barriers may also prevent or delay a 
patient from seeking medical care, particularly as documented in Central and South 
American groups.55,58 For instance, an individual distrusts the medical system, while a 
systemic barrier may include the lack of drugs or HCP’s.32,48,55,56 Individuals in impoverished 
communities in Latin America and in the U.S. lack health insurance or the means to access 
medical care, even if they wanted to get diagnosed and treated.57 These challenges are also 
reflected in the Latin American immigrants in the U.S. and other non-endemic countries. In 
rare occasions, individuals recognize the exposure to a kissing bug or develop clinical 
manifestations (i.e., a chagoma) that may prompt medical attention. Figure 7 summarizes 
some of the individual-level barriers. 
Due to the rarity in reporting autochthonous cases, there is still a lack of overall 
awareness among HCP’s in the U.S., including in Texas.23 HCP’s may consider CD only as a 
neglected tropical disease and not recognize the risk factors for local and acquired infections 
in Texas. They also may not consider their patients from Latin America or from mothers 
from Latin America at risk if they have never encountered the disease before and know very 
little about it.  
There are few comprehensive resources targeting HCP’s that illustrate the clinical 
criteria used to evaluate and diagnose CD.8,15 The TDSHS and the CDC have outlined 
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general recommendations for the clinical diagnosis and treatment of CD.2,15 However, there 
are no specific recommendations in Texas for HCP’s to target screening to Latin American 
immigrants or women of child bearing age. A patient profile could help frame the risks of 
exposure to guide HCP’s in deciding if further screening or serological testing is needed. No 
patient profile currently exists that identifies populations in Texas (or the U.S.) with a higher 
risk of exposure or transmission. Without such guidance, HCP’s may not perform a thorough 
medical history (i.e., discuss potential exposure to the vector and parasite).60-62 For example, 
the HCP’s may not ask the patient about travel history or previous place of residence. Thus, 
even if a HCP is more familiar or aware of CD, s/he may have limited experience in 
identifying infected individuals with the indeterminate form; performing clinical evaluations; 
ordering appropriate laboratory tests; or coordinating with health officials. Consequently, 
lack of awareness or experience may delay a patient from receiving adequate treatment. 
Infectious disease HCP’s are hypothesized to be the most aware of CD compared to 
cardiologists and family/ general practice physicians given their experience in diagnosing 
related parasitic diseases. Infectious disease HCP’s were thus a focal group since other 
general practice HCP’s may refer patients to them. Cardiologists were hypothesized to also 
be aware and knowledgeable of CD since the chronic phase of the disease involves heart-
related complications. However, in general, cardiologists may lack the awareness to 
recognize the acute or chronic asymptomatic CD cases and understand the importance or 
value of screening high risk populations. Cardiologists may facilitate the communication 
between other provider specialties, since they may be somewhat more familiar and aware of 
CD than other general practitioners. The research aim is to identify and describe gaps related 
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to knowledge, attitudes, and practices in the screening, diagnosis and treatment of CD among 
practicing physicians in Texas. Specifically, though a mixed methods approach, an online 
questionnaire to quantify and describe knowledge among specialists, including: cardiologists, 
infectious disease specialists and family practice physician; Conduct key informant 
interviews to explore the barriers to screening, diagnosis and treatment amongst physicians 
who have treated CD and those who have not treated CD 
Materials and Methods 
Questionnaire 
Study design and population 
The study design was cross-sectional, in which data was collected from three online 
questionnaires from July 5, 2018 through October 1, 2018. Having a baseline to quantify 
general knowledge on CD, as well as specific diagnostic procedures, practices, and overall 
attitudes on CD is crucial for the development of targeted HCP educational efforts and the 
dissemination of resources. 
Thus, similar to the recent study assessing CD awareness among Ohio HCP, the 
questionnaires focused on cardiologists, infectious disease specialists, and family care 
physicians. The rationale was that these providers as are more likely to provide medical care 
to most patients. Although primary care physicians and other primary healthcare workers 
such as physician assistant and nurse practitioners act as gate keepers in referring their 
patients to specialized care, due to time constraints and limited resources the scope of this 
research was only on licensed practicing physicians in Texas who were listed with a primary 
specialty in cardiology, family medicine/ general practice, or infectious disease medicine.  I 
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expected the sample will be representative and reflect the knowledge, attitudes, and beliefs of 
the targeted population, but findings may not be necessarily generalizable to all HCP’s in 
Texas. However, given, the design of this research, the findings will guide future research 
and outreach efforts for specific HCP populations and specific Texas geographical locations. 
In turn, this target population will engage with patients seeking primary care as a result of 
vector exposure, blood donation letters, or from exhibiting clinical symptoms.  
Instrument development 
A questionnaire was developed to describe: 1) the overall awareness of CD; 2) 
screening, diagnosis, and reporting procedures; 3) and risk and exposure factors specific to 
Texas. Questionnaires used to collect information related to knowledge, attitudes, and 
practices (KAP) have been used by the WHO, particularly in developing countries to better 
understand the community members’ perceptions about specific health concerns.76 Multiple 
choice items and ordered-category items (i.e., Likert scales) are ways to objectively assess 
the knowledge.77 
Prior to this research, no tool was available to assess Chagas KAP among physicians 
to measure specific domains (e.g., recognizing risk factors, performing screening and 
diagnostic practices, frequency of CD-related resources). Thus, specific questions were 
formulated to ensure physician attitudes about CD as well as their experience and self-
efficacy in making a CD diagnosis were captured. The questionnaire was tailored to the three 
clinically-focused specialties. Survey questions from published research62 as well as from an 
online continuing education course from the CDC78 were used to create the items. 
Questionnaire items included: physician demographics (i.e., practice type and years since 
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graduation); clinical manifestation; risk of transmission; and whether a Latin American 
immigrant population is served/ proportion served. The questionnaire will include both right/ 
wrong items as well as self-reported level of confidence scales.  
The three instruments were piloted among Texas Chagas Taskforce members, and 
practicing physicians (cardiologist, infectious disease specialist, and general practice 
provider), and non-CD experts to ensure reliability, validity of questions, and address any 
issues including completion time and ease of use across various platforms including smart 
phones. Follow-up meetings were conducted to discuss issues and revisions to questions and 
responses. For instance, after discussing with the physicians and other individuals who 
piloted the questionnaire, the response choices for various knowledge items were revised to 
eliminate similar or confusing answers, and thus make it easier to assess whether or not the 
concept was known to the physician.  
Sampling and recruitment 
Sampling and recruitment were achieved through contact and coordination with local, 
county, and statewide medical networks, societies and groups with access to physicians 
throughout San Antonio and the state (e.g., the Texas Medical Association, Bexar County 
Medical Society, Harris County Health, Metropolitan Health District, and TDSHS, the Bexar 
County Health Collaborative, UT Health in San Antonio, UTHealth Tyler Population Health 
at the UT System).  
Sample size 
In the past, TMA conducted two annual questionnaires that supported state and 
legislative advocacy efforts. A 2015 Questionnaire on meaningful use program for the Center 
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for Medicare and Medicaid Services (CMS) had a 4.96% (n= 543) response rate based on 
10,943 eligible participants.80 However, a 2016 questionnaire on electronic health record 
(EHR) usage and experiences with a sampling frame of 39,165 (Texas physicians with email 
address in the TMA database) had a lower response rate of 2.77% (n=1,084).81 Initially, 
response rate between 2.0 and 5.0% was expected. If the response rate within this range is 
not achieved, other professional medical societies will be contacted (i.e., Texas Infectious 
Disease Society; Texas Chapter of the American College of Cardiology).  
Data collection and management 
Qualtrics (Research Core), an online application, was used to design, manage, and 
implement the questionnaire.84 The questionnaires were anonymous and self-administered. 
Participants had a month to complete the questionnaire. The response rate was monitored 
weekly. The recorded responses from the Qualtrics repository were exported as a CSV file 
for each questionnaire. The raw dataset was managed using Microsoft Excel with each 
question response that was initially coded as text numerically recoded to dichotomous or 
categorical values. Individual data dictionaries were created for each questionnaire. Copies of 
the original data files were saved in order to facilitate corresponding changes. A Do file 
(using Stata) was created for each questionnaire to denote changes made to the original 
dataset. 
Among the 27 sampled ID specialists, 4 did not consent to participate and 3 
additional participants were not licensed by the TMB. One participant indicated that s/he was 
a cardiologist, so the responses were grouped in the cardiology group. A total of 34 
physicians were sampled for the family/ general practice questionnaire. Nine did not consent, 
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three additional participants were not licensed by the TMB, and one did not complete any 
questionnaire items other than the specialty. Thus a total of 11 ID specialists was excluded 
from the analysis. There were 11 sampled cardiologists (including the response from 
captured in the ID questionnaire), 6 of which did not consent and only 4 were licensed by the 
TMB. Only three were included in the analysis. 
Data analysis 
Descriptive statistics were calculated as frequencies and proportions using Stata 
(14.2).85 Pearson’s Chi square tests were used to compare differences in the response choice 
proportions (e.g., knowledge and attitude items), by physician group. Fisher’s exact test was 
used in cells with 5 or fewer counts. A p-value less than 0.05 was considered statistically 
significant. A summed index score77 for the correct knowledge items was created that ranged 
from 0 to 13. No partial credit was assigned for partially correct responses, rather a “1” was 
assigned for identifying the correct choice. 
Key Informant Interviews 
Study design and sampling 
The purpose of the semi-structured interviews was to explore specific domains 
quantified from the questionnaires. Initially a list of physicians (n= 24) that had treated CD 
patients was requested by the CDC. However, the CDC did not allow access to directly 
contact the physicians. Instead assistance was requested from the Texas Chagas Taskforce to 
identify and recruit physicians to participate as key informants. Four of the physicians listed 
were already part of the Taskforce and agreed to participate. An additional set of physicians 
(n= 10) were identified by taskforce member. Only half agreed to participate and confirmed a 
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date and time for the call. In total, 13 physicians were identified and recruited to participate 
using purposive, convenience, and snowball sampling, four of which indicated that they had 
not previously managed any type of care for a patient with CD. 
Interview questions  
As summarized by Padgett, the purpose of qualitative interviews is “to reveal key 
domains in which the experts add a top-down insider perspective that would otherwise be 
missed without their participation”.86 Physicians were asked about their practice: the number 
of years in their specialty; whether they practice in a rural or urban area; type of medical 
practice (i.e., hospital, private, teaching). They were asked to describe their medical 
education and if they had training or medical experience in any country that is endemic to 
CD. Physicians were prompted to discuss their experience(s) in managing the care to CD 
patients (as defined by the continuum from screening and diagnosis, to treatment, to follow-
up care) and elaborate on take-home messages, perceived barriers, and resources that helped 
them better understand CD. The script and guiding questions are shown in Appendix C. 
Recruitment 
Physicians listed in the sampling frame were emailed a brief description of the study. 
Once a physician agreed to participate, a follow-up email was sent to confirm the telephone 
interview. The informed consent and a summary of the key questions were attached in the 
email. A study identification number (Study ID) was assigned to each participant for each 
corresponding group.  The Study ID consisted of 4 digits. The first digit starting from the left 
referred to the physician specialty: 0 if unknown at the time (i.e., if HCP provided contact 
information at a workshop or from online questionnaire); 1 for infectious disease; or 2 for 
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cardiology. The next digit indicated whether the physician had treated for Chagas disease: 0 
if it was not known at the time the Study ID was described; 1 if they had treated CD patients; 
2 if they had not treated CD patients. Finally, the two out-right digits denoted the total 
sampling frame from 01 to 99.  
A Study Participant List was created that linked the study ID to the names and contact 
information of the participants. A copy of the KI tracking table is shown in Appendix G. The 
purpose was to ensure confidentiality but be able to link physicians to their form and follow-
up if needed. Initially, data collection was expected to conclude once saturation (i.e., “when 
additional analyses of the data bring redundancy and reveal no new information”86) was 
reached.87 Given the challenges in recruiting physicians especially those with no knowledge 
of CD, or experience in managing the care of a CD patient the resulting domains and 
sampling strategies were homogenous. Thus, saturation was reached faster than anticipated. 
Interviews were conducted from late June through the end of August of 2018. 
Data collection and management 
Interviews ranged from 12 to 45 minutes in duration. All twelve were digitally 
recorded and securely stored. The script was used to guide the discussion. Notes were written 
down notes during the interview on the form, which were then scanned and securely stored 
electronically and managed via NVivo for Mac, 88 which is a qualitative data analysis (QDA) 
software used “to store data and facilitate coding and analysis.”86 All of the twelve key 
informants (KI) audio recordings were transcribed by Adept Word Management Inc. 
(https://adeptwordmanagement.com/). The audio transcripts were emailed back as Word files 
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and stored in NVivo. Inaudible sections were reviewed by the PI to ensure the KI’s message 
was accurately reflected. 
Data analysis 
A grounded theory (GT) approach was used to guide the thematic analysis of the 
participant’s feedback. GT is an approach that was first described by Glaser and Strauss86,89 
in 1967 for qualitative research with the goal of developing “new, contextualized theories”90 
that explain a “process, an action, or an interaction shaped by the views of a large number of 
participants.”91 A GT approach was relevant for this research given the lack of existing 
frameworks or models to explain the uptake of information among physicians regarding CD 
risk factors in the U.S. and its screening and diagnostic procedures.  
GT involves “inductive coding from the data, memo writing to document analytic 
decisions, and weaving of theoretical ideas and concepts without permitting them to drive or 
constrain the study’s emergent findings.”86 The salient feature with this approach is that the 
data drives the emergence of themes (i.e. inductive) rather than relying on other research to 
describe the phenomenon or use “prefigured codes or themes” from the existing literature.91 
Themes or categories are “broad units of information that consist of several codes aggregated 
to form a common idea.”91 
Using NVivo, field notes, guides/ scripts, and the audio transcriptions were reviewed. 
Cases were defined as the KI participants and coded accordingly. Descriptive themes were 
developed initially as primary nodes. The nodes were reviewed and compared to identify 
patterns. Axial coding was performed after the interviews were open-coded. Emerging 
themes were identified to describe the experiences in participating physicians that lead to 
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screening and diagnosing CD and thus having an increased awareness (i.e., the identification 
of the core phenomenon denoted in GT). Finally, selective coding was used to weave in the 
codes and propose hypotheses to describe the links between strategies (i.e., the actions taken 
in response to the core phenomenon); the causal conditions (i.e., the factors leading to the 
core phenomenon); the contextual and intervening factors (i.e., the broad and specific factors 
that influenced the strategies); and the outcomes. 
Results 
Knowledge, Attitudes, and Practices from Questionnaires 
Participant demographics 
Initially, a total of 71 physicians were sampled: 10 for cardiology; 34 for family/ 
general practice; and 27 infectious disease specialists. After excluding respondents who were 
not eligible to participate (i.e., did not consent to participate; or not licensed by the Texas 
Medical Board) and who did not respond to any other questionnaire items other than the 
consent, a total of 43 individual physician responses was analyzed: 21 (48.8%) for family/ 
general practice; 19 (44.2%) for infectious disease; and 3 (7.0%) for cardiology. Over 37% 
(n= 16) were female and the median age was 51. Over 41% (n= 18) indicated that they 
primarily practiced medicine in a teaching hospital in contrast to 5 who practiced medicine in 
a private setting. More than 65% (n= 28) practiced in urban areas. Almost a third of 
participants (n= 14) indicated that they had 20 years of experience in their respective 
specialty. The demographic characteristics by physician specialty are summarized in Table 1.  
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Attitudes on Chagas disease 
General attitudes: Although the majority of participants indicated that they believed 
that CD is under diagnosed in Texas (a combined 76.7% of those that either strongly agreed 
or somewhat agreed, n= 33), nearly 19% (n= 8) were ambivalent. Similarly, whether CD is 
potentially misdiagnosed, 14% (n= 6) did not have an opinion for or against, yet the majority 
agreed with the statement. More participants (nearly third, n= 14) disagreed that in Texas, 
diagnosis and treatment of CD is relatively easy and with few barriers, while a quarter (n= 
11) had no opinion about this statement. The difference between groups was statistically 
significant in that ID specialists were more likely to have some degree of disagreement as 
compared with general or family physicians. Over a third of family or general practice 
physicians disagreed to some extent that their training prepared them to recognize patients 
who many need to be screened. In contrast, two-thirds of ID specialists believed that their 
training allowed to recognize patients. Table 2 shows the breakdown for each attitudinal and 
Likert item, by physician specialty.  
Confidence in screening and diagnosing skills: Collectively, nearly 70% were 
confident in identifying risk factors for CD in patients. ID specialists were more confident, 
compared to family/ general practice physicians and cardiologists. Nearly all of the ID 
specialists surveyed (94.7%, n= 18) were confident (either somewhat or very) in being able 
to recognize the vector compared to only 43% of family physicians that reported any 
confidence in doing so. Overall, 23% of participants were not confident in recognizing the 
vector. When asked about confidence in obtaining social history, few indicated having no 
confidence at all (11%, n= 5). More than half (53%, n= 23) reported having no confidence in 
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requesting the Current Procedural Terminology laboratory codes for diagnosing CD. 
Moreover, less confidence was reported in coordinating with local and health departments or 
contacting the CDC in managing the care of a CD patient, 42% and 40% respectively. The 
complete list of agreement items is shown in Table 3. 
Additional screening attitudes 
Family/ general practice: Among the 21 physicians who completed the general/ 
family practice questionnaire, there were differences in opinion regarding the screening and 
the diagnosis, in which 38% had neutral attitudes towards being able to either screen or 
diagnose through their family practice. Table 4 shows the responses. These items were only 
asked in this questionnaire. 
Infectious disease specialists and cardiologists: Three additional items were asked 
in the ID specialist and cardiologist questionnaires, as shown in Table 5. This included 1 
agreement and two confidence questions. There was a total of 22 respondents but up to 7 
(28%) did not provide a response. When asked if they routinely screened who present with 
risk factors, 40% (n= 10) disagreed somewhat. However, 64% (n= 16) had confidence in 
their skills to continue to provide follow-up medical care to CD patients. In contrast, 
physicians were more likely to be less confident in using an ECG to screen and diagnose for 
chronic CD—28% (n= 7) with no confidence. 
Management of patients 
Blood donation letter: Physicians who completed the ID and the cardiology 
questionnaires were asked to rank the processes or steps in coordinating care to a potential 
patient with a blood donation letter (i.e., Table 6). Both groups prioritized obtaining social 
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history of patient. While ID specialists indicated that they would consult with the CDC last, 
two cardiologists indicated instead that they would coordinate with local or TDSHS last. 
Exposure to vector: Similarly, family/ general practice physicians were asked to 
rank their priorities when managing the care of a patient who may have been exposed to a 
triatomine vector. Nearly 62% indicated that they would obtain the patient’s social history 
first and almost 48% reported that they would follow-up with antitrypanosomal treatment 
last. Findings are shown in Table 7. 
Other specialty attitudes 
Risk factors: Among the ID specialists, nearly half were neutral on whether CD 
patients are more likely to present with comorbidities than non-CD patients (Table 8). 
Knowledge 
Correct responses, common items: the correct responses for the common 
knowledge questions are shown in Table 9.  Appendix Table 1 details the full responses and 
questions. Collectively, the least correctly answered item was regarding treatment options 
(#12), in which 9% (all 4 of whom were ID specialists) indicated that benznidazole had been 
approved by the FDA in children, yet nifurtimox still required CDC investigational protocol. 
In contrast, nearly 70% (n= 30) were knowledgeable on the clinical manifestations of chronic 
cardiomyopathy (item #8). Less than 40% (n= 17) correctly answered that the seropositive 
results from two different immunoassays and/ or PCR performed at the CDC are the methods 
required for confirmatory diagnosis of CD (item # 11). Moreover, nearly 40% were unsure 
about the total number of reported CD cases to TDSHS (appendix results Table 1). 
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Indexed scores: the descriptive statistics for the summed scores for the common 
knowledge items are shown in Table 10. ID specialists scored the highest, with a mean 
unadjusted score of 69 compared to 37 among family/ general practice physicians. 
Screening knowledge among infectious disease specialists and cardiologists: two 
additional questions on screening knowledge were asked in the ID and cardiologist 
questionnaires. Less than a third (n= 6) correctly identified all of the clinical disorders that 
may present in the development of chronic Chagas cardiomyopathy (table 11). Nearly 41% 
(n= 9) correctly indicated that a complete physical examination, ECG, and a detailed history 
are important elements of the clinical evaluation of a newly diagnosed chronic CD patient 
who is asymptomatic. 
Additional knowledge for infectious disease specialists: Table 12 shows the 
variance in response choices, in which over a fifth (n= 4) correctly identified the typical 
manifestations of chronic Chagas cardiomyopathy, although more than half (n= 10) did not 
provide a response. A higher proportion of ID specialists selected all of the possible cardiac 
examination findings but more than half correctly answered the reactivation concern.  
Additional knowledge for cardiologists: Table 13 illustrates the responses for the 3 
cardiologists regarding additional screening.  
Practices 
Overview: Only 7 participants indicated that they directly screened and/or confirmed 
a diagnosis for Chagas in patients in their medical care in Texas in the past five years, all of 
whom were ID specialists. Three indicated that they had managed the care of a CD patient 
who was referred to care from a blood donation. When asked about the frequency of 
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considering CD exposure risks, 23% never considered a mother or sibling with CD, 26% 
never considered the history of the patient’s blood transfusions/ organ transplants, and 21% 
never considered the patient’s travel history to areas where Chagas is endemic. Preferred 
resources for medical information included medical websites (23% always referred to 
websites such as Up to Date or Medline Plus) compared to TDSHS communiques or TMA 
emails that were never used by 21% of respondents. 
Practices, exposure risks consideration, all questionnaires: all participants were 
asked to report the consideration of four CD exposure risks (Table 14). Non-response was a 
large proportion for each item. In general, overall frequency was rare or never, but the 
differences were noted when examining the ID group, in which more frequently reported 
considering mother or sibling with CD, history of blood transfusions, and travel to CD-
endemic countries as exposure risks.  
Usage of resources: When asked to indicate the frequency of resources referenced to 
review information on CD, participants overall used medical website more often than any of 
the other resource, including local or county health department or TDSHS websites or alerts 
from TMA, which are never used by 12% of physicians.  
In addition to asking about the frequency of resources, physicians were asked about 
their likelihood in using other resources to learn more about CD (Table 16). Over a quarter 
(n= 11) would use courses as the means to learn more about CD; nearly 28% (n= 12) would 
use seminars; and 23% (n=10) would specifically use manuals. The highest proportion, 30% 
(n= 13), indicated that they would use other resources. Among ID specialists, 42% (n= 8) 
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identified other resources as: websites; live meetings or CME; online resources to streamline 
treatment; web-based materials; webinars; and brief communications.  
Direct screening and diagnosis practices: A total of 7 ID’s reported that they had 
directly screened and/ or confirmed a diagnosis for CD disease in patients in their medical 
care in Texas over the last 12 months. Two ID specialists reported screening and testing in 1 
patient to confirm diagnosis; one indicated screening 15 to 20 patients; and one ID specialist 
screened 2 patients. Two consulted with local our county health departments in the past year, 
compared to 4 that coordinated with the CDC to confirm a CD disease diagnosis. Participants 
who completed the family practice and cardiology questionnaires did not directly screen or 
confirm a CD diagnosis in Texas in the past year; same was true for the cardiologists. From 
those that did screen, we asked them to report the frequency of coordinating with the CDC: 
almost half (3 out of 7) always did (compared to 3 that were not sure or that did not respond). 
Three also indicated that they always coordinated with the local/ county health departments 
(Q611 and 613). Comments regarding the screening and diagnosing of patients are shown in 
Table 17. 
Feedback regarding practices: Table 18 shows the feedback from the ID specialists 
when asked to comment about their experience in confirming a CD diagnosis, obtaining and 
coordinating treatment for patients, and in coordinating with local and state health 
department officials. Half of the comments describe barriers in regards to the testing and 
diagnostics; two allude to barriers in treatment; and one about the challenges in coordinating 
care of a CD patient with local and state health department officials. 
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Practices when a patient is exposed to a vector: Only 1 physician indicated that 
they had at least one patient in the last five years that were exposed to the vector (Q65). Thus 
it is hard to present the practices reported (e.g., Q66_1 to Q66_13), nonetheless they 
indicated that they: 1) often perform physical examinations; b) rarely request laboratory 
diagnostics; c) always reviewed the travel history; d) often performed other screening 
differential diagnoses; e) often referred to ID; and f) sometimes consulted with TDHS to 
confirm vector and presence of parasite. 
Blood donation letter practices among family physicians: Among those that 
completed the family practice/ general physician questionnaire, none indicated that they had 
provided care to a Chagas disease patient with a blood donation letter. Thus, there are no 
responses for Q64.  
Blood donation letter practices, infectious disease specialists: the results are 
shown in Table 19, in which only 3 had experience managing the care of a patient with a 
positive CD diagnosis from a blood donation screening. All three indicated that they always 
reviewed the patient’s travel history and requested the serology to confirm the CD diagnosis. 
One reported to have often evaluated the patient’s cardiopulmonary function (i.e., performing 
a stress test), while another reported having performed this procedure as only sometimes, and 
1 never has performed it. Two always performed cardiovascular testing to assess myocardial 
damage and one reported to sometimes perform this procedure. The ID specialists who have 
managed patients referred from a blood screening letter were more likely to consult with 
CDC than with the TDSHS to coordinate the patient’s treatment. 
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Blood donation letter practices, cardiology:  None of the three participants reported 
that they had provided care to CD patients with a blood donation letter over the past five 
years. 
Screening practices for patients with idiopathic cardiomyopathy: Respondents to 
the ID and the cardiologist questionnaires were asked to report the frequency of screening 
procedures for patients presenting with idiopathic cardiomyopathy (Table 20). Non-responses 
accounted for a large proportion in each of the four items. Physicians were more likely to 
review travel history, look for signs of cardiac arrhythmias, and perform cardiovascular 
testing in patients with idiopathic cardiomyopathy more frequently than they were to evaluate 
cardiopulmonary function. 
Feedback from Key Informants  
A total of 12 physicians participated: 10 were conducted via telephone and 1 
physician was interviewed in person. One physician emailed brief responses since they were 
not available to participate via telephone. With the exception of one physician, the remaining 
10 physicians were eager and very enthusiastic to discuss their perspectives and share their 
insight. Appendix G denotes the participant’s characteristics with their names redacted.  
Participant demographics 
Table 21 summarizes KI demographics. Most (61%, n= 8) were infectious disease 
specialists, 4 cardiologists, and 1 family provider. Seventy-seven percent had managed care 
to CD patients. There were slightly more KI participants that were male, and on average had 
been practicing for almost 12 years. The overall majority (84%, n= 11) practiced within an 
institution and were located either in San Antonio, Houston, or Dallas. Four indicated that 
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they had medical training or experience in Mexico, Central America, or South America. On 
average, physicians who had managed the care of CD patients had seen six patients in Texas. 
Major categories 
After open and axial coding, 5 major categories emerged which included: knowledge 
on CD; other perspectives on CD in Texas; physician practices on CD; barriers to care/ 
management of CD patients; and recommendations to improve awareness. Not surprising, the 
richest data were in the knowledge among physicians, their practices, and barriers.  
Attitudes, awareness and knowledge 
Participants indicated that their peers had limited awareness and knowledge overall 
on CD, but also regarding the need to screen and diagnose their patients. There was a 
consensus that CD “might not be on their radar.” More specifically, their colleagues may not 
necessarily be aware of the risk for local CD transmission in Texas. According to a 
cardiologist, “we need to start thinking of this no longer just as a disease of underdeveloped 
countries or—endemic areas outside of the US, but really begin to think of it as a disease 
that’s more prevalent in the US, although rare.” The reasons for this lack of awareness or 
limited knowledge was attributed to lack of experience and training. Some indicated that CD 
was not part of their medical curriculum. 
Participants reflected on their experiences that contributed to their better 
understanding of CD and how it translated to their scope of practice after they had managed 
the care of a patient. For ID specialists, for example, CD was either not part of their training 
or had very limited emphasis. However, all of the participants that had managed the care of a 
CD patient reiterated how that experience was the most helpful in considering CD diagnosis 
 100 
afterwards, and in feeling more confident in performing the screening, diagnostics, or where 
to access the information needed to streamline the process. As summarized by an ID 
specialist, “the more you see it, the more comfortable you’ll be.” In addition to professional 
experience augmenting their knowledge and confidence in screening, diagnosing, and 
treating patients, participants indicated how colleagues influenced their level of awareness 
and knowledge.  
Specific knowledge in screening, serology, clinical manifestations (i.e., what to look 
for), and local transmission in Texas was gained after managing a CD case. One cardiologist 
elaborated that:  
The biggest thing that I learned is about the serology because I think we told 
one of those patients that, “No, we did a confirmatory test. You actually do 
have Chagas.” And then we, of course, had to go back and say, “Well, it turns 
out our confirmatory test was the same one you had before. And they were 
both false-positives.” I think if there’s anything that I can say that I learned 
that is extremely important, it’s that about the commercial test being possibly 
the same thing. 
Physician practices in the management of CD patients 
Several physicians cited Up to Date as a main resource to review screening and 
evaluation criteria for CD. Some referenced the CDC training module. An ID specialists said 
she reviewed the Mandell, Douglas and Bennett’s Principles and Practice of Infectious 
Diseases. Peer-reviewed journals including The New England Journal of Medicine, The 
Journal of the American College of Cardiology, and the Journal of the American Medical 
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Association, which had published the 2007 systematic review on the evaluation and 
treatment of Chagas disease in the United States15were additional resources. Several 
recognized the value of accessing CDC staff experts to confirm diagnosis and coordinate 
treatment. For one of the interviewed cardiologists, having the CDC as a resource “available 
to me was critical to my being able to manage the patient.” 
Through their anecdotal experiences, physicians became more aware and 
knowledgeable, and thus more inclined to consider a CD diagnosis in their patients. An ID 
specialist detailed the following: 
So what we have done is if they have a positive screen test then we bring them 
over, we do history and physical, we focus on how many lived outside of the 
country, have lived in the more classic endemic areas, had mothers that were 
born in those areas, had history of having received a blood donation, lived in 
substandard housing, or had exposure to hunting and camping and fishing 
and outdoor kinds of activities; whether they have dogs on their property, 
whether they have seen reduviid bugs or whatever. So we kind of get into all 
that history, and we do a basic physical exam and do an EKG with a thirty-
second rhythm strip just so we have it already, and then we—in the same visit, 
we just go ahead and draw CDC-confirmatory testing and send that off. So 
when we started this, that was like a later thing, and we would get RIPA first, 
and if the RIPA was negative, then we were done. 
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Barriers 
At the systems-level, limited access to medical care and health insurance gaps in 
covering the patient’s screening and diagnostics were some of the key barriers identified by 
participating physicians. Additionally, several indicated the lack of available physician 
resources including screening guidelines and protocols to improve screenings in populations 
at highest risk of CD. There were frequent remarks on the administrative challenges in 
accessing the antitrypanosmal drugs to prescribe to their patients. There were concerns on the 
specificity and sensitivity of screening and diagnostics. The limited epidemiological evidence 
was another barrier. Finally, few indicated that their exposure and training on CD during 
their Examples of the physicians’ feedback on barriers are shown in Table 22. 
Regarding barriers at the physician level, themes emerged regarding the lack of 
awareness about CD in general or about the risk for local transmission in Texas. Participants 
commented on how physicians in Texas have limited knowledge on CD, which in turn 
translates to a lack of confidence and expertise in screening and diagnosing patients. Finally, 
given the patient demographics, physicians were asked about their proficiency in speaking 
Spanish. The majority acknowledged that they could “get by” but in most cases would need 
to request a translator to interpret to discuss the details of the screening procedures or the 
treatment.  
Finally, though not prompted, several participants provided patient-specific socio-
cultural barriers such as refusal of medical treatment due to lacking “respect for this 
disorder”. This theme was expanded to a separate category reflecting physicians’ 
perspectives in which their patients did not fully understand CD. That is, their patients did 
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not understand that the asymptomatic phase may progress to life-threatening complications if 
left untreated. The adverse physiological complications and interactions with the treatment 
were cited as a patient barrier. 
Participant recommendations 
Increasing education among physicians was the most detailed and frequently 
discussed recommendation. Strategies to achieve that include revising the undergraduate 
medical education curriculum so that students gain more depth and understand that CD is not 
relegated to a tropical infectious disease that is of concern for specific patient populations in 
Texas. Another approach to increasing education in providers about CD is to engage the 
public, leadership within the health system, and policymakers. Concerned patients, as 
described by the participants, can be the vehicle of change to prompt unaware physicians to 
refer to the literature and other CD resources and become more knowledgeable. In contrast, 
another physician recommended that leadership within hospital, for example, can disseminate 
FAQ’s and other memos that highlight the importance of considering CD in certain 
populations or remind physicians about the possibility of local transmission.  
A few physicians proposed a peer-to-peer model in which CD experts within their 
respective field can “take the mantle for this cause” and help raise the awareness. In turn, 
specific outreach efforts include peer-review journals that are specific to those medical 
specialties that are more likely to be reviewed by those physicians. The proposed 
recommendations also highlighted not just the importance of educating providers, but having 
materials, resources, and the research that is up to date and accessible to physicians. Many 
indicated the need for epidemiological surveillance and research within the human 
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population to gain a better understanding of risks and prevalence. Findings from these 
research activities can be presented at focused conferences that will pique the interest of 
attendees and thus leave an impression. Participation can be incentivized with continued 
medical education credit. 
In addition to presenting research at conferences, another approach that was discussed 
was story telling: 
The other way to get uptake and change people’s behavior is by story-telling 
which is not evidence-based, so we tend not to gravitate to it. But if we have a 
couple of big-name cases, like if there were somebody willing to put this on 
television. 
Two physicians indicated the value in social media and web-based approached to 
education. Similar to conferences, physicians in rural or isolated communities would benefit 
from webinars. Another physician proposed raising awareness about CD via Facebook ads, 
that can be targeted for very specific populations. Thus, these recommendations reflect the 
need to address the barriers discussed in the previous section. 
Discussion 
There were differences in the level of CD knowledge by physician specialty and by 
domains. As hypothesized, ID specialists had a greater grasp on the nuances of CD and were 
more confident than family providers. The low response rate for the cardiologist 
questionnaire did not allow for meaningful comparisons across all three physician groups. 
However, the qualitative data from the cardiologists interviewed suggests that their peers are 
generally unaware of CD and have limited knowledge on screening and diagnostic 
 105 
procedures (i.e., “I don't know that Chagas disease has registered in the minds of my heart 
failure colleagues, perhaps, the level that it should”). 
In general, most questionnaire participants believed that CD is currently under 
diagnosed in Texas, but no consensus was reached regarding the ease of diagnosing and 
treating patients. ID specialists perceived this as a barrier, which was statistically significant, 
as compared to the family/ general practice physicians. Frequent references to the 
complexities in diagnosing patients from the KI feedback support this finding. Thus 
physicians perceive there are challenges and barriers to being able to screen and diagnose CD 
patients.  
ID specialists were statistically more likely to report a higher confidence in their 
training, which was further explored in the interviews, that despite the “peripheral” training 
they received they had the “tools” given how “not uncommon for us to encounter a disease 
for the very first time”. No surprising, ID specialists were thus confident in their skills 
including in recognizing the risk factors and vectors, which was supported by the statistically 
significant differences. Their knowledge scores support the increased level of knowledge 
among ID specialists (i.e., a mean of 69.2% compared to 37.0% among family practice 
physicians). Findings from Stimpert and Montgomery (2010) corroborate the ID specialists’ 
increased knowledge.62  
The utilization of physician resources on CD was further described by the qualitative 
data and is congruent with findings from the questionnaires. In general physicians do not 
reference materials disseminated by state or county health departments, but instead prefer 
websites such as Up to Date, CDC resources, and peer-reviewed articles. Moreover, there 
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seems to be some reluctance in coordinating with local and state level officials, perhaps as a 
result of the experiences. As one physician there was “an abundance of paperwork” that 
might a barrier. Another physician indicated that the health departments should provide 
“assistance in diagnosis and in obtaining drugs for treatment.” The qualitative data did not 
provide additional insight into this because the key informants, even though the majority had 
experience managing the care of patients, did not provide any feedback about working with 
local and county health departments. 
These findings, particularly the feedback from the KI, complement the work by 
Forsyth (2017)56 and Manne-Goehler et al (2015)115 in contextualizing the barriers to 
screening, diagnosing, treatment of CD. Although the focus was on barriers in Latin 
American communities and the U.S. respectively, parallels can be drawn that explain the 
possibility for missed CD diagnosis in Texas. Accessing treatment was identified as barrier 
among the KI, but was considered a significant barrier by some of the questionnaire 
participants. However, the questions regarding the current treatment drugs and 
recommendations were the most incorrectly answered knowledge items, suggesting the need 
to educate physicians on these and thus a patient receiving treatment remains a barrier. 
Moreover, KI discussed socio-cultural patient barriers that are also highlighted as salient 
barriers that prevent the patient from engaging in the health system, including the failure in 
recognizing CD as a potentially life-threatening condition, or distrust in the system. Even if 
the patient has access to a physician, and the physician recognizes the clinical manifestations 
or the risk factors, and is thus willing and inclined to screen and diagnose, the patient may 
eventually refuse treatment. 
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Strengths and limitations 
This is the first exploratory mixed methods study that examined differences in 
knowledge, attitudes, and practices among physician groups. While other research has 
collected KAP on CD among physicians, no studies to date have focused on examining 
physicians in Texas. Through the grounded theory approach and qualitative research design, 
further insights were discovered among this hard to reach population. However, sampling 
and recruiting physicians represented the biggest challenge for this study. Due to the lack of a 
sampling frame, the research employed snowball sampling. As such, coverage and response 
bias were of concern. Physician networks were consulted to recruit our participants. Thus our 
samples were in more likelihood, already physicians with some knowledge or interest in CD. 
Recommendations 
Future research is needed to address and describe and explore the reasons for CD 
remaining under-recognized by physicians and perceptions regarding whether or not CD is a 
problem in Texas. Recommendations from physicians encompass top-down and ground level 
strategies to improve the awareness and education, that engage both the provider, patients, 
and other key stakeholders (i.e., policymakers). One interesting specific recommendation was 
that key CD experts in their respective specialties serve as “ambassadors” to raise awareness 
and educate other physicians. 
Implications 
 Follow-through on the recommendations outlined by KI will likely improve the 
awareness and knowledge among Texas physicians. This study provides a rudimentary 
baseline on which to continue to expand further research and documents the anecdotal 
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experiences on physicians. Additional hypotheses-driven research framed with probability 
sampling can better quantity differences in KAP, particularly among cardiologists and 
physicians with limited experience managing the care of CD patients, and among physicians 
practicing in rural counties. 
Conclusion 
Results from the questionnaires and feedback from key informants illustrate the 
opportunity to continue to increase the level of knowledge regarding CD in Texas. 
Specifically, there are knowledge gaps in understanding the screening and diagnostic 
processes as well as the treatment. Physician input is also invaluable in guiding how to best 
disseminate the latest clinical knowledge to physicians to ensure uptake and maintenance 
(i.e., consideration of certain CD risk exposures in their patient population).   
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Tables and Figures 
 
Results Table 1: Participant Demographics, by Completion of Specialty 
Questionnaire  
 
Demographic 
Characteristic 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 
(%) 
Infectious 
Disease 
n= 19 
(%) 
Cardiology 
n= 3 
(%) 
Primary physician 
Specialty     
Infectious Disease 18 (41.9)       0 18 (94.7)    0 
General / Family 
Practice 17 (39.5) 17 (81.0)       0    0 
Cardiology 3 (7.0)       0       0 3 (100.0) 
Secondary physician 
specialty     
Pediatrics 3 (7.0)   3 (14.1)       0    0 
Immunology 2 (4.7) 1 (4.8) 1 (5.3)    0 
Age, 
Mean (S.D.) 51.1 (16.59) 48.5 (13.30) 50.2 (16.54) 52.5 (9.19) 
Sex     
Female 16 (37.2) 10 (47.6) 5 (26.3) 1 (33.3) 
Male 15 (34.9)  6 (28.6) 7 (36.8) 2 (66.7) 
No response 12 (27.9)  5 (23.8) 7 (36.8)     0 
Medical setting     
Teaching 18 (41.9) 9 (42.3) 7 (36.8) 2 (66.7) 
Community 6 (14.0) 5 (23.8)      1 (5.3)     0 
Private 5 (11.6)      2 (9.5) 3 (15.8)     0 
No response 14 (32.6) 5 (23.8) 8 (42.1) 1 (33.3) 
Geographical setting     
Urban 28 (65.1) 14 (66.7) 12 (63.2) 2 (66.7) 
Rural 2 (4.7) 2 (9.5) 0     0 
No response 13 (30.2)   5 (23.8) 7 (36.9) 1 (33.3) 
Years in practice     
< 5   7 (16.3)   4 (19.1) 3 (15.8)     0 
5 to 10 3 (7.0)       0 2 (10.5) 1 (33.3) 
10 to 15 3 (7.0) 2 (9.5)      1 (5.3)     0 
15 to 20 2 (4.7) 1 (4.8)      1 (5.3)     0 
> 20 14 (32.6)   8 (38.1) 5 (26.3) 1 (33.3) 
No response 14 (32.6)   6 (28.6) 7 (36.8) 1 (33.3) 
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Demographic 
Characteristic 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 
(%) 
Infectious 
Disease 
n= 19 
(%) 
Cardiology 
n= 3 
(%) 
Hispanic population 
served, Mean (S.D.) 51.0 (27.19) 45.5 (27.31) 55.9 (28.9) 63.0 (4.24) 
Medical training     
Mexico 1 (2.3) 1 (4.8)      0     0 
South America 2 (4.7)       0 2 (10.5)     0 
Have directly screened or 
confirmed a diagnosis for 
CD 
7 (16.3)       0 7 (36.8)     0 
Received patients via 
blood donation letters 3 (7.0)       0 3 (15.8)     0 
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Results Table 2: Responses to Agreement Items, All Questionnaires  
 
Questionnaire Item 
Total 
 
n= 43 (%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 (%) 
Cardiology 
n= 3 (%) p-value* 
CD is under diagnosed in Texas      0.501 
Strongly agree   17 (39.5)  7 (33.3) 9 (47.4) 1 (33.3)  
Somewhat agree  16 (37.2)  7 (33.3) 8 (42.1) 1 (33.3)  
Neither   8 (18.6)  6 (28.6) 1 (5.3) 1 (33.3)  
Somewhat disagree 2 (4.7) 1 (4.8) 1 (5.3)     0  
Strongly disagree        0         0         0     0  
No response        0         0         0     0  
CD is potentially misdiagnosed     0.494 
Strongly agree  16 (37.2) 7 (33.3)   8 (42.1) 1 (33.3)  
Somewhat agree  19 (44.1) 9 (42.9)   8 (42.1) 2 (66.7)  
Neither   6 (14.0) 5 (23.8) 1 (5.3)     0  
Somewhat disagree 2 (4.7)        0   2 (10.5)     0  
Strongly disagree        0        0         0     0  
No response        0        0                0     0  
Process required to confirm is complex and 
time consuming     0.237 
Strongly agree  6 (14.0) 2 (9.5)  4 (21.1)     0  
Somewhat agree 22 (51.2) 10 (47.6) 11 (57.9) 1 (33.3)  
Neither  9 (20.9)   7 (33.3) 1 (5.3) 1 (33.3)  
Somewhat disagree  5 (11.6) 2 (9.5)  2 (10.5) 1 (33.3)  
Strongly disagree 1 (2.3)         0 1 (5.3)     0  
No response        0         0         0     0  
Few barriers in order to diagnose or treat     <0.05 
Strongly agree 1 (2.3) 1 (4.8)         0     0  
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Questionnaire Item 
Total 
 
n= 43 (%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 (%) 
Cardiology 
n= 3 (%) p-value* 
Somewhat agree 7 (16.3)   4 (19.1)   2 (10.5) 1 (33.3)  
Neither 11 (25.6)   9 (42.9) 1 (5.3) 1 (33.3)  
Somewhat disagree 17 (39.5)   5 (23.8) 11 (57.9) 1 (33.3)  
Strongly disagree  7 (16.3) 2 (9.5)   5 (26.3)     0  
No response 0         0         0     0  
Accessing treatment is not a barrier for their 
patient population     0.772 
Strongly agree 4 (9.3) 1 (4.8) 2 (10.5) 1 (33.3)  
Somewhat agree 12 (27.9)   6 (28.6) 5 (26.3) 1 (33.3)  
Neither 10 (23.3)   6 (28.6) 3 (15.8)  1 (33.3)  
Somewhat disagree 13 (30.2)   7 (33.3) 6 (31.6)      0  
Strongly disagree 3 (7.0) 1 (4.8) 2 (10.5)      0  
No response 1 (2.3)         0        1 (5.3)      0  
Training prepared physician to recognize 
patients who may need to be screened     <0.005 
Strongly agree  6 (14.0)        0  6 (31.6)     0  
Somewhat agree 14 (32.6) 4 (19.1)  8 (42.1) 2 (66.7)  
Neither 4 (9.3) 3 (14.3) 1 (5.3)     0  
Somewhat disagree 13 (30.2) 12 (57.1) 1 (5.3)     0  
Strongly disagree 4 (9.3) 2 (9.5) 1 (5.3) 1 (33.3)  
No response 2 (4.7)         0   2 (10.5)     0  
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Results Table 3: Responses to Confidence Items, All Questionnaires  
 
Questionnaire Item 
Total 
 
 
n= 43 (%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
 
n= 19 (%) 
Cardiology 
 
 
n= 3 (%) 
p-value* 
Confidence in identifying risk factors     <0.005 
Very confident  11 (25.6)  3 (14.3)   7 (36.8) 1 (33.3)  
Somewhat confident 19 (44.2)  8 (38.1) 11 (57.9)     0  
Not at all confident 10 (23.3)  8 (38.1)         0 2 (66.7)  
No response 3 (7.0) 2 (9.5) 1 (5.3)     0  
Confidence in recognizing the vector     <0.005 
Very confident 16 (37.2)   3 (14.3) 11 (57.9) 2 (66.7)  
Somewhat confident 14 (32.6)  6 (28.6)   7 (36.8) 1 (33.3)  
Not at all confident 10 (23.3) 10 (47.6)         0     0  
No response 3 (7.0) 2 (9.5) 1 (5.3)     0  
Confidence in obtaining social history     0.098 
Very confident 17 (39.5)   5 (23.8) 11 (57.9) 1 (33.3)  
Somewhat confident 19 (44.2) 10 (47.6) 7 (36.8) 2 (66.7)  
Not at all confident 5 (11.6)   5 (23.8)        0     0  
No response 2 (4.7) 1 (4.8) 1 (5.3)     0  
Confidence in requesting the Current 
Procedural Terminology laboratory codes for 
diagnosing CD 
    0.309 
Very confident 2 (4.7) 1 (4.8) 3 (15.6)     0  
Somewhat confident 13 (30.2)   5 (23.8) 7 (36.8)     0  
Not at all confident 23 (53.5) 14 (66.7) 7 (36.8) 2 (66.7)  
No response 4 (9.3) 1 (4.8) 2 (10.5) 1 (33.3)  
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Questionnaire Item 
Total 
 
 
n= 43 (%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
 
n= 19 (%) 
Cardiology 
 
 
n= 3 (%) 
p-value* 
Confidence in coordinating and following-up 
with the CDC when consulting about a CD 
patient 
    0.081 
Very confident  8 (18.6) 2 (9.5) 6 (31.6)     0  
Somewhat confident 13 (30.2)  6 (28.6) 7 (36.8)     0  
Not at all confident 18 (41.9) 12 (57.1) 4 (21.1) 2 (66.7)  
No response 4 (9.3) 1 (4.8) 2 (10.5) 1 (33.3)  
Confidence in contacting and coordinating 
with the local and/or state health department 
when consulting about a CD patient 
    <0.05 
Very confident 8 (18.6) 2 (9.5) 6 (31.6)     0  
Somewhat confident 14 (32.6)  6 (28.6) 8 (42.1)     0  
Not at all confident 17 (39.5) 12 (57.1) 3 (15.8) 2 (66.7)  
No response 4 (9.3) 1 (4.8) 2 (10.5) 1 (33.3)  
 115 
Results Table 4: Attitudes of Family or General Practice Physicians Questionnaire 
 
Questionnaire Item n= 21  (%) 
Screening for CD is possible through my general or 
family practice  
Strongly agree 2 (9.5) 
Somewhat agree   7 (33.3) 
Neither   8 (38.1) 
Somewhat disagree   4 (19.1) 
Strongly disagree                    0 
No response                    0 
Diagnosis of CD is possible through my general or 
family practice 
 
Strongly agree 2 (9.5) 
Somewhat agree   7 (33.3) 
Neither   8 (38.1) 
Somewhat disagree   4 (19.1) 
Strongly disagree                    0 
No response                    0 
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Results Table 5: Attitudes of Infectious Disease Specialists and Cardiologists  
 
Questionnaire Item 
Total 
 
n= 22 (%) 
Infectious 
Disease 
n= 19 (%) 
Cardiology 
n= 3 (%) p-value* 
Routinely screen for CD in patients who present with risk 
factors     0.523 
Strongly agree   3 (12.0) 3 (15.8) 0  
Somewhat agree   6 (24.0) 5 (26.3) 1 (33.3)  
Neither 1 (4.0)      1 (5.3) 0  
Somewhat disagree 10 (40.0) 9 (47.4) 1 (33.3)  
Strongly disagree          0 0 0  
No response 5 (20.0) 1 (5.3) 1 (33.3)  
Confidence in continuing to provide follow-up medical care to 
CD patients    <0.05 
Very confident   6 (24.0)   6 (31.6) 0  
Somewhat confident  10 (40.0) 10 (52.6) 0  
Not at all confident 2 (8.0) 1 (5.3) 2 (66.7)  
No response   7 (28.0)   2 (10.5) 1 (33.3)  
Confidence in using electrocardiogram (ECG) to screen and 
diagnose for chronic CD 
   0.263 
Very confident   3 (12.0)  2 (10.5) 1 (33.3)  
Somewhat confident 10 (40.0) 10 (52.6) 0  
Not at all confident 7 (28.0) 6 (31.6) 2 (66.7)  
No response 5 (20.0)       1 (5.3) 0  
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Results Table 6: Priorities* for Managing Care in Blood Donation Letter Patient 
 
Statement Infectious Disease 
n=19 (%) 
Cardiology  
n= 3 (%) 
Coordinate with local or DSHS 4th (42.1) 5th (66.7) 
Consult with CDC 5th (57.9) 4th 66.7) 
Perform physical evaluation and additional 
testing 
2nd (42.1) 2nd (66.7) 
Confirm diagnosis via commercial serology 3rd (31.6) 3rd (66.7) 
Obtain history 1st (52.6) 1st (66.7) 
*Only the largest proportion out of the total sample for each statement is shown, from most 
important (#1) to least (#5) 
 
Results Table 7: Priorities* for Managing Care for a CD Patient Potentially Exposed to a 
Vector  
 
Statement Family  
n= 21 (%) 
Obtain history 1st (61.9) 
Consult with Texas DSHS for guidance on screening and diagnosis 
protocol 
2nd (57.7) 
Request serology testing from a commercial laboratory 3rd (33.3) 
Perform other differential diagnosis and refer patient to infectious 
disease specialist if necessary 
4th (33.3) 
Initiate anitrypanosomal treatment 5th (47.6) 
*Only the largest proportion out of the total sample for each statement is shown, from most 
important (#1) to least (#5) 
 
Results Table 8: Attitudes among Infectious Disease Specialists 
 
Questionnaire Item Infectious Disease n= 19 (%) 
CD patients are more likely to present with 
comorbidities than non-CD disease patients  
Strongly agree 0 
Somewhat agree 4 (21.1) 
Neither 9 (47.4) 
Somewhat disagree 5 (26.3) 
Strongly disagree 0 
No response 1 (5.3) 
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Results Table 9: Summary of Correct Knowledge Items, All Questionnaires 
 
Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 
(%) 
Infectious 
Disease 
n= 19 
(%) 
Cardiology 
n= 3 
(%) 
p-value 
#1. Vector transmission     <0.005 
Feces 23 (53.5)   6 (28.6) 15 (79.0) 2 (66.7)  
Incorrect or non-responses 20 (46.5) 15 (71.2) 4 (21.1) 1 (33.3)  
#2. Common route of 
transmission in the US     
0.083 
Vector exposure while 
residing in Mexico, Central 
or South America 
29 (67.4) 11 (52.4) 16 (84.2) 2 (66.7) 
 
Incorrect or non-responses 14 (32.6) 10 (47.6) 3 (15.8) 1 (33.3)  
#3. Total number of 
reported CD cases to DSHS     
1.00 
Between 75 and 100   7 (16.3)   4 (19.1) 3 (15.8) 0  
Incorrect or non-responses 36 (83.7) 17 (81.0) 16 (84.2) 3 (100.0)  
#4. Clinical course for CD     <0.005 
Acute for 1-8 weeks after 
exposure, asymptomatic for 
decades in most; 
symptomatic in a few 
21 (48.8) 7 (33.3) 14 (73.7) 0 
 
Incorrect or non-responses 22 (51.2) 14 (66.7) 5 (26.3) 3 (100.0)  
#5. Characteristic symptoms 
for acute phase of CD     
0.729 
All of the above 23 (53.5) 10 (47.6) 11 (57.9) 2 (66.7)  
Incorrect or non-responses 20 (46.5) 11 (52.4)   8 (42.1) 1 (33.3)  
#6. Proportion of patients 
with chronic CD that 
develop symptoms 
    
<0.05 
Between 20 and 40% 14 (32.6)   3 (14.3) 11 (57.9) 0  
Incorrect or non-responses 29 (67.4) 18 (85.7) 8 (42.1) 3 (100.0)  
#7. Symptoms that may 
develop in patients with 
chronic CD disease 
    
0.331 
All of the above 28 (65.1) 13 (61.9) 14 (73.7) 1 (33.3)  
Incorrect or non-responses 15 (34.9)   8 (38.1) 5 (26.3) 2 (66.7)  
#8. Chronic CD 
cardiomyopathy possible 
manifestations 
    
0.101 
Any of the above 30 (69.8) 13 (61.9) 16 (84.2) 1 (33.3)  
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 
(%) 
Infectious 
Disease 
n= 19 
(%) 
Cardiology 
n= 3 
(%) 
p-value 
Incorrect or non-responses 13 (30.2)   8 (38.1) 3 (15.8) 2 (66.7)  
#9. Screening and diagnosis 
steps     
0.708 
All of the above 26 (60.5) 13 (61.9) 12 (63.2) 1 (33.3)  
Incorrect or non-responses 17 (39.5)   8 (38.1) 7 (36.8) 2 (66.7)  
#10. Social history needed to 
assess potential route of 
exposures 
    
0.628 
All of the above 27 (62.8) 13 (61.9) 13 (68.4) 1 (33.3)  
Incorrect or non-responses 16 (37.2)   8 (38.1) 6 (31.6) 2 (66.7)  
#11. Method for confirming 
CD diagnosis      
0.090 
Seropositive results from 2 
different immunoassays 
and/ or PCR performed at 
the CDC 
17 (39.5)   5 (23.8) 11 (57.9) 1 (33.3) 
 
Incorrect or non-responses 26 (60.4) 16 (76.2) 8 (42.1) 2 (66.7)  
#12. Treatment drugs     0.074 
Second and third choices 
only 4 (9.3) 0 4 (21.1) 0 
 
Incorrect or non-responses 39 (90.7) 21 (100.0) 15 (78.9) 3 (100.0)  
#13. Treatment patient 
recommendations     
0.110 
Always recommended for 
patients up to age 18 and 
generally recommended for 
patients aged 18 to 50 
12 (27.9) 3 (14.3) 8 (42.1) 1 (33.3) 
 
Incorrect or non-responses 31 (72.1) 18 (85.7) 11 (57.9) 2 (66.7)  
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Results Table 10: Summary of Correct Knowledge Items and Scores, All Questionnaires 
 
Questionnaire Item 
Total 
 
 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 
(%) 
Infectious 
Disease 
 
n= 19 
(%) 
Cardiology 
 
 
n= 3 
(%) 
Total* Raw Score**     
Mean 7.9 4.8 9.0 4.0 
Median 8.0 6.0 10.0 4.0 
S.D. 3.06 4.09 3.22 0 
Total Percentile Score     
Mean 60.6 37.0 69.2 30.8 
Median 61.5 46.2 76.9 30.8 
S.D. 23.59 31.49 24.8 0 
Adjusted Raw Score n= 34 n= 15 n= 17 n= 2 
Mean 7.0 6.7 8.7 4.0 
Median 6.5 7.0 9.0 4.0 
S.D. 3.62 3.17 3.08 0 
Adjusted Percentile Score n= 34 n= 15 n= 17 n= 2 
Mean 53.6 51.8 67.0 30.8 
Median 50.0 53.8 69.2 30.8 
S.D. 27.8 24.4 23.67 0 
*For all questionnaire participants including those with non-responses 
** Score range: 1013 (i.e., lowest to highest correct number of responses). Observations with a 
total score of 0 were excluded. S.D.: Standard Deviation. Refer to Appendix for the question and 
the full response options. 
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Results Table 11: Knowledge on Screening for Cardiologists and Infectious Disease 
Specialists 
 
Questionnaire Item Total n= 22 (%) 
Infectious 
Disease 
n= 19 (%) 
Cardiology 
n= 3 (%) 
In addition to heart failure, major 
clinical disorders that manifest 
frequently and concurrently to 
chronic Chagas cardiomyopathy 
 
  
Cardiac arrhythmias 11 (50.0) 10 (52.6) 1 (33.3) 
Thromboembolism (systemic and 
pulmonary) 0 
0 0 
Chest pain syndrome 0 0 0 
**All of the above   6 (27.3)   5 (26.3) 1 (33.3) 
Not sure 1 (4.5) 1 (5.3) 0 
No response   4 (18.2)   3 (15.8) 1 (33.3) 
What are the important elements of 
the clinical evaluation of a newly 
diagnosed chronic CD patient who is 
asymptomatic? 
 
  
Complete physical examination, 
complete blood count, and 
chemistry panel 
0 0 0 
♦Complete physical examination, 
electrocardiogram (ECG) with 30 
second rhythm strip, and a detailed 
history 
9 (40.9) 8 (42.1) 1 (33.3) 
Complete physical examination, 
ECG with 30 second rhythm strip, 
chest radiograph, barium swallow, 
and detailed history 
4 (18.2) 
4 (21.1) 0 
None of the above 0 0 0 
Not sure 1 (4.5) 0 1 (33.3) 
No response 8 (36.4) 7 (36.8) 1 (33.3) 
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Results Table 12: Specific Knowledge and Indexed Scores for Infectious Disease 
Specialists 
 
Questionnaire Item n = 19 (%) 
In general, which of the following is typical of chronic CD 
cardiomyopathy? 
 
Right bundle branch block   5 (26.3) 
Ventricular tachycardia 1 (5.3) 
Left anterior fascicular block 1 (5.3) 
♦All of the above  4 (21.1) 
Not sure 0 
No response 10 (52.6) 
In patients with chronic CD cardiomyopathy, cardiac 
examination typically demonstrates which of the following? 
 
Murmurs of mitral and / or tricuspid regurgitation 0 
Wide splitting of the second heart sound due to right bundle 
branch block 
3 (15.8) 
A prominent diffuse apical thrust 0 
♦All of the above  5 (26.3) 
Not sure  4 (21.1) 
No response 10 (52.6) 
Reactivation of CD is a concern for patients who:  
Are chronically infected and are receiving immune-suppressive 
treatment because of organ transplantation 0 
Are chronically infected and have HIV/AIDS 2 (10.5) 
Are chronically infected and receive a live0attenuated 
influenza vaccine 0 
♦First and second responses only 10 (52.6) 
Not sure 0 
No response 10 (52.6) 
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Results Table 13: Specific Knowledge for Cardiologists 
 
Questionnaire Item* n= 3  (%) 
Which of the following are typical of Chagas cardiomyopathy 
as evaluated using electrocardiograph? 
 
♦Right bundle branch block often associated with left anterior 
hemiblock, ST-T changes, abnormal Q waves, various degrees 
of AV block, sick sinus syndrome, and low QRS voltage 
1 (33.3) 
Mainly conduction abnormalities including first-degree AV 
block, left bundle0branch block, and non0specific 
interventricular conduction delays 
0 
Right bundle0branch block only 0 
None of the above 0 
Not sure 1 (33.3) 
No response 1 (33.3) 
In patients with chronic CD cardiomyopathy, cardiac 
examination typically demonstrates which of the following? 
 
Murmurs of mitral and / or tricuspid regurgitation 0 
Wide splitting of the second heart sound due to right bundle 
branch block 
1 (33.3) 
A prominent diffuse apical thrust 0 
♦All of the above 0 
Not sure 1 (33.3) 
No response 1 (33.3) 
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Results Table 14: Consideration of Risk Factors, Frequency by Physician Specialty 
 
Questionnaire Item: Exposure Risk Total n= 43 (%) 
Family or 
General Practice 
n = 21 (%) 
Infectious 
Disease 
n = 22 (%) 
Cardiology 
n= 3 (%) 
Mother or sibling with CD     
Always 3 (7.0) 1 (4.8) 3 (15.8) 0 
Often 2 (4.7) 0 2 (10.5) 0 
Sometimes 3 (7.0) 0 3 (15.8) 0 
Rarely   8 (18.6) 5 (23.8) 3 (15.8) 0 
Never 10 (23.2) 7 (33.3) 1 (5.3) 2 (66.7) 
No response 16 (37.2) 8 (38.1) 7 (36.8) 1 (33.3) 
History of blood transfusions     
Always 3 (7.0) 0 3 (15.8)  
Often 1 (2.3) 0 1 (5.3) 0 
Sometimes   6 (14.0) 1 (4.8) 5 (26.3) 0 
Rarely  7 (16.6) 5 (23.8) 2 (10.5) 0 
Never 11 (25.6) 8 (38.1) 1 (5.3) 2 (66.7) 
No response 15 (34.9) 7 (33.3) 7 (36.8) 1 (33.3) 
Travel to Mexico, Central, or South America     
Always   5 (11.7) 1 (4.8) 4 (21.1) 0 
Often 2 (4.7) 0 2 (10.5) 0 
Sometimes   7 (16.3) 1 (4.8) 5 (26.3) 1 (33.3) 
Rarely   5 (11.6) 4 (19.1) 1 (5.3) 0 
Never  9 (20.9) 8 (38.1) 0 1 (33.3) 
No response 15 (34.9) 7 (33.3) 7 (36.8) 1 (33.3) 
Consumption of food or drinks contaminated with the 
parasite     
Always 1 (2.3) 1 (4.8) 0 0 
Often 1 (2.3) 0 1 (5.3) 0 
Sometimes 4 (9.3) 1 (4.8) 2 (10.5) 1 (33.3) 
Rarely   5 (11.6) 4 (19.1) 1 (5.3) 0 
Never 17 (39.5) 8 (38.1) 8 (42.1) 1 (33.3) 
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Questionnaire Item: Exposure Risk Total n= 43 (%) 
Family or 
General Practice 
n = 21 (%) 
Infectious 
Disease 
n = 22 (%) 
Cardiology 
n= 3 (%) 
No response 15 (34.8) 7 (33.3) 7 (36.8) 1 (33.3) 
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Results Table 15: Resources Physicians Reference when Managing Care of a Patient with 
CD 
 
Usage of Resources 
Total 
n= 43 
(%) 
Family/ 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n=19  
(%) 
Cardiology 
n= 3  
(%) 
Medical websites (e.g., Up to 
Date, Medline Plus)   
  
Always 10 (23.3) 7 (33.3) 2 (10.5) 1 (33.3) 
Often 9 (20.9) 4 (19.1) 5 (26.3) 0 
Sometimes 5 (11.6) 1 (4.8) 4 (21.1) 0 
Rarely 0 0 0 0 
Never 2 (4.7) 2 (9.5) 0 0 
No response 17 (39.5) 7 (33.3) 8 (42.1) 2 (66.7) 
Official local or county 
health department websites   
  
Always 1 (2.3) 1 (4.8) 0 0 
Often 3 (7.0) 2 (9.5) 2 (10.5) 0 
Sometimes 13 (30.2) 6 (28.6) 6 (31.6) 1 (33.3) 
Rarely 3 (7.0) 1 (4.8) 2 (10.5) 0 
Never 5 (11.6) 4 (19.1) 1 (5.3) 0 
No response 17 (39.5) 7 (33.3) 8 (42.1) 2 (66.7) 
TDSHS website     
Always 1 (2.3) 1 (4.8) 0 0 
Often 1 (2.3) 5 (23.8) 1 (5.3) 0 
Sometimes 8 (18.6) 3 (14.3) 5 (26.3) 0 
Rarely 6 (14.0) 2 (9.5) 3 (15.8) 1 (33.3) 
Never 5 (11.6) 3 (14.3) 2 (10.5) 0 
No response 17 (39.5) 7 (33.3) 8 (42.1) 2 (66.7) 
The CDC website     
Always 8 (18.6) 4 (19.1) 3 (15.8) 1 (33.3) 
Often 9 (20.9) 4 (19.1) 5 (26.3) 0 
Sometimes 5 (11.6) 2 (19.1) 3 (15.8) 0 
Rarely 0 0 0 0 
Never 2 (4.6) 2 (9.5) 0 0 
No response 17 (39.5) 7 (33.3) 8 (42.1) 2 (66.7) 
Official communiques and 
health alerts from TDSHS   
  
Always 2 (4.7) 1 (4.8) 1 (5.3) 0 
Often 1 (2.3) 0 1 (5.3) 0 
Sometimes 11 (25.6) 5 (23.8) 6 (31.6) 0 
Rarely 5 (11.6) 2 (9.5) 2 (10.5) 1 (33.3) 
Never 9 (20.9) 6 (28.6) 1 (5.3) 2 (66.7) 
No response 15 (34.9) 7 (33.3) 8 (42.1)  
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Usage of Resources 
Total 
n= 43 
(%) 
Family/ 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n=19  
(%) 
Cardiology 
n= 3  
(%) 
Email alerts from TMA     
Always 1 (2.3) 1 (4.8) 0 0 
Often 2 (4.7) 1 (4.8) 1 (5.3) 0 
Sometimes 6 (14.0) 3 (14.3) 2 (10.6) 1 (33.3) 
Rarely 8 (18.6) 4 (19.1) 4 (21.1) 0 
Never 9 (20.9) 5 (23.8) 4 (21.1) 0 
No response 17 (39.5) 7 (33.3) 8 (42.1) 2 (66.7) 
MMWR     
Always 0 0 0 0 
Often 2 (4.7) 0 2 (10.5) 0 
Sometimes 7 (16.3) 1 (4.8) 6 (31.6) 0 
Rarely 9 (20.9) 6 (28.6) 3 (15.8) 0 
Never 8 (18.6) 7 (33.3) 0 1 (33.3) 
No response 18 (41.9) 7 (33.3) 9 (42.1) 2 (66.7) 
 
Results Table 16: Likelihood of Resources Used to Learn More about Chagas Disease 
 
Resources Total n= 43 (%) 
Family/ 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n=19 (%) 
Cardiology 
n= 3 (%) 
Courses 11 (25.6) 6 (28.6) 4 (21.1) 1 (33.3) 
Seminars 12 (27.9) 6 (28.6) 4 (21.1) 2 (66.7) 
Manuals 10 (23.3) 6 (28.6) 4 (21.1) 0 
Other 13 (30.2) 5 (23.8) 8 (42.1) 0 
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Results Table 17: Screening and Diagnosis Practices among Infectious Disease 
Specialists 
 
Screening and Diagnosing Practices n= 19 (%) 
Method(s) used to screen for CD  
Physical assessment  3 (15.8) 
12-lead electrocardiogram  2 (10.5) 
Patient’s medical and social history  5 (26.3) 
Lab method(s) used to confirm CD diagnosis  
PCR performed at the CDC   3 (15.8) 
Commercial antibody testing using ARUP 2 (9.1) 
Commercial antibody testing using Mayo Medical Lab 0 
Commercial antibody testing using Quest Diagnostics 1 (5.3) 
Commercial antibody testing using Labcorp 1 (5.3) 
Not sure   2 (10.5) 
Consultation and coordination with:  
Local/ county health department  2 (10.5) 
The CDC  4 (21.1) 
Classification of cases  
Acute 0 
Chronic indeterminate 3 (15.8) 
Chronic cardiomyopathy 2 (10.5) 
Chronic gastrointestinal 0 
Other 0 
Not sure  2 (10.5) 
Source of transmission  
Locally0acquired 1 (5.3) 
Imported   2 (10.5) 
Not sure   3 (15.8) 
Missing 1 (5.3) 
Referred to other specialties  
Yes (all to cardiology) 3 (15.8) 
No 3 (15.8) 
Missing          1 (5.3) 
Referred by other specialties  
Yes (family med; internal; cardiology) 4 (21.1) 
No 2 (10.5) 
Not applicable—did not screen or diagnose 13 (68.4) 
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Results Table 18: Additional Comments Regarding Screening Practices 
 
Additional Comments (#) Comment 
Experience in confirming a 
CD diagnosis (Q6.6) 
“More than one serological test type, PCR, not finding 
circulating typomastigotes, not finding cardiac amstigotes 
(biopsy)”  
Experience obtaining and 
coordinating treatment for 
patients (Q6.12) 
“I have found many patients with evidence of some form of CD 
disease in Central America (a project)” 
Experience in coordinating 
with local and state health 
department 
“Abundant paperwork” 
 “Assistance in diagnosis and in obtaining drugs for treatment” 
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Results Table 19: Frequency of Procedures in Patients Referred from a Blood Donation 
Letter 
 
Questionnaire Item: Procedure Infectious Disease n= 19 (%) 
Review the patient’s travel history  
Always 3 (15.8) 
Often 0 
Sometimes 0 
Rarely 0 
Never 0 
Did not provide care to a patient with blood donation latter 16 (84.2) 
Request serology to confirm diagnosis  
Always  3 (15.8) 
Often 0 
Sometimes 0 
Rarely 0 
Never 0 
No response 16 (84.2) 
Evaluate patient’s cardiopulmonary function (i.e., exercise stress 
test)  
Always 0 
Often 1 (5.2) 
Sometimes 1 (5.2) 
Rarely 0 
Never 1 (5.2) 
No response 16 (84.2) 
Perform cardiovascular testing to assess myocardial damage  
Always   2 (10.5) 
Often 0 
Sometimes 1 (5.2) 
Rarely 0 
Never 0 
No response 16 (84.2) 
Consult with TDSHS to manage treatment  
Always 1 (5.2) 
Often 0 
Sometimes 1 (5.2) 
Rarely 1 (5.2) 
Never 0 
No response 16 (84.2) 
Consult with the CDC to manage treatment  
Always   2 (10.5) 
 Often 1 (5.2) 
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Questionnaire Item: Procedure Infectious Disease n= 19 (%) 
Sometimes 0 
Rarely 0 
Never 0 
No response 16 (84.2) 
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Results Table 20: Frequency of Procedures when Presenting with Idiopathic 
Cardiomyopathy among Cardiologists and Infectious Disease Specialists 
 
Questionnaire Item: Procedure 
Total 
n= 22  
(%) 
Infectious 
Disease 
n= 19  
(%) 
Cardiology 
n= 3  
(%) 
Review the patient’s travel history    
Always   4 (18.2)   4 (21.1) 0 
Often   4 (18.2)   4 (21.1) 0 
Sometimes   3 (13.6)   2 (10.5) 1 (33.3) 
Rarely 1 (4.5) 1 (5.3) 0 
Never 1 (4.5) 0 1 (33.3) 
No response   9 (40.9)   8 (42.1) 1 (33.3) 
Look for signs of cardiac arrhythmias 
that may arise due to chronic Chagas 
cardiomyopathy 
   
Always   4 (18.2) 3 (15.8) 1 (33.3) 
Often   4 (18.2) 4 (21.1) 0 
Sometimes   3 (13.6) 3 (15.8) 0 
Rarely 1 (4.5) 1 (5.3) 0 
Never 2 (9.1) 1 (5.3) 1 (33.3) 
No response   8 (36.4) 7 (36.8) 1 (33.3) 
Evaluate patient’s cardiopulmonary 
function (i.e., exercise stress test)    
Always 1 (4.5) 0 1 (33.3) 
Often 1 (4.5) 1 (5.3) 0 
Sometimes   8 (36.4) 7 (31.6) 1 (33.3) 
Rarely 2 (9.1) 2 (10.5) 0 
Never 1 (4.5) 1 (5.3) 0 
No response 10 (45.5) 9 (47.4) 1 (33.3) 
Perform cardiovascular testing to assess 
myocardial damage    
Always   5 (22.7) 3 (15.8) 2 (66.7) 
Often 2 (9.1) 2 (10.5) 0 
Sometimes   6 (27.3) 6 (31.6) 0 
Rarely 1 (4.5) 1 (5.3) 0 
Never 0 0 0 
No response 8 (36.4) 7 (36.8) 1 (33.3) 
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Results Table 21: Key Informant Demographics 
 
Characteristic 
Total 
n= 13 
(%) 
Managed 
CD Care 
n= 10 
(%) 
Had Not 
Managed CD 
Care 
n= 3 
(%) 
p-value 
Specialty    0.245 
Infectious disease  8 (61.5) 7 (70.0) 1 (33.3)  
Cardiology  4 (30.8) 3 (30.0) 1 (33.3)  
Family practice 1 (7.7) 0 1 (33.3)  
Sex    0.563 
Male 7 (53.9) 5 (50.0) 2 (66.7)  
Female 6 (46.2) 5 (50.0) 1 (33.3)  
Years in specialty    - 
Mean, (S.D.) 11.8 (9.52) 11.9 (10.73) 11.3 (5.03)  
Practice setting    0.577 
Institution 11 (84.6) 8 (80.0) 3 (100.0)  
Community clinic 2 (15.4) 2 (20.0) 0  
City    0.738 
San Antonio 6 (45.2) 5 (50.0) 1 (33.3)  
Houston 5 (38.5) 3 (30.0) 2 (66.7)  
Dallas 2 (15.4) 2 (20.0) 0  
Training in endemic 
countries    
- 
Mexico 1 (7.7) 1 (10.0) 0  
Central America   2 (15.4) 0 2 (66.7)  
South America 1 (7.7) 1 (10.0) 0  
Number of CD patients    - 
Mean, (S.D.)  6.4 (8.04)   
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Results Table 22: Perceived Barriers Preventing the Management of Care for Patients with Chagas Disease 
 
Level Theme Example(s) of Participant Feedback 
System 
Limited access to medical 
care 
He doesn’t even live in a place with an ID doctor. He lives in the middle of nowhere in 
rural west Texas. 
 
Lack of insurance to cover 
diagnostic or screening tests 
Not every Texan is going to be able to receive—just due to, I think, maybe insurance 
approvals 
 
In other areas where people don’t have access to that insurance, and you can’t get an EKG 
or an echo or even see a provider—like you were saying, in rural areas 
 
No clear and up to date 
guidelines, protocols, and 
patient risk profile resources 
When rare stuff comes up that they’re not used to looking at when they’re doing blood 
donor screening or something, there are guidelines about what to do with HIV testing, 
Hepatitis B testing, and Hepatitis C testing. You can look this up, but it’s kind of hard to 
figure out if you don’t know where to look. Like, what am I supposed to do with this? 
 
I think the most important message is that although you may not have seen Chagas Disease 
in your practice before, there are patients out there walking around with indeterminate 
Chagas Disease, and it’s not a false-positive necessarily 
 
Well, I think that the biggest that I faced in regards to diagnosis is—determining which 
children should be screened for Chagas disease. There are certain high-risk situations that I 
think—definitely weren’t testing. 
 
Physician access to 
pharmaceutical drugs 
I think the biggest challenges for us were—on accessing the medications. 
 
It would be optimal for me, being in a teaching hospital, if it were on a formulary so that I 
could just say, “Give me some benznidazole.” 
 
Well, I guess I would say that the only real problem—getting the drug was the biggest 
challenge 
 
Lack specificity and 
sensitivity in screening and 
diagnostic tools 
What I’m amazed is sort of the screening tests and how neither sensitive nor specific they 
are. 
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Level Theme Example(s) of Participant Feedback 
Now barriers in screening are a—I guess are a concern is the right word regarding the 
sensitivity and specificity of commercially available test 
 
Lack of epidemiological 
evidence 
EPI surveillance is pricey and not available—not systematically available with Chagas 
 
Outdated education during 
undergraduate medical 
education suggesting that CD 
should not be considered in 
the U.S. 
The education that I had about Chagas disease as limited in medical school—medical 
school training—was that Chagas disease was not generally a disease present in the United 
States and if it were present, the cardiac manifestations are not likely to be present before 
adulthood, therefore on those two bases, that most of my patients are, in fact, from the U.S. 
and virtually none of them are in the twenty plus age range, that it's simply not a 
consideration. So, that—that was my attitude and opinion before I became sensitized to 
Chagas. 
Physician 
Limited knowledge or 
expertise to screen and/ or 
diagnose 
Sort of—not neglected only in the sense of a tropical disease being neglected, but also 
neglected by physicians in the difference of diagnosis, it’s kind of funny. So with that, I 
don’t think there’s a huge expertise. 
 General unawareness 
I don't know that Chagas disease has registered in the minds of my heart failure colleagues, 
perhaps, the level that it should. 
 
But I would still say of people and most physicians—they would—be unaware of some of 
it. I’m just—the more I learn with <<researcher name redacted>>, the more intrigued I am 
of the lack of awareness of the disease. 
 
Not knowing CD is in Texas 
and local transmission 
They were not from an endemic area but were hunters between me and you and San 
Antonio—from Aliceville, from some other rural areas—who had tested positive but had 
not traveled outside the country. But then people were kind of interested in that component 
of it. And I think that they were not aware—of a potential local-acquisition disease. 
 
Most doctors know of Chagas disease, but especially because we don’t see it a whole lot in 
Texas, some people might not—that might not be on their radar. 
 
I don't know that Chagas disease has registered in the minds of my heart failure colleagues, 
perhaps, the level that it should. 
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Level Theme Example(s) of Participant Feedback 
 
Language as a communication 
barrier 
Definitely language barriers—absolutely—would be difficulties in patients, you know, 
receiving additional care, additional imaging I think, from a cardiovascular perspective, as 
well. 
Patient Patient refusing treatment 
I think barriers, with respect to patients not having a respect for this disorder and this 
disease— 
 
So this one—the patient who had early cardiomyopathy, he might’ve still been a candidate 
for treatment because it was really super mild, but he lived in the middle of nowhere in the 
Valley. He was getting out of the Air Force. He was not all that motivated anyway to get 
treated with months of non-FDA-approved drugs 
 
Patient fearing to engage in 
the health system 
definitely like racial barriers, they’re definitely just like social barriers or just, I think—I 
think the fear of patients who may be not appropriately documented, you know, seeking 
out care and that, you know, them limiting the chance of them being screened and 
diagnosed 
 
Patient not understanding or 
“respecting” the disease 
them thinking that it is truly a disease that still only exists in Central and South America, 
not within the United States, so they may think that they’re immune because they’re here 
 
This is a really, really big problem, you know because—my case, my eighteen-year-old 
male, he isn’t dying, you know, he’s—he overall feels good right now 
 
Patient complications from 
treatment 
Yeah, I mean, it’s a big challenge, you know, with the toxicity to the medication 
 
  
And then the second aspect that’s always difficult is the medication itself. You know, the 
benznidazole and the nifurtimox. It’s a two-to-three-month treatment duration. And there’s 
a lot of nausea and vomiting with a lot of patients. And actually, the older the patient is—
which—I deal with adults. I don’t see kids. But the older the patient is, the more likely 
they’re probably going to have the side effects. And on top of that—I’ve never seen the 
neurotoxicity or the photosensitivity or any of that, but one thing we always check for is 
liver inflammation from the medication, and also effects on their white blood cell count, 
hemoglobin and platelets also. The medication can alter those. 
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CONCLUSION 
Main Findings 
The maps illustrate the barriers and challenges to accessing and receiving care for CD 
in Texas. Particularly, they demonstrate the potential for increased CD diagnosis in urban 
counties. Nonetheless, CD diagnosis are possible in rural areas, as indicated by TDSHS 
reported CD cases data. Moreover, the maps indicate the overall likelihood of currently 
missed CD diagnosis throughout the state. The mapped data also visualize the potential risk 
of local transmission throughout the state. Thus, this begins to shed light into physicians 
under recognizing CD as a potential threat. The maps also stress the importance that missed 
CD diagnosis are due not just due to limited physician access, but maybe also due a lack of 
access to knowledgeable physicians who may be trained and willing to recognize the risks 
and follow-through with screening and diagnosis. 
The findings from the questionnaires are consistent with the literature60,62,75,116 and 
reinforce CD knowledge gaps by physician specialties, particularly among general or family 
practitioners. The lack or limited knowledge, as a physician or systems-level barrier, prevents 
or delays CD diagnosis. More than half of the participants did not answer the correct 
response in 6 of the 13 knowledge items. This included: the prevalence of total reported CD 
cases to TDSHS; the clinical course for CD; the proportion of patients with chronic CD that 
develop symptoms; methods for confirming CD diagnosis; pharmaceutical drugs for 
treatment; and treatment recommendations for patients. The questionnaire responses from the 
screening and diagnosis practice items indicate that only one-fifth of surveyed physicians 
were frequently assessing CD exposure risks among their patient populations. This is 
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congruent in a recent study by Edwards et al (2018). A national population of pediatric ID 
specialists were sampled and specific items on screening practices and knowledge in their 
pediatric Latino immigrant population were assessed. There was a low level of knowledge 
regarding congenital transmission prevalence and risk factors and rarely or ever considered a 
diagnosis of congenital CD in a newborn infant born to immigrants from Mexico or Central 
America or South America.116 
This thus demonstrates the need to improve outreach and education among physicians 
so that more of them recognize the need to assess CD exposure risks more frequently. 
Interestingly, the majority perceived that CD is under diagnosed in Texas and potentially 
misdiagnosed. Moreover, in general, questionnaire participants believed that the process to 
confirm CD is complex. Access to treatment by their patient population was not seen as a 
barrier, yet medical training was: ID specialists believed that they are trained to recognize 
patients who may need to be screened as compared to family or general practice physicians.  
Training and experience, according to the KI, were essential in shaping physicians’ 
understanding of CD in Texas. Findings from a study in Spain support this, in which 
physicians who worked in a community clinic in which immigrant patients were screened for 
CD were more knowledgeable about CD than physicians who practiced in a clinic where no 
screening was performed.61 Unpublished participant data from a 2017 Texas Chagas 
Taskforce workshop on CD further illustrate the value in training and educating physicians. 
Knowledge scores increased from 69% prior to the session to 90% after the materials were 
presented. 
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Ultimately, the emerging themes from the KI further solidify the framework for 
existing barriers that are congruent with other proposed frameworks115,117. Specific physician 
recommendations to enhance awareness and improve knowledge on CD in Texas include: 1) 
engage patients and physician leadership; 2) increase surveillance to better understand 
prevalence; 3) improve access to physician resources and how materials on CD are 
disseminated; and 4) improving and updating physician resources. 
Study Strengths 
This is the first study aimed to examine CD knowledge among three specialties 
(infectious disease, cardiology, general/ family practice) throughout Texas. The findings 
build on the seminal work Stimpert and Montgomery (2010).62 This study is also unique in 
that incorporates ICD-9 and ICD-10 coding to illustrate the potential for missed CD 
diagnosis. Principles of community engagement were applied to ensure to validate the tools 
and recruit participants. Finally, this research employed a mixed methodology that will help 
inform and guide future research on CD and other neglected diseases. The findings and 
recommendations will be disseminated through the appropriate means (e.g., Texas Chagas 
Taskforce meetings; updates to collaborators; and peer-reviewed articles). 
Study Limitations 
Nonetheless, given the nested, explanatory mixed methodology design, the results do 
not statistically support a hypothesis or association. The generalizability of the results is 
limited given the non-probability sampling. Coverage error was a limitation for Aim 2a in 
that not all eligible physicians (i.e., within cardiology, family practice, or ID specialists) were 
affiliated or were members of the physician network(s) that sent out the email invitation(s) to 
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participate in the questionnaires (i.e., not all eligible physicians had a nonzero chance of 
being included in the sample). This was also a concern for the key informants, in which a 
new sampling frame was developed that relied on the Texas Chagas Taskforce contacts and 
collaborators, rather than on the CDC list of physicians who had treated for CD in Texas. 
Sampling error occurred as a failure to open or read the email invitations to participate in the 
questionnaire or KI interview. Not surprisingly, the majority of questionnaire participants 
practiced in urban areas, while most of the KI’s were in Houston or San Antonio. Thus, 
physicians practicing in rural counties had very limited representation. The contextual 
barriers, as perceived by physicals in these rural communities, were not identified by this 
research, the challenge remains in the application of translating the proposed 
recommendations into these settings without identifying feedback from these stakeholders. 
Furthermore, the recruited questionnaire participants might reflect those HCP’s who 
might be more interested in CD, and thus be more aware or biased, and therefore more 
willing to participate. Furthermore, there may be response bias in answering the questions. 
The missing data was another limitation, that could be attributed to measurement error. Non-
response bias was another limitation illustrated in the low participation from cardiologists for 
the questionnaires and their unwillingness to answer all the questions.  
There were limitations for using administrative data for Aim 1 (i.e., the Texas 
PUDF). The hospital inpatient dataset does not reflect all the missed CD cardiomyopathy 
cases since it includes only discharge data for inpatients only (e.g., outpatient hospital data is 
excluded). Moreover, county names are suppressed so the enumeration of all CD diagnostics 
is incomplete. Although a cardiologist was consulted, a focused literature review, including 
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the most recent guidelines published by the American Heart Association regarding Chagas 
cardiomyopathy,118 other recent findings on the clinical evaluation of CCC113,114, can be used 
to improve the definition of missed diagnosed CD cases. Finally, the implication of 
participant under-representation from rural counties limits the  
Recommendations 
The impetus to continue to raise awareness and education amongst physicians in 
Texas remains a priority at the systems and physician levels. A multi-level approach to 
reducing the number of missed CD diagnosis in Texas is needed that does not rely uniquely 
on individual uptake of CD knowledge. Table 3 summarizes the recommendations framed at 
the systems, physician, and patient levels. These recommendations can be framed as 
responses to the barriers identified in Figure 9. 
At the systems-level, curricula that discuss the specific context to CD in Texas are 
needed. As such, policymakers must be engaged so that they recognize the value in revising 
the undergraduate medical curriculum on CD. More time must be allotted to this topic to 
ensure physicians in training recognize the risk factors in their patient populations in Texas. 
Nonetheless, improved surveillance and data are needed for physicians to recognize the 
problem that CD is not just likely from patients who lived in endemic countries, rather that 
local transmission is possible and has been reported in Texas. 
At the physician level, there are various opportunities to engage with physicians 
through the continuum of CD care, as first demonstrated in Figure 8. A physician managing 
the medical care potential CD patient (i.e., before performing screening or requesting 
diagnostics), must be able to synthesize the information received form the patient. To do that, 
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however, they must first recognize the potential for CD (i.e., be inclined to consider CD), 
have access to the latest clinical guidelines and diagnostic procedures, collaborate with other 
physicians (or non-physician CD experts; work outside their medical “silo”), and be able to 
communicate the results of the screening or diagnostics and discuss treatment options, side 
effects, and follow-up management. One recommendation is to have Spanish resources 
readily accessible for the patient in situations in which translating services are not costly or 
timely. 
Access to resources and educational opportunities that inform or guide physician 
screening practices must be targeted. For example, many of the KI’s cited the pivotal JAMA 
article15 alongside CDC materials, and Up to Date9 as helpful resources. None of the 
questionnaire participants reported frequent usage of local, county, or health department 
resources. Instead, efforts, as framed by the findings, must focus on continuing medical 
education (CME) workshops and webinars, and conferences.  
Web-based outreach is particularly beneficial for physicians in rural or remote areas. 
The potential for a Chagas webinar has been demonstrated in the continuing efforts from the 
Texas Chagas Taskforce. That is, in February 2, 2018, a total of 17 physicians participated in 
a CD webinar. Targeted physician recruitment through existing physician networks can 
further improve participation and ultimately knowledge on CD. 
Additionally, experts in the field (i.e., cardiologists or IDs) must recognize the 
opportunity to educate physicians in other specialties about their case studies and other CD 
                                                 
9 Marin-Neto et al (2018). Chagas Heart Disease: https://www.uptodate.com/contents/chagas-heart-
disease-clinical-manifestations-and-diagnosis  
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research. Peer-to-peer models are way to improve uptake and maximize the impact of 
physician awareness and education. Engaged medical leadership is a recommendation that 
has also been discussed elsewhere.116  
Other specific outreach strategies to improve the uptake of information at the 
individual physician level includes the usage of peer-reviewed journals that are specific to 
physician specialties. For example, a recent update to the clinical management of Chagas 
cardiomyopathy was published by the American Heart Association and endorsed by the 
Inter-American Society of Cardiology summarizes and lists the current.118  
The patient engagement framework (Figure 8) further demonstrates the potential 
impact of improving physician awareness and education. For example, a recent kissing bug 
and CD field guide was developed and released by the Texas Chagas Taskforce. The kissing 
bug field guide is available online through the TDSHS and various statewide web resources 
with the purpose of engaging the community at large that may be at risk of exposure to 
infected triatomines, and educating them about the long-term adverse health outcomes of 
delaying screening and diagnosing if exposed. This outreach effort had gathered statewide 
awareness and has empowered community members to discuss with their provider the risk of 
CD and be their own health advocate.  
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Table 3: Recommendations to Improve Chagas Disease Education at the System, 
Physician and Patient Levels 
 
Level Recommendation Strategy/ Example 
Systems 
Improve/ facilitate access to 
resources for physicians 
Ensure that specialty journals provide updates to 
CD clinical care (e.g., America Heart 
Association) 
 
Encourage usage of Up to Date among other 
physicians 
Improve undergraduate medical 
education 
Engage policymakers so that more time can be 
spent to contextualize CD in the U.S. 
Improve awareness within 
medical systems 
Engage physician leadership so that briefs and 
alerts are disseminated throughout hospital 
Continue research and 
surveillance to improve 
prevalence estimates and ensure 
physicians can access data 
Pilot studies to better understand prevalence in 
specific communities 
 
Conduct routine surveillance at local/ regional 
blood banks (i.e., not just first time donors) 
 
Disseminate updates from TDSHS in specialty 
journals or TMA 
Physician 
Promote collaboration between 
physicians/ Increase awareness/  
Encourage dissemination of CD case studies/ 
research by physicians at local/ society 
conferences 
Increase awareness 
Use story telling 
 
Use social media including Facebook to target 
physicians 
 
Use conferences to share knowledge, including 
available CME 
Target rural or physicians in 
remote locations 
Use webinars and other streaming educational 
opportunities 
Patient 
Increase awareness and improve 
education 
Educate community members (e.g., Kissing Bug 
Field Guide) 
 
Next Steps and Implications 
Physicians who may not consider CD as current or potential threat in Texas believe 
that epidemiological research and disease surveillance are needed to estimate the human 
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prevalence of CD and better quantify the need to screen and diagnose to guide their practices. 
Public health CD surveillance in Texas is needed to monitor incident cases and assess the 
risk of local transmission.39 Texas, like the other states where CD is reportable, publish a 
report and update their website as the means to disseminate surveillance data. Additional 
dissemination methods employed by other states like Tennessee include peer-reviewed 
literature and targeted reports to healthcare providers. These additional strategies might help 
increase awareness. Interestingly, Texas is the only state out the six that currently utilized the 
Taskforce to increase physicians awareness.39 Texas Chagas Taskforce activities are in line 
with the proposed recommendations, including the development and publication of a 
healthcare provider protocol and a testing algorithm.10 However as indicated through the 
findings, one of the main barriers lies in the reluctance or unwillingness to access or utilize 
CD resources from local or county, or state health departments. Further research can explain 
the underlying reasons for this. The findings also support the need for improved diagnostic 
tools and updated physician guidelines. The uptake and impact of the recently published 
AHA statement and guidelines to raise the recognition of Chagas cardiomyopathy remains to 
be seen. Understanding the experiences and attitudes of rural-based physicians is also critical 
to improve the understanding of KAP of CD among these physicians and thus increase 
screening, diagnosis, and management of care to high-risk patients. Furthermore, additional 
research must explore the patient’s perspectives.   
                                                 
10 Texas Department of State Health Services (2018). Chagas disease for healthcare providers: 
http://www.dshs.state.tx.us/IDCU/disease/chagas/Chagas-Disease-Exposure-and-Testing-Flowchart-
Provider-Version0918.pdf 
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Chagas Disease Questionnaire for Cardiologists
SURVEY FLOW
Consent and Eligibility
Definitions
Attitudes (5 Questions)
Knowledge (14 Questions)
Knowledge for Cardiologists (3 Questions)
Practices: Actual Chagas (20 Questions)
Practices:  Other Activities- Rated (7 Questions)
Participant Demographics (10 Questions)
Questionnaire Conclusion and Follow-up 
Q1.2 Thank you for your interest in completing the following online questionnaire.     The purpose of this 
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and 
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas 
Medical Board.    
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You 
can close this page now.
Q1.3 
INFORMED CONSENT
INVITATION TO TAKE PART 
You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in 
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science 
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the 
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as 
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised 
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also 
refuse to answer any question(s).
 PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below. 
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes 
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of 
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15-
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minute key informant phone interview. You will then be prompted to provide your email address if you 
agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the 
Chagas disease knowledge questions.
PURPOSE 
The purpose of this research study is to examine the level of knowledge, awareness, and 
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas 
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks. 
BENEFITS 
The potential benefits to participating in this study include the self-assessment of Chagas disease, which 
will allow you as a physician to understand where your current knowledge deficits might be and if further 
resources should be reviewed to be up to date. In more general terms, the results from this study can 
help point towards statewide knowledge deficits and gaps that might be present and push towards 
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.). 
You may receive no direct benefit from being in the study; however, you taking part may help patients 
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease 
knowledge section.
RISKS AND/OR DISCOMFORTS 
The risks and discomfort associated with participation in this study are no greater than those ordinarily 
encountered in daily life or during the performance of routine exams. The experience is expected to be 
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this 
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing 
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire, 
please be advised that you may refuse to take part or choose to stop taking part, at any time.  You may 
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to 
have your responses excluded from the analysis. 
COSTS, REIMBURSEMENT AND COMPENSATION 
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY 
Identifying information will not appear on records retained by the sponsor, with the exception of your birth 
year and your email address if you choose to provide that information for participation in follow-up 
interviews. You will not be personally identified in any reports or publications that may result from this 
study.  
QUESTIONS 
If you have questions at any time about this research study, please feel free to contact the PI at (915) 
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice 
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the 
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss 
problems, concerns, and questions; obtain information about the research; and offer input about current 
or past participation in a research study. 
SIGNATURES 
Submit your consent below to participate in this research only if you understand the information given to 
you about the research and you choose to take part. No signature is required to proceed if you confirm 
your consent below. Make sure that any questions have been answered and that you understand the 
study. 
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For 
any questions about research subject's rights, or to report a research-related injury, call the CPHS at 
(713) 500-7943.
Q1.5 If you wish to participate, please indicate below:
o Yes, I agree to participate.  (1) 
o No, I do not wish to participate.  (2) 
Skip To: End of Survey If Q1.5 = 2
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Q1.6 Are you an MD or DO licensed by the Texas Medical Board to practice in the state of Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q1.6 = 2
Q1.7 
Thank you for your interest. However, this questionnaire is intended for physicians.
 
 You may close this page now.
Skip To: End of Survey If Q1.7(1) Is Displayed
Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:
o General Practice/ Family Medicine  (1) 
o Infectious Disease  (2) 
o Cardiology  (3) 
o Other  (4) 
Display This Question:
If Q1.8 = 4
Q1.9 If Other, please describe:
________________________________________________________________
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Q2.1 DEFINITIONS     
Definitions used for the purpose of this questionnaire:     
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory 
diagnostics are required.    
Diagnosis: the clinical and serological testing required to confirm Chagas disease.    
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas 
disease.
Q3.1 
ATTITUDES ON CHAGAS DISEASE  
  The following sections are about your opinions and attitudes regarding Chagas disease.      
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Q3.2 To what extent do you agree or disagree with the following statements?
Strongly 
agree (1)
Somewhat 
agree (2)
Neither agree 
nor disagree 
(3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. Chagas 
disease is under 
diagnosed in 
Texas (i.e., 
failure to 
recognize or 
correctly 
diagnose a 
disease or 
condition in a 
significant 
proportion of the 
population). (1) 
o o o o o
b. Chagas 
disease is 
potentially 
misdiagnosed 
in patients (e.g., 
incorrectly 
diagnosed cases 
of chronic 
Chagas 
cardiomyopathy 
for idiopathic 
cardiomyopathy). 
(2) 
o o o o o
c.The process 
required to 
confirm Chagas 
disease is 
complex and 
thus time 
consuming. (4) 
o o o o o
d. In Texas, 
diagnosis and 
treatment of 
Chagas disease 
is a relatively 
easy process 
with few barriers. 
(9) 
o o o o o
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Q3.3 As a cardiologist, to what extent do you agree or disagree with the following statements?
Strongly 
agree (1)
Somewhat 
agree (2)
Neither agree 
or disagree 
(3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. My medical 
training prepared 
me to recognize  
patients who may 
need to be 
screened for 
Chagas disease. 
(8) 
o o o o o
b. I routinely 
screen for 
Chagas disease 
in patients who 
present with risk 
factors. (11) 
o o o o o
c. Accessing 
Chagas disease 
treatment is not a 
barrier for the 
population I 
serve. (12) 
o o o o o
d. I have access 
to a 12-lead 
electrocardiogram 
with a 30 second 
lead to screen for 
Chagas 
cardimyopathy 
within my 
practice. (14) 
o o o o o
e. I have access 
to cardiac 
ultrasound 
equipment to 
perform 
echocardiograms 
to screen for 
Chagas disease 
within my 
practice. (16) 
o o o o o
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Q3.4 How confident are you in performing the following when screening for Chagas disease in your 
patient population?
Very confident (1) Somewhat confident (2) Not at all confident (3)
a. Identifying risk 
factors for Chagas 
disease in patients. (1) o o o
b. Recognizing the 
vector that transmits 
Chagas disease. (11) o o o
c. Obtaining a patient's 
social history to identify 
potential risk factors for 
Chagas disease. (13) 
o o o
d. Using 
electrocardiogram 
(ECG) to screen and 
diagnose for chronic 
Chagas disease. (12) 
o o o
e. Using a stress test to 
evaluate clinical 
manifestations to 
screen and diagnose 
for chronic Chagas 
cardiomyopathy. (16) 
o o o
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Q3.5 How confident are you in performing the following in patients with Chagas disease?
Very confident (1) Somewhat confident (2) Not at all confident (3)
a. Contacting and 
coordinating with the 
local and/or state 
health department 
when consulting about 
a Chagas patient. (1) 
o o o
b. Contacting, 
coordinating, and 
following-up with the 
Centers for Disease 
Control and Prevention 
(CDC) when consulting 
about a Chagas 
patient. (2) 
o o o
c. Requesting the 
Current Procedural 
Terminology laboratory 
codes for diagnosing 
Chagas disease. (4) 
o o o
d. Continuing to provide 
follow-up medical care 
to Chagas patients. (5) o o o
Q3.6 What would be the recommended sequence when managing care of a Chagas patient who has a 
blood donation letter? Please rank from 1 to 5 on how you would prioritize (drag and drop).
______ Coordinate with local health department and Texas Department of State Health Services (DSHS) 
to confirm diagnosis. (1)
______ Consult with the CDC to manage patient's treatment protocol. (2)
______ Perform baseline clinical workup that includes physical exam, 12-lead ECG, and additional 
testing if warranted. (5)
______ Confirm diagnosis via commercial serology testing. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
Q4.1 KNOWLEDGE     The following sections are to help us asses Texas physicians' knowledge about 
the cause, transmission, and clinical aspects of Chagas disease.   
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Q4.2 How does the vector with the parasite transmit Chagas disease to humans?
o The infected vector penetrates the human host skin during bloodmeal, transmitting parasite 
through saliva.  (1) 
o Through infected feces of the vector, that is deposited during the bloodmeal, most commonly 
when the person rubs the infected feces into the bite wound while scratching the area.  (2) 
o The infected vector regurgitates after bloodmeal, transmitting parasite to the human.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?
o From drinking unpasteurized juices.  (1) 
o From exposure to vectors while residing in Mexico, Central, or South America.  (2) 
o From their mothers (i.e., congenital transmission).  (3) 
o From another infected person.  (4) 
o Not sure.  (5) 
Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total 
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and 
2016?
o Less than 5.  (1) 
o Between 20 and 30.  (2) 
o Between 75 and 100.  (3) 
oMore than 1,000.  (4) 
o Not sure.  (5) 
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Q4.5 Which of the following best describes the clinical course of Chagas disease?
o Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2 
months, and rarely progresses into the chronic phase.  (1) 
o Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 2-
4 weeks following exposure to parasite.  (2) 
o Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the 
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.  
(3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.6 The acute phase of Chagas disease may be characterized by which of the following:
o Fever  (1) 
o Swelling at the site of inoculation  (2) 
o No symptoms  (3) 
o All of the above  (4) 
o Not sure  (5) 
Q4.7 In addition to heart failure, what major clinical disorders manifest frequently and concurrently that 
lead to chronic Chagas cardiomyopathy?
o Cardiac arrhythmias  (1) 
o Thromboembolism (systemic and pulmonary)  (2) 
o Chest pain syndrome  (3) 
o All of the above  (4) 
o Not sure  (5) 
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Q4.8 Approximately what percentage of patients worldwide with chronic Chagas disease eventually 
develop the clinical (symptomatic) form of the disease?
o Less than 1%.  (1) 
o Between 20 and 40%.  (2) 
oMore than 50%.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.9 Persons infected with chronic Chagas disease may develop which of the following?
o Cardiac conduction abnormalities and/ or cardiomyopathy.  (1) 
oMegaesophagus and/or megacolon.  (2) 
o Co-clinical manifestations.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
Q4.10 Which of the following may occur in patients with chronic Chagas cardiomyopathy?
o None- can present without clinical manifestations and be asymptomatic.  (1) 
o Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema.  (2) 
o Sudden death.  (3) 
o Any of the above.  (4) 
o Not sure.  (5) 
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Q4.11 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of 
the patient, and conduct a thorough history in a patient who:
o Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagas-
positive.  (1) 
oWas exposed or potentially exposed to a vector in a period longer than 8 weeks.  (2) 
o Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas 
cardiomyopathy.  (3) 
o All of the above.  (4) 
o Not sure  (5) 
Q4.12 In patients who test positive for Chagas disease after a blood donation or from a laboratory 
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:
o Travel to or residence in areas endemic for Chagas disease.  (1) 
o Previous history of blood transfusions or organ/ tissue transplants.  (2) 
o Possibility of congenital Chagas disease transmission.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
Q4.13 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas 
disease?
o Seropostive results from 2 different immunoassays and/or PCR performed at the CDC.  (1) 
o Positive serology from blood screening donations.  (2) 
o Detection of apolipoprotein A-1 (APOA1) upregulation in human serum.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
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Q4.14 Which of the following describes the current treatment options for Chagas disease?
o Benzindazole and nifurtimox are available only under current investigational protocol by the CDC 
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic 
infection who have no indication of advanced cardiomyopathy.  (1) 
o Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 2-
12 years of age and is available commercially.  (4) 
o Nifurtimox is only available by the CDC under investigational protocol.  (5) 
o Second and third choices only.  (8) 
o Not sure.  (7) 
Q4.15 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?
o No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be 
effective.  (1) 
o Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease.  (2) 
o Treatment is always recommended for patients up to age 18 years of age and generally 
recommended for patients aged 18 to 50.  (3) 
o Only Chagas disease patients manifesting with moderate to severe cardiomyopathy.  (4) 
o Not sure.  (5) 
Q5.1 SPECIFIC KNOWLEDGE ON CHAGAS DISEASE SCREENING & DIAGNOSTICS     The following 
questions are specific to you as a cardiologist in identifying the clinical manifestations of Chagas disease 
and screening the patient.
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Q5.2 What are the important elements of the clinical evaluation of a newly diagnosed chronic Chagas 
patient who is asymptomatic?
o Complete physical examination, complete blood count (CBC), and chemistry panel.  (1) 
o Complete physical examination, electrocardiogram (ECG) with 30 second rhythm strip, and 
detailed history.  (7) 
o Complete physical examination, ECG with 30 second rhythm strip, chest radiograph, barium 
swallow, and detailed history.  (8) 
o None of the above.  (9) 
o Not sure.  (10) 
Q5.3 Which of the following are typical of Chagas cardiomyopathy as evaluated using 
electrocardiograph?
o Right bundle branch block often associated with left anterior hemiblock, ST-T changes, abnormal 
Q waves, various degrees of AV block, sick sinus syndrome, and low QRS voltage.  (1) 
oMainly conduction abnormalities including first-degree AV block, left bundle-branch block, and 
nonspecific interventricular conduction delays.  (6) 
o Right bundle-branch block only.  (7) 
o None of the above.  (8) 
o Not sure.  (9) 
Q5.4 In patients with chronic Chagas cardiomyopathy, cardiac examination typically demonstrates which 
of the following?
oMurmurs of mitral and/ or tricuspid regurgitation.  (1) 
oWide splitting of the second heart sound due to right bundle branch block.  (6) 
o A prominent diffuse apical thrust.  (7) 
o All of the above.  (8) 
o Not sure.  (9) 
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Q6.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE     
The following are about your practices related to the identification, screening, and treatment of actual 
Chagas disease case(s).     
Q6.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened 
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = 1
Q6.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test 
to confirm diagnosis?
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive 
a positive confirmatory diagnosis?
o Yes  (8) 
o No  (9) 
Display This Question:
If Q6.4 = 8
Q6.5 In the past year, if you screened suspected Chagas patients, how many that were positive were 
confirmed by the CDC?
________________________________________________________________
Display This Question:
If Q6.4 = 8
Q6.6 Please provide additional comments regarding your experience in confirming a Chagas disease 
diagnosis:
________________________________________________________________
________________________________________________________________
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________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to 
screen for Chagas disease? Select all that apply.
▢Physical assessment.  (2) 
▢12 lead strip electrocardiogram.  (3) 
▢Patient's medical and social history.  (4) 
Display This Question:
If Q6.2 = 1
Q6.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county 
health departments to coordinate treatment?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = 1
Q6.9 If you screened patients for Chagas disease in the past year, did you coordinate with the CDC to 
confirm diagnosis?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = 1
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Q6.10 If you screened and/ or diagnosed patients for Chagas disease in the past year, what method(s) 
did you use to confirm diagnosis for Chagas disease? Select all that apply.
▢PCR performed at the CDC.  (1) 
▢Commercial antibody testing- ARUP Lab.  (2) 
▢Commercial antibody testing- Mayo Medical Lab.  (3) 
▢Commercial antibody testing- Quest Diagnostics.  (4) 
▢Commercial antibody testing- Labcorp.  (5) 
▢Not sure.  (6) 
Display This Question:
If Q6.2 = 1
Q6.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you 
coordinate with the CDC for treatment?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q6.2 = 1
Q6.12 Please provide additional comments regarding your experience obtaining and coordinating 
treatment for patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = 1
Q6.13 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you 
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q6.2 = 1
Q6.14 Please provide additional comments regarding your experience in coordinating with local and state 
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q6.2 = 1
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Q6.15 If you screened patients in the past year and diagnosis was confirmed, please indicate the 
classification of the case(s):
▢Acute  (1) 
▢Chronic-indeterminate  (2) 
▢Chronic-cardiomyopathy  (3) 
▢Chronic-gastrointestinal  (4) 
▢Other  (6) 
▢Not sure  (5) 
Display This Question:
If Q6.15 = 6
Q6.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.17 Please indicate the source(s) of transmission:
▢Locally-acquired  (1) 
▢ Imported  (2) 
▢Not sure  (3) 
Display This Question:
If Q6.2 = 1
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Q6.18 Did you refer out the patient to any other specialist?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.18 = 1
Q6.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q6.2 = 1
Q6.20 Was the patient referred to you by another physician?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.20 = 1
Q6.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q7.1 PHYSICIAN PRACTICES  
 The following are Chagas disease screening and diagnosing practices related to your medical specialty.
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Q7.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in 
your patients?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Mother or 
sibling with 
Chagas 
disease. (2) 
o o o o o o
b. History of 
blood 
transfusions 
or organ/ 
tissue 
transplants. 
(3) 
o o o o o o
c. Travel to 
Mexico, 
Central, or 
South 
America. (4) 
o o o o o o
d. 
Consumption 
foods or 
drinks 
contaminated 
with the 
parasite. (5) 
o o o o o o
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Q7.3 In general, how often do you perform the following in patients under your medical care who present 
with idiopathic cardiomyopathy?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Review the 
patient's travel 
history. (3) o o o o o o
b. Look for signs 
of cardiac 
arrhythmias that 
may arise due to 
chronic Chagas 
cardiomyopathy. 
(5) 
o o o o o o
c. Evaluate 
patient's 
cardiopulmonary 
function (i.e., 
exercise stress 
test). (17) 
o o o o o o
d. Perform 
cardiovascular 
testing (chest x-
ray, 
echocardiogram, 
etc.) to asses 
myocardial 
damage. (2) 
o o o o o o
Q7.4 In the past 5 years while practicing medicine in Texas, have you provided care to a Chagas disease 
patient with a blood donation letter?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q7.4 = 1
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Q7.5 In the past 5 years while practicing in Texas, how often did you perform the following in patients 
under your medical care who received a positive Chagas diagnosis (i.e., letter) from a blood donation 
screening?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Review the 
patient's travel 
history. (6) o o o o o o
b. Request 
serology to 
confirm Chagas 
diagnosis. (5) 
o o o o o o
c. Evaluate 
patient's 
cardiopulmonary 
function (i.e., 
exercise stress 
test). (7) 
o o o o o o
d. Perform 
cardiovascular 
testing (chest x-
ray, 
echocardiogram, 
etc.) to asses 
myocardial 
damage. (20) 
o o o o o o
e. Consult with 
the Texas DSHS 
to manage 
treatment. (9) 
o o o o o o
f. Consult with 
the CDC to 
manage 
treatment. (21) 
o o o o o o
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Q7.6 In thinking about resources you reference when managing the care of a patient who may potentially 
have Chagas disease, how often do you access:
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Medical 
websites 
(e.g., 
UpToDate, 
MedlinePlus, 
etc.) (1) 
o o o o o o
b. Official 
local or 
county health 
department 
websites. (2) 
o o o o o o
c. The Texas 
DSHS 
website. (3) o o o o o o
d. The CDC 
website. (4) o o o o o o
e. Official 
communiques 
and health 
alerts from 
Texas DSHS. 
(5) 
o o o o o o
f. Email alerts 
from the 
Texas 
Medical 
Association. 
(6) 
o o o o o o
g. Morbidity 
and Mortality 
Weekly 
Report 
(MMWR) 
email updates 
from the 
CDC. (7) 
o o o o o o
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Q7.7 Which of the following would you be interested in accessing in order to strengthen your ability to 
help patients with Chagas disease? Select all that apply.
▢Courses  (1) 
▢Seminars  (2) 
▢Manuals  (3) 
▢Other resources  (4) 
Display This Question:
If Q7.7 = 4
Q7.8 If you indicated other, please describe:
________________________________________________________________
Q8.1 DEMOGRAPHICS     The following section is about demographics and your medical practice.
Q8.2 How many years have you been practicing in family or general practice?
o Less than 5 years.  (1) 
o 5 to 10 years.  (2) 
o 10 to 15 years.  (3) 
o 15 to 20 years.  (4) 
oMore than 20 years.  (5) 
Q8.3 Which of the following best describes the current type of medical setting you currently practice in?
o Private  (1) 
o Teaching  (2) 
o Community  (3) 
o Other  (4) 
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Display This Question:
If Q8.3 = 4
Q8.4 If other, please describe:
________________________________________________________________
Q8.5 Which of the following best describes the setting where you practice at?
o Urbanized area (i.e., 50,000 or more people).  (1) 
o Rural area (i.e., at least 2,500 people but than 50,000).  (2) 
o None of the above.  (3) 
Q8.6 In your current medical practice, what proportion of total patients you see on average that are 
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()
Q8.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q8.8 Are you male or female?
oMale  (1) 
o Female  (2) 
Q8.9 What is your year of birth? (YYYY)
________________________________________________________________
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Q8.10 Please indicate if you received medical training in any of the following places:
oMexico  (1) 
o Central America  (2) 
o South America  (3) 
o None of the above  (4) 
o Prefer not to answer  (5) 
Display This Question:
If Q8.10 = 2
Q8.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q8.10 = 3
Q8.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q9.1 
CONCLUSION
Q9.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will 
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas 
disease throughout the state.     In addition to the questionnaire, we are conducting additional research 
via phone interviews with practicing physicians to identify and explore additional barriers related to 
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead 
to missed Chagas diagnosis and frame recommendations to improve awareness and education among 
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do 
decide to provide your contact information to participate in the phone interviews.   
Q9.3 Would you like participate in a 15-minute phone interview?
o Yes, I would like to participate.  (1) 
o No, I decline.  (2) 
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Display This Question:
If Q9.3 = 1
Q9.4 Please provide your email:
________________________________________________________________
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Chagas Disease Questionnaire for Family or General Practice 
Physicians
Survey Flow
Consent and Eligibility
Definitions 
Attitudes (4 Questions)
Knowledge (13 Questions)
Practices: Actual Chagas (20 Questions)
Practices: Common, Other Activities- Rated (8 Questions)
Participant Demographics (11 Questions)
Questionnaire Conclusion and Follow-up
Q1.2 Thank you for your interest in completing the following online questionnaire.     The purpose of this 
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and 
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas 
Medical Board. 
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You 
can close this page now.
Q1.3 
INFORMED CONSENT
You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in 
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science 
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the 
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as 
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised 
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also 
refuse to answer any question(s).
 PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below. 
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes 
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of 
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15-
minute key informant phone interview. You will then be prompted to provide your email address if you 
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agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the 
Chagas disease knowledge questions.
PURPOSE 
The purpose of this research study is to examine the level of knowledge, awareness, and 
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas 
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks. 
BENEFITS 
The potential benefits to participating in this study include the self-assessment of Chagas disease, which 
will allow you as a physician to understand where your current knowledge deficits might be and if further 
resources should be reviewed to be up to date. In more general terms, the results from this study can 
help point towards statewide knowledge deficits and gaps that might be present and push towards 
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.). 
You may receive no direct benefit from being in the study; however, you taking part may help patients 
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease 
knowledge section.
RISKS AND/OR DISCOMFORTS 
The risks and discomfort associated with participation in this study are no greater than those ordinarily 
encountered in daily life or during the performance of routine exams. The experience is expected to be 
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this 
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing 
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire, 
please be advised that you may refuse to take part or choose to stop taking part, at any time.  You may 
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to 
have your responses excluded from the analysis. 
COSTS, REIMBURSEMENT AND COMPENSATION 
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY 
Identifying information will not appear on records retained by the sponsor, with the exception of your birth 
year and your email address if you choose to provide that information for participation in follow-up 
interviews. You will not be personally identified in any reports or publications that may result from this 
study.  
QUESTIONS 
If you have questions at any time about this research study, please feel free to contact the PI at (915) 
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice 
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the 
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss 
problems, concerns, and questions; obtain information about the research; and offer input about current 
or past participation in a research study. 
SIGNATURES 
Submit your consent below to participate in this research only if you understand the information given to 
you about the research and you choose to take part. No signature is required to proceed if you confirm 
your consent below. Make sure that any questions have been answered and that you understand the 
study. 
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For 
any questions about research subject's rights, or to report a research-related injury, call the CPHS at 
(713) 500-7943.
Q1.5 If you wish to participate, please indicate below:
o Yes, I agree to participate.  (1) 
o No, I do not wish to participate.  (2) 
Skip To: End of Survey If Q1.5 = No, I do not wish to participate.
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Q1.6 Are you an MD or DO licensed by the Texas Medical Board to practice in the state of Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q1.6 = No
Q1.7 
Thank you for your interest. However, this questionnaire is intended for physicians.
 
 You may close this page now.
Skip To: End of Survey If Q1.7() Is Displayed
Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:
o General Practice/ Family Medicine  (1) 
o Infectious Disease  (2) 
o Cardiology  (3) 
o Other  (4) 
Display This Question:
If Q1.8 = Other
Q1.9 If Other, please describe:
________________________________________________________________
Q2.1 DEFINITIONS     
Definitions used for the purpose of this questionnaire:     
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory 
diagnostics are required.    
Diagnosis: the clinical and serological testing required to confirm Chagas disease.    
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas 
disease.
Q3.1 
ATTITUDES ON CHAGAS DISEASE  
  The following sections are about your opinions and attitudes regarding Chagas disease.      
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Q3.2 To what extent do you agree or disagree with the following statements?
Strongly 
agree (1)
Somewhat 
agree (2)
Neither agree 
nor disagree 
(3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. Chagas 
disease is under 
diagnosed in 
Texas (i.e., 
failure to 
recognize or 
correctly 
diagnose a 
disease or 
condition in a 
significant 
proportion of the 
population). (1) 
o o o o o
b. Chagas 
disease is 
potentially 
misdiagnosed 
in patients (e.g., 
incorrectly 
diagnosed cases 
of chronic 
Chagas 
cardiomyopathy 
for idiopathic 
cardiomyopathy). 
(2) 
o o o o o
c.The process 
required to 
confirm Chagas 
disease is 
complex and 
thus time 
consuming. (4) 
o o o o o
d. In Texas, 
diagnosis and 
treatment of 
Chagas disease 
is a relatively 
easy process 
with few barriers. 
(9) 
o o o o o
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Q3.3 As a general practice or family physician, to what extent do you agree or disagree with the following 
statements?
Strongly agree 
(1)
Somewhat 
agree (2)
Neither agree 
or disagree (3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. My medical 
training 
prepared me 
to recognize 
patients who 
may need to 
be screened 
for Chagas 
disease. (8) 
o o o o o
b. Screening 
for Chagas 
disease is 
possible 
through my 
general or 
family practice. 
(11) 
o o o o o
c. Diagnosis 
for Chagas 
disease is 
possible 
through my 
general or 
family practice. 
(13) 
o o o o o
d. Accessing 
Chagas 
disease 
treatment is 
not a barrier 
for the 
population I 
serve. (12) 
o o o o o
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Q3.4 How confident are you in performing the following when screening and diagnosing Chagas disease 
in your patient population?
Very confident (1) Somewhat confident (2) Not at all confident (3)
a. Identifying risk 
factors for Chagas 
disease in patients. (1) o o o
b. Recognizing the 
vector that transmits 
Chagas disease. (11) o o o
c. Obtaining a patient's 
social history to identify 
potential risk factors for 
Chagas disease. (12) 
o o o
d. Requesting the 
Current Procedural 
Terminology laboratory 
codes for diagnosing 
Chagas disease. (5) 
o o o
e. Contacting and 
coordinating with the 
local health department 
and/or the Texas 
Department of State 
Health Services 
(DSHS) when 
consulting about a 
Chagas patient. (6) 
o o o
f. Contacting, 
coordinating, and 
following-up with the 
Centers for Disease 
Control and Prevention 
(CDC) when consulting 
about a Chagas 
patient. (7) 
o o o
Q3.5 What would be the recommended sequence when managing care of a patient who may have 
been exposed to parasite (i.e., exposure to vector in Texas or in endemic areas) within an 8-week period 
and presents with acute symptoms? Please rank from 1 to 5 on how you would prioritize (drag and drop).
______ Initiate antitrypanosomal treatment. (1)
______ Request serology testing from a commercial laboratory. (5)
______ Perform other tests for differential diagnosis and refer patient to infectious disease specialist if 
necessary. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
______ Consult with the Texas DSHS for guidance on screening and diagnosis protocol. (2)
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Q4.1 KNOWLEDGE     The following sections are to help us asses Texas physicians' knowledge about 
the cause, transmission, and clinical aspects of Chagas disease.   
Q4.2 How does the vector with the parasite transmit Chagas disease to humans?
o The infected vector penetrates the human host skin during bloodmeal, transmitting parasite 
through saliva.  (1) 
o Through infected feces of the vector, that is deposited during the bloodmeal, most commonly 
when the person rubs the infected feces into the bite wound while scratching the area.  (2) 
o The infected vector regurgitates after bloodmeal, transmitting parasite to the human.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?
o From drinking unpasteurized juices.  (1) 
o From exposure to vectors while residing in Mexico, Central, or South America.  (2) 
o From their mothers (i.e., congenital transmission).  (3) 
o From another infected person.  (4) 
o Not sure.  (5) 
Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total 
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and 
2016?
o Less than 5.  (1) 
o Between 20 and 30.  (2) 
o Between 75 and 100.  (3) 
oMore than 1,000.  (4) 
o Not sure.  (5) 
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Q4.5 Which of the following best describes the clinical course of Chagas disease?
o Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2 
months, and rarely progresses into the chronic phase.  (1) 
o Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 2-
4 weeks following exposure to parasite.  (2) 
o Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the 
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.  
(3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.6 The acute phase of Chagas disease may be characterized by which of the following:
o Fever  (1) 
o Swelling at the site of inoculation  (2) 
o No symptoms  (3) 
o All of the above  (4) 
o Not sure  (5) 
Q4.7 Approximately what percentage of patients worldwide with chronic Chagas disease eventually 
develop the clinical (symptomatic) form of the disease?
o Less than 1%.  (1) 
o Between 20 and 40%.  (2) 
oMore than 50%.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
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Q4.8 Persons infected with chronic Chagas disease may develop which of the following?
o Cardiac conduction abnormalities and/ or cardiomyopathy.  (1) 
oMegaesophagus and/or megacolon.  (2) 
o Co-clinical manifestations.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
Q4.9 Which of the following may occur in patients with chronic Chagas cardiomyopathy?
o None- can present without clinical manifestations and be asymptomatic.  (1) 
o Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema.  (2) 
o Sudden death.  (3) 
o Any of the above.  (4) 
o Not sure.  (5) 
Q4.10 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of 
the patient, and conduct a thorough history in a patient who:
o Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagas-
positive.  (1) 
oWas exposed or potentially exposed to a vector in a period longer than 8 weeks.  (2) 
o Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas 
cardiomyopathy.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
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Q4.11 In patients who test positive for Chagas disease after a blood donation or from a laboratory 
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:
o Travel to or residence in areas endemic for Chagas disease.  (1) 
o Previous history of blood transfusions or organ/ tissue transplants.  (2) 
o Possibility of congenital Chagas disease transmission.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
Q4.12 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas 
disease?
o Seropostive results from 2 different immunoassays and/or PCR performed at the CDC.  (1) 
o Positive serology from blood screening donations.  (2) 
o Detection of apolipoprotein A-1 (APOA1) upregulation in human serum.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
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Q4.13 Which of the following describes the current treatment options for Chagas disease?
o Benzindazole and nifurtimox are available only under current investigational protocol by the CDC 
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic 
infection who have no indication of advanced cardiomyopathy.  (1) 
o Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 2-
12 years of age and is available commercially.  (4) 
o Nifurtimox is only available by the CDC under investigational protocol.  (5) 
o Second and third choices only.  (8) 
o Not sure.  (7) 
Q4.14 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?
o No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be 
effective.  (1) 
o Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease.  (2) 
o Treatment is always recommended for patients up to age 18 years of age and generally 
recommended for patients aged 18 to 50.  (3) 
o Only Chagas disease patients manifesting with moderate to severe cardiomyopathy.  (4) 
o Not sure.  (5) 
Q5.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE     
The following are about your practices related to the identification, screening, and treatment of actual 
Chagas disease case(s).     
Q5.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened 
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q5.2 = Yes
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Q5.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test 
to confirm diagnosis?
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive 
a positive confirmatory diagnosis?
o Yes  (8) 
o No  (9) 
Display This Question:
If Q5.4 = Yes
Q5.5 In the past year, if you screened suspected Chagas patients, how many that were positive were 
confirmed by the CDC?
________________________________________________________________
Display This Question:
If Q5.4 = Yes
Q5.6 Please provide additional comments regarding your experience in confirming a Chagas disease 
diagnosis:
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q5.2 = Yes
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Q5.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to 
screen for Chagas disease? Select all that apply.
▢Physical assessment.  (2) 
▢12 lead strip electrocardiogram.  (3) 
▢Patient's medical and social history.  (4) 
Display This Question:
If Q5.2 = Yes
Q5.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county 
health departments to coordinate treatment?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q5.2 = Yes
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Q5.9 If you screened for patients for Chagas disease in the past year, did you coordinate with the CDC to 
confirm diagnosis?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q5.2 = Yes
Q5.10 If you screened and/ or  diagnosed patients for Chagas disease in the past year, what method(s) 
did you use to confirm diagnosis for Chagas disease? Select all that apply.
▢PCR performed at the CDC.  (1) 
▢Commercial antibody testing- ARUP Lab.  (2) 
▢Commercial antibody testing- Mayo Medical Lab.  (3) 
▢Commercial antibody testing- Quest Diagnostics.  (4) 
▢Commercial antibody testing- Labcorp.  (5) 
▢Not sure.  (6) 
Display This Question:
If Q5.2 = Yes
Q5.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you 
coordinate with the CDC for treatment?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q5.2 = Yes
Q5.12 Please provide additional comments regarding your experience obtaining and coordinating 
treatment for patient(s):
________________________________________________________________
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________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.13 If you screened and/ or diagnosed patients for Chagas in the past year, how often did you 
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q5.2 = Yes
Q5.14 Please provide additional comments regarding your experience in coordinating with local and state 
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q5.2 = Yes
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Q5.15 If you screened and/ or diagnosed patients for Chagas disease in the past year and diagnosis was 
confirmed, please indicate the classification of the case(s):
▢Acute  (1) 
▢Chronic-indeterminate  (2) 
▢Chronic-cardiomyopathy  (3) 
▢Chronic-gastrointestinal  (4) 
▢Other  (6) 
▢Not sure  (5) 
Display This Question:
If Q5.15 = Other
Q5.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.17 Please indicate the source(s) of transmission:
▢Locally-acquired  (1) 
▢ Imported  (2) 
▢Not sure  (3) 
Display This Question:
If Q5.2 = Yes
Q5.18 Did you refer out the patient to any other specialist?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q5.18 = Yes
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Q5.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q5.2 = Yes
Q5.20 Was the patient referred to you by another physician?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q5.20 = Yes
Q5.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q6.1 PHYSICIAN PRACTICES  
 The following are Chagas disease screening and diagnosing practices related to your medical specialty.
IRB NUMBER: HSC-SPH-17-1039
IRB APPROVAL DATE: 07/02/2018
Page 19 of 25
Q6.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in 
your patients?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Mother or 
sibling with 
Chagas 
disease. (2) 
o o o o o o
b. History of 
blood 
transfusions 
or organ/ 
tissue 
transplants. 
(3) 
o o o o o o
c. History of 
travel to 
Mexico, 
Central, and 
South 
America. (4) 
o o o o o o
d. 
Consumption 
of foods or 
drinks 
contaminated 
with the 
parasite. (5) 
o o o o o o
Q6.3 In the past 5 years while practicing medicine in Texas, have provided care to a Chagas disease 
patient with a blood donation letter?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.3 = Yes
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Q6.4 How often did you perform the following in patients under your medical care who receive a positive 
Chagas diagnosis (i.e., letter) from a blood donation screening?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Perform a 
physical 
examination. 
(1) 
o o o o o o
b. Request 
commercial 
laboratory 
diagnostics. 
(5) 
o o o o o o
c. Review 
the patient's 
travel 
history. (6) 
o o o o o o
d. Perform 
other 
screening 
tests for 
differential 
diagnosis 
(e.g., ECG). 
(7) 
o o o o o o
e. Refer to a 
cardiologist. 
(9) o o o o o o
f. Refer to 
an infectious 
disease 
specialist. 
(15) 
o o o o o o
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Q6.5 In the past 5 years while practicing medicine in Texas, have you had a patient that was exposed to 
the vector seek medical care from you?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.5 = Yes
Q6.6 How often did you perform the following in patients under your medical care who were exposed to 
a vector?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Perform a 
physical 
examination. 
(1) 
o o o o o o
b. Request 
commercial 
laboratory 
diagnostics. 
(2) 
o o o o o o
c. Review 
the patient's 
travel 
history. (3) 
o o o o o o
d. Perform 
other 
screening 
tests for 
differential 
diagnosis 
(e.g., ECG). 
(4) 
o o o o o o
e. Refer to 
an infectious 
disease 
specialist. 
(11) 
o o o o o o
f. Consult 
with Texas 
DSHS to 
confirm 
vector and/ 
or presence 
of parasite. 
(13) 
o o o o o o
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Q6.7 In thinking about resources you reference when managing the care of a patient who may potentially 
have Chagas disease, how often do you access:
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Medical 
websites 
(e.g., 
UpToDate, 
MedlinePlus, 
etc.) (1) 
o o o o o o
b. Official 
local or 
county health 
department 
websites. (2) 
o o o o o o
c. The Texas 
DSHS 
website. (3) o o o o o o
d. The CDC 
website. (4) o o o o o o
e. Official 
communiques 
and health 
alerts from 
Texas DSHS. 
(5) 
o o o o o o
f. Email alerts 
from the 
Texas 
Medical 
Association. 
(6) 
o o o o o o
g. Morbidity 
and Mortality 
Weekly 
Report 
(MMWR) 
email updates 
from the 
CDC. (7) 
o o o o o o
IRB NUMBER: HSC-SPH-17-1039
IRB APPROVAL DATE: 07/02/2018
Page 23 of 25
Q6.8 Which of the following would you be interested in accessing in order to strengthen your ability to 
help patients with Chagas disease? Select all that apply.
▢Courses  (1) 
▢Seminars  (2) 
▢Manuals  (3) 
▢Other resources  (4) 
Display This Question:
If Q6.8 = Other resources
Q6.9 If you indicated other, please describe:
________________________________________________________________
Q7.1 DEMOGRAPHICS     The following section is about demographics and your medical practice.
Q7.2 How many years have you been practicing in family or general practice?
o Less than 5 years.  (1) 
o 5 to 10 years.  (2) 
o 10 to 15 years.  (3) 
o 15 to 20 years.  (4) 
oMore than 20 years.  (5) 
Q7.3 Which of the following best describes the current type of medical setting you currently practice in?
o Private  (1) 
o Teaching  (2) 
o Community  (3) 
o Other  (4) 
Display This Question:
If Q7.3 = Other
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Q7.4 If other, please describe:
________________________________________________________________
Q7.5 Which of the following best describes the setting where you practice at?
o Urbanized area (i.e., 50,000 or more people).  (1) 
o Rural area (i.e., at least 2,500 people but than 50,000).  (2) 
o None of the above.  (3) 
Q7.6 In your current medical practice, what proportion of total patients you see on average that are 
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()
Q7.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q7.8 Are you male or female?
oMale  (1) 
o Female  (2) 
Q7.9 What is your year of birth? (YYYY)
________________________________________________________________
Q7.10 Please indicate if you received medical training in any of the following places:
oMexico  (1) 
o Central America  (2) 
o South America  (3) 
o None of the above  (4) 
o Prefer not to answer  (5) 
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Display This Question:
If Q7.10 = Central America
Q7.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q7.10 = South America
Q7.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q8.1 
CONCLUSION
Q8.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will 
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas 
disease throughout the state.     In addition to the questionnaire, we are conducting additional research 
via phone interviews with practicing physicians to identify and explore additional barriers related to 
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead 
to missed Chagas diagnosis and frame recommendations to improve awareness and education among 
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do 
decide to provide your contact information to participate in the phone interviews.   
Q8.3 Would you like participate in a 15-minute phone interview?
o Yes, I would like to participate.  (1) 
o No, I decline.  (2) 
Display This Question:
If Q8.3 = Yes, I would like to participate.
Q8.4 Please provide your email:
________________________________________________________________
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Chagas Disease Questionnaire for Infectious Disease Specialists
SURVEY FLOW
Consent and Eligibility
Definitions
Attitudes (5 Questions)
Knowledge (14 Questions)
Knowledge for Infectious Disease Specialists (5 Questions)
Practices: Actual Chagas (20 Questions)
Practices:  Other Activities- Rated (7 Questions)
Participant Demographics (10 Questions)
Questionnaire Conclusion 
Q1.2 Thank you for your interest in completing the following online questionnaire.     The purpose of this 
brief 20-minute questionnaire is to gain a better understanding of Chagas disease awareness, and 
practices among cardiologists, infectious disease specialists and family physicians licensed by the Texas 
Medical Board.    
If you would like to participate in the questionnaire, please continue to the next page.
If you do not wish to participate in the questionnaire, we thank you for your time and interest. You 
can close this page now.
Q1.3 
INFORMED CONSENT
INVITATION TO TAKE PART 
You are invited to take part in a research project called, Chagas Disease Awareness among Physicians in 
Texas, conducted by doctoral candidate Gerardo J. Pacheco of the University of Texas Health Science 
Center at Houston (UTHealth) School of Public Health. For this research project, he will be called the 
Principal Investigator or PI.
Your decision to take part is voluntary. This research project has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston as 
HSC-SPH-17-1039. Although we appreciate your valuable input in this questionnaire, please be advised 
that you may refuse to take part or choose to stop taking part, at any time. Additionally, you may also 
refuse to answer any question(s).
 PROCEDURES
If you agree to take part in this study, you will first confirm your consent by answering the question below. 
Once you consent, you will be directed to the questionnaire. It contains sections regarding your attitudes 
and perspectives, knowledge, and current practices about Chagas disease in Texas. At the completion of 
the questionnaire, you will be prompted to respond whether or not you would like to participate in a 15-
IRB NUMBER: HSC-SPH-17-1039
IRB APPROVAL DATE: 07/02/2018
Page 2 of 28
minute key informant phone interview. You will then be prompted to provide your email address if you 
agree to participate. Conversely, if you decline, you will be directed to a page with the answer key to the 
Chagas disease knowledge questions.
PURPOSE 
The purpose of this research study is to examine the level of knowledge, awareness, and 
practices among licensed physicians in Texas regarding screening, diagnosis, and treatment of Chagas 
as well as to illustrate the potential for missed cases for Chagas disease diagnosis in Texas.
TIME COMMITMENT
The questionnaire will require 20-25 minutes to complete and will be available for up to two weeks. 
BENEFITS 
The potential benefits to participating in this study include the self-assessment of Chagas disease, which 
will allow you as a physician to understand where your current knowledge deficits might be and if further 
resources should be reviewed to be up to date. In more general terms, the results from this study can 
help point towards statewide knowledge deficits and gaps that might be present and push towards 
recommendations for targeted outreach and workshops (e.g., by specialty, location, etc.). 
You may receive no direct benefit from being in the study; however, you taking part may help patients 
receive better in the future.
An answer key is provided at the end of the questionnaire for you to review the Chagas disease 
knowledge section.
RISKS AND/OR DISCOMFORTS 
The risks and discomfort associated with participation in this study are no greater than those ordinarily 
encountered in daily life or during the performance of routine exams. The experience is expected to be 
informative and interesting and thus a generally positive experience.
Confidentiality: Although every measure will be taken to properly safeguard all data pertaining to this 
study, there is a possible risk of breach of confidentiality.
Questionnaire: You may get tired when we are asking you questions or you are completing 
questionnaires. You do not have to answer any questions you do not want to answer.
STUDY WITHDRAWAL
Your decision to take part is voluntary. Although we appreciate your valuable input in this questionnaire, 
please be advised that you may refuse to take part or choose to stop taking part, at any time.  You may 
decide to stop taking part in the study at any time, but you must submit in writing to the PI if you choose to 
have your responses excluded from the analysis. 
COSTS, REIMBURSEMENT AND COMPENSATION 
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If you decide to take part in this research study, you will not incur any additional costs.
You will not be paid for taking part in this study.
CONFIDENTIALITY 
Identifying information will not appear on records retained by the sponsor, with the exception of your birth 
year and your email address if you choose to provide that information for participation in follow-up 
interviews. You will not be personally identified in any reports or publications that may result from this 
study.  
QUESTIONS 
If you have questions at any time about this research study, please feel free to contact the PI at (915) 
240-2821 as he will be glad to answer your questions. You can contact the PI to discuss problems, voice 
concerns, obtain information, and offer input in addition to asking questions about the research.
If you have any questions or concerns about your rights as a research subject, call the Committee for the 
Protection of Human Subjects at (713) 500-7943. You may also call the Committee if you wish to discuss 
problems, concerns, and questions; obtain information about the research; and offer input about current 
or past participation in a research study. 
SIGNATURES 
Submit your consent below to participate in this research only if you understand the information given to 
you about the research and you choose to take part. No signature is required to proceed if you confirm 
your consent below. Make sure that any questions have been answered and that you understand the 
study. 
CPHS STATEMENT: This study (HSC-SPH-17-1039) has been reviewed by the Committee for the 
Protection of Human Subjects (CPHS) of the University of Texas Health Science Center at Houston. For 
any questions about research subject's rights, or to report a research-related injury, call the CPHS at 
(713) 500-7943.
Q1.5 If you wish to participate, please indicate below:
o Yes, I agree to participate.  (1) 
o No, I do not wish to participate.  (2) 
Skip To: End of Survey If Q1.5 = No, I do not wish to participate.
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Q1.6 Are you and MD or DO licensed by the Texas Medical Board to practice in the state of Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q1.6 = No
Q1.7 
Thank you for your interest. However, this questionnaire is intended for physicians.
 
 You may close this page now.
Skip To: End of Survey If Q1.7() Is Displayed
Q1.8 Please indicate your primary medical specialty. If it is not listed below, select “Other”:
o General Practice/ Family Medicine  (1) 
o Infectious Disease  (2) 
o Cardiology  (3) 
o Other  (4) 
Display This Question:
If Q1.8 = Other
Q1.9 If Other, please describe:
________________________________________________________________
Q2.1 DEFINITIONS     
Definitions used for the purpose of this questionnaire:     
Screening: clinical decision-making process or differential diagnosis to determine if further laboratory 
diagnostics are required.    
Diagnosis: the clinical and serological testing required to confirm Chagas disease.    
Vector: Triatomine or Reduviid insect that is able to transmit the parasite T cruzi that causes Chagas 
disease.
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Q3.1 
ATTITUDES ON CHAGAS DISEASE  
  The following sections are about your opinions and attitudes regarding Chagas disease.      
Q3.2 To what extent do you agree or disagree with the following statements?
Strongly 
agree (1)
Somewhat 
agree (2)
Neither agree 
nor disagree 
(3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. Chagas 
disease is under 
diagnosed in 
Texas (i.e., 
failure to 
recognize or 
correctly 
diagnose a 
disease or 
condition in a 
significant 
proportion of the 
population). (1) 
o o o o o
b. Chagas 
disease is 
potentially 
misdiagnosed 
in patients (e.g., 
incorrectly 
diagnosed cases 
of chronic 
Chagas 
cardiomyopathy 
for idiopathic 
cardiomyopathy). 
(2) 
o o o o o
c. The process 
required to 
confirm Chagas 
disease is 
complex and 
thus time 
consuming. (4) 
o o o o o
d. In Texas, 
diagnosis and 
treatment of 
Chagas disease 
is a relatively 
easy process 
with few barriers. 
(9) 
o o o o o
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Q3.3 As an infectious disease specialist, to what extent do you agree or disagree with the following 
statements?
Strongly agree 
(1)
Somewhat 
agree (2)
Neither agree 
or disagree (3)
Somewhat 
disagree (4)
Strongly 
disagree (5)
a. My medical 
training 
prepared me 
to recognize  
patients who 
may need to 
be screened 
for Chagas 
disease. (8) 
o o o o o
b. I routinely 
screen for 
Chagas 
disease in 
patients who 
present with 
risk factors. 
(11) 
o o o o o
c. Accessing 
Chagas 
disease 
treatment is 
not a barrier 
for the 
population I 
serve. (12) 
o o o o o
d. Chagas 
disease 
patients are 
more likely to 
present with 
comorbidities 
than non-
Chagas 
disease 
patients. (14) 
o o o o o
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Q3.4 How confident are you in performing the following when screening for Chagas disease in your 
patient population?
Very confident (1) Somewhat confident (2) Not at all confident (3)
a. Identifying risk 
factors for Chagas 
disease in patients. (1) o o o
b. Recognizing the 
vector that transmits 
Chagas disease. (11) o o o
c. Obtaining a patient's 
social history to identify 
potential risk factors for 
Chagas disease. (13) 
o o o
d. Using 
electrocardiogram 
(ECG) to screen and 
diagnose for chronic 
Chagas disease. (12) 
o o o
Q3.5 How confident are you in performing the following in patients with Chagas disease?
Very confident (1) Somewhat confident (2) Not at all confident (3)
a. Contacting and 
coordinating with the 
local and/or state 
health department 
when consulting about 
a Chagas patient. (1) 
o o o
b. Contacting, 
coordinating, and 
following-up with the 
Centers for Disease 
Control and Prevention 
(CDC) when consulting 
about a Chagas 
patient. (2) 
o o o
c. Requesting the 
Current Procedural 
Terminology laboratory 
codes for diagnosing 
Chagas disease. (4) 
o o o
d. Continuing to provide 
follow-up medical care 
to Chagas patients. (5) o o o
Q3.6 What would be the recommended sequence when managing care of a Chagas patient who has a 
blood donation letter? Please rank from 1 to 5 on how you would prioritize (drag and drop).
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______ Coordinate with local health department and Texas Department of State Health Services (DSHS) 
to confirm diagnosis. (1)
______ Consult with the CDC to manage patient's treatment protocol. (2)
______ Perform baseline clinical workup that includes physical exam, 12-lead ECG, and additional 
testing if warranted. (5)
______ Confirm diagnosis via commercial serology testing. (3)
______ Obtain thorough history to evaluate potential routes of exposure. (4)
Q4.1 KNOWLEDGE     The following sections are to help us asses Texas physicians' knowledge about 
the cause, transmission, and clinical aspects of Chagas disease.   
Q4.2 How does the vector with the parasite transmit Chagas disease to humans?
o The infected vector penetrates the human host skin during bloodmeal, transmitting parasite 
through saliva.  (1) 
o Through infected feces of the vector, that is deposited during the bloodmeal, most commonly 
when the person rubs the infected feces into the bite wound while scratching the area.  (2) 
o The infected vector regurgitates after bloodmeal, transmitting parasite to the human.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.3 How do the majority of people with Chagas disease living in the United States acquire the infection?
o From drinking unpasteurized juices.  (1) 
o From exposure to vectors while residing in Mexico, Central, or South America.  (2) 
o From their mothers (i.e., congenital transmission).  (3) 
o From another infected person.  (4) 
o Not sure.  (5) 
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Q4.4 Since becoming a reportable condition in the state of Texas in 2013, approximately how many total 
Chagas confirmed cases (local and imported) have been reported to the Texas DSHS, between 2013 and 
2016?
o Less than 5.  (1) 
o Between 20 and 30.  (2) 
o Between 75 and 100.  (3) 
oMore than 1,000.  (4) 
o Not sure.  (5) 
Q4.5 Which of the following best describes the clinical course of Chagas disease?
o Acute for 10 to 30 days following exposure to parasite, is self-limiting in most persons within 2 
months, and rarely progresses into the chronic phase.  (1) 
o Acute for a week following exposure to parasite. If left untreated, it is a chronic lifelong infection 2-
4 weeks following exposure to parasite.  (2) 
o Acute for 1-8 weeks following exposure to parasite; asymptomatic for years to decades in the 
majority of infected persons; but becoming symptomatic in a portion of persons infected with parasite.  
(3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.6 The acute phase of Chagas disease may be characterized by which of the following:
o Fever  (1) 
o Swelling at the site of inoculation  (2) 
o No symptoms  (3) 
o All of the above  (4) 
o Not sure  (5) 
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Q4.7 In addition to heart failure, what major clinical disorders manifest frequently and concurrently that 
lead to chronic Chagas cardiomyopathy?
o Cardiac arrhythmias  (1) 
o Thromboembolism (systemic and pulmonary)  (2) 
o Chest pain syndrome  (3) 
o All of the above  (4) 
o Not sure  (5) 
Q4.8 Approximately what percentage of patients worldwide with chronic Chagas disease eventually 
develop the clinical (symptomatic) form of the disease?
o Less than 1%.  (1) 
o Between 20 and 40%.  (2) 
oMore than 50%.  (3) 
o None of the above.  (4) 
o Not sure.  (5) 
Q4.9 Persons infected with chronic Chagas disease may develop which of the following?
o Cardiac conduction abnormalities and/ or cardiomyopathy.  (1) 
oMegaesophagus and/or megacolon.  (2) 
o Co-clinical manifestations.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
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Q4.10 Which of the following may occur in patients with chronic Chagas cardiomyopathy?
o None- can present without clinical manifestations and be asymptomatic.  (1) 
o Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, and edema.  (2) 
o Sudden death.  (3) 
o Any of the above.  (4) 
o Not sure.  (5) 
Q4.11 You should request commercial laboratory diagnostic serology tests, initiate a clinical evaluation of 
the patient, and conduct a thorough history in a patient who:
o Has tested positive for T cruzi during a blood donation or has a sibling or mother who is Chagas-
positive.  (1) 
oWas exposed or potentially exposed to a vector in a period longer than 8 weeks.  (2) 
o Presents with onset of cardiac disease manifestations that are compatible with chronic Chagas 
cardiomyopathy.  (3) 
o All of the above.  (4) 
o Not sure  (5) 
Q4.12 In patients who test positive for Chagas disease after a blood donation or from a laboratory 
diagnostics, obtaining a social history is needed to assess potential routes of exposure, including:
o Travel to or residence in areas endemic for Chagas disease.  (1) 
o Previous history of blood transfusions or organ/ tissue transplants.  (2) 
o Possibility of congenital Chagas disease transmission.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
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Q4.13 Which of the following best describes the method(s) for a confirmatory diagnosis of Chagas 
disease?
o Seropostive results from 2 different immunoassays and/or PCR performed at the CDC.  (1) 
o Positive serology from blood screening donations.  (2) 
o Detection of apolipoprotein A-1 (APOA1) upregulation in human serum.  (3) 
o All of the above.  (4) 
o Not sure.  (5) 
Q4.14 Which of the following describes the current treatment options for Chagas disease?
o Benzindazole and nifurtimox are available only under current investigational protocol by the CDC 
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic 
infection who have no indication of advanced cardiomyopathy.  (1) 
o Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 2-
12 years of age and is available commercially.  (4) 
o Nifurtimox is only available by the CDC under investigational protocol.  (5) 
o Second and third choices only.  (8) 
o Not sure.  (7) 
Q4.15 Should patients with chronic Chagas disease be treated with antitrypanosomal drugs?
o No, there is no evidence that antitrypanosomal treatment for chronic Chagas disease can be 
effective.  (1) 
o Yes, only patients younger than 5 years of age should be treated for chronic Chagas disease.  (2) 
o Treatment is always recommended for patients up to age 18 years of age and generally 
recommended for patients aged 18 to 50.  (3) 
o Only Chagas disease patients manifesting with moderate to severe cardiomyopathy.  (4) 
o Not sure.  (5) 
Q5.1 SPECIFIC KNOWLEDGE ON CHAGAS DISEASE SCREENING & DIAGNOSTICS     The following 
questions are specific to you as an infectious disease specialist in identifying the clinical manifestations of 
Chagas disease and screening the patient.
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Q5.2 What are the important elements of the clinical evaluation of a newly diagnosed chronic Chagas 
patient who is asymptomatic?
o Complete physical examination, complete blood count (CBC), and chemistry panel.  (1) 
o Complete physical examination, electrocardiogram (ECG) with 30 second rhythm strip, and 
detailed history.  (7) 
o Complete physical examination, ECG with 30 second rhythm strip, chest radiograph, barium 
swallow, and detailed history.  (8) 
o None of the above.  (9) 
o Not sure.  (10) 
Q5.3 In general, which of the following is typical of chronic Chagas cardiomyopathy?
o Right bundle branch block.  (1) 
o Ventricular tachycardia.  (6) 
o Left anterior fascicular block.  (7) 
o All of the above.  (8) 
o Not sure.  (9) 
Q5.4 In patients with chronic Chagas cardiomyopathy, cardiac examination typically demonstrates which 
of the following?
oMurmurs of mitral and/ or tricuspid regurgitation.  (1) 
oWide splitting of the second heart sound due to right bundle branch block.  (6) 
o A prominent diffuse apical thrust.  (7) 
o All of the above.  (8) 
o Not sure.  (9) 
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Q5.5 Reactivation of Chagas disease is a concern for patients who:
o Are chronically infected and are receiving immuno-suppressive treatment because of organ 
transplantation.  (1) 
o Are chronically infected and have HIV/AIDS.  (2) 
o Are chronically infected and receive a live-attenuated influenza vaccine.  (3) 
o First and second responses only.  (4) 
o Not sure.  (5) 
Q5.6 Which of the following describes the current treatment options for Chagas disease?
o Benzindazole and nifurtimox are available only under current investigational protocol by the CDC 
in children up to 18 years of age with chronic infections and in adults up to age 50 with chronic 
infection who have no indication of advanced cardiomyopathy.  (1) 
o Benznidazole has been approved by the U.S. Food and Drug Administration (FDA) for patients 2-
12 years of age and is available commercially.  (4) 
o Nifurtimox is only available by the CDC under investigational protocol.  (5) 
o Second and third responses only.  (6) 
o Not sure.  (7) 
Q6.1 PRACTICES RELATED TO SCREENING, DIAGNOSING, AND TREATING CHAGAS DISEASE     
The following are about your practices related to the identification, screening, and treatment of actual 
Chagas disease case(s).     
Q6.2 Over the past five years since becoming a reportable condition in Texas, have you directly screened 
and/ or confirmed a diagnosis for Chagas in patients in your medical care in Texas?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = Yes
Q6.3 In the past year, how many patients that you suspected for Chagas disease did you screen and test 
to confirm diagnosis?
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.4 In the past year, out of those patients that you screened and/ or diagnosed, did any of them receive 
a positive confirmatory diagnosis?
o Yes  (8) 
o No  (9) 
Display This Question:
If Q6.4 = Yes
Q6.5 In the past year, if you screened suspected Chagas patients, how many that were positive were 
confirmed by the CDC?
________________________________________________________________
Display This Question:
If Q6.4 = Yes
Q6.6 Please provide additional comments regarding your experience in confirming a Chagas disease 
diagnosis:
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.7 In the past year, if you have screened suspected Chagas patients, what method(s) did you use to 
screen for Chagas disease? Select all that apply.
▢Physical assessment.  (2) 
▢12 lead strip electrocardiogram.  (3) 
▢Patient's medical and social history.  (4) 
Display This Question:
If Q6.2 = Yes
Q6.8 If you screened patients for Chagas disease in the past year, did you consult with local/ county 
health departments to coordinate treatment?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = Yes
Q6.9 If you screened patients for Chagas disease in the past year, did you coordinate with the CDC to 
confirm diagnosis?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.2 = Yes
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Q6.10 If you screened and/ or diagnosed patients for Chagas disease in the past year, what method(s) 
did you use to confirm diagnosis for Chagas disease? Select all that apply.
▢PCR performed at the CDC.  (1) 
▢Commercial antibody testing- ARUP Lab.  (2) 
▢Commercial antibody testing- Mayo Medical Lab.  (3) 
▢Commercial antibody testing- Quest Diagnostics.  (4) 
▢Commercial antibody testing- Labcorp.  (5) 
▢Not sure.  (6) 
Display This Question:
If Q6.2 = Yes
Q6.11 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you 
coordinate with the CDC for treatment?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q6.2 = Yes
Q6.12 Please provide additional comments regarding your experience obtaining and coordinating 
treatment for patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
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Display This Question:
If Q6.2 = Yes
Q6.13 If you screened and/ or diagnosed patients for Chagas disease in the past year, how often did you 
coordinate with the local health department and/ or Texas DSHS to confirm diagnosis?
o Always  (1) 
o Sometimes  (2) 
o Never  (4) 
o Not sure  (3) 
Display This Question:
If Q6.2 = Yes
Q6.14 Please provide additional comments regarding your experience in coordinating with local and state 
health department officials when diagnosing a Chagas patient(s):
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
Display This Question:
If Q6.2 = Yes
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Q6.15 If you screened patients in the past year and diagnosis was confirmed, please indicate the 
classification of the case(s):
▢Acute  (1) 
▢Chronic-indeterminate  (2) 
▢Chronic-cardiomyopathy  (3) 
▢Chronic-gastrointestinal  (4) 
▢Other  (6) 
▢Not sure  (5) 
Display This Question:
If Q6.15 = Other
Q6.16 Please describe the classification of the Chagas case(s) if "other" was selected:
________________________________________________________________
Display This Question:
If Q6.2 = Yes
Q6.17 Please indicate the source(s) of transmission:
▢Locally-acquired  (1) 
▢ Imported  (2) 
▢Not sure  (3) 
Display This Question:
If Q6.2 = Yes
Q6.18 Did you refer out the patient to any other specialist?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.18 = Yes
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Q6.19 If you did refer out, please indicate to what other physician specialty:
________________________________________________________________
Display This Question:
If Q6.2 = Yes
Q6.20 Was the patient referred to you by another physician?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q6.20 = Yes
Q6.21 What was the physician specialty/ies that referred the Chagas patient(s) to you?
________________________________________________________________
Q7.1 PHYSICIAN PRACTICES  
 The following are Chagas disease screening and diagnosing practices related to your medical specialty.
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Q7.2 In general, how often do you consider each of the following as exposure risks for Chagas disease in 
your patients?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Mother or 
sibling with 
Chagas 
disease. (2) 
o o o o o o
b. History of 
blood 
transfusions 
or organ/ 
tissue 
transplants. 
(3) 
o o o o o o
c. Travel to 
Mexico, 
Central, or 
South 
America. (4) 
o o o o o o
d. 
Consumption 
foods or 
drinks 
contaminated 
with the 
parasite. (5) 
o o o o o o
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Q7.3 In general, how often do you perform the following in patients under your medical care who present 
with idiopathic cardiomyopathy?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Review the 
patient's travel 
history. (3) o o o o o o
b. Look for signs 
of cardiac 
arrhythmias that 
may arise due to 
chronic Chagas 
cardiomyopathy. 
(5) 
o o o o o o
c. Evaluate 
patient's 
cardiopulmonary 
function (i.e., 
exercise stress 
test). (17) 
o o o o o o
d. Perform 
cardiovascular 
testing (chest x-
ray, 
echocardiogram, 
etc.) to asses 
myocardial 
damage. (2) 
o o o o o o
Q7.4 In the past 5 years while practicing medicine in Texas, have you provided care to a Chagas disease 
patient with a blood donation letter?
o Yes  (1) 
o No  (2) 
Display This Question:
If Q7.4 = Yes
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Q7.5 In the past 5 years while practicing in Texas, how often did you perform the following in patients 
under your medical care who received a positive Chagas diagnosis (i.e., letter) from a blood donation 
screening?
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Review the 
patient's travel 
history. (6) o o o o o o
b. Request 
serology to 
confirm Chagas 
diagnosis. (5) 
o o o o o o
c. Evaluate 
patient's 
cardiopulmonary 
function (i.e., 
exercise stress 
test). (7) 
o o o o o o
d. Perform 
cardiovascular 
testing (chest x-
ray, 
echocardiogram, 
etc.) to asses 
myocardial 
damage. (20) 
o o o o o o
e. Consult with 
the Texas DSHS 
to manage 
treatment. (9) 
o o o o o o
f. Consult with 
the CDC to 
manage 
treatment. (21) 
o o o o o o
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Q7.6 In thinking about resources you reference when managing the care of a patient who may potentially 
have Chagas disease, how often do you access:
Never (1) Rarely (2) Sometimes (3) Often (4) Always (5) N/A (6)
a. Medical 
websites 
(e.g., 
UpToDate, 
MedlinePlus, 
etc.) (1) 
o o o o o o
b. Official 
local or 
county health 
department 
websites. (2) 
o o o o o o
c. The Texas 
DSHS 
website. (3) o o o o o o
d. The CDC 
website. (4) o o o o o o
e. Official 
communiques 
and health 
alerts from 
Texas DSHS. 
(5) 
o o o o o o
f. Email alerts 
from the 
Texas 
Medical 
Association. 
(6) 
o o o o o o
g. Morbidity 
and Mortality 
Weekly 
Report 
(MMWR) 
email updates 
from the 
CDC. (7) 
o o o o o o
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Q7.7 Which of the following would you be interested in accessing in order to strengthen your ability to 
help patients with Chagas disease? Select all that apply.
▢Courses  (1) 
▢Seminars  (2) 
▢Manuals  (3) 
▢Other resources  (4) 
Display This Question:
If Q7.7 = Other resources
Q7.8 If you indicated other, please describe:
________________________________________________________________
Q8.1 DEMOGRAPHICS     The following section is about demographics and your medical practice.
Q8.2 How many years have you been practicing in family or general practice?
o Less than 5 years.  (1) 
o 5 to 10 years.  (2) 
o 10 to 15 years.  (3) 
o 15 to 20 years.  (4) 
oMore than 20 years.  (5) 
Q8.3 Which of the following best describes the current type of medical setting you currently practice in?
o Private  (1) 
o Teaching  (2) 
o Community  (3) 
o Other  (4) 
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Display This Question:
If Q8.3 = Other
Q8.4 If other, please describe:
________________________________________________________________
Q8.5 Which of the following best describes the setting where you practice at?
o Urbanized area (i.e., 50,000 or more people).  (1) 
o Rural area (i.e., at least 2,500 people but than 50,000).  (2) 
o None of the above.  (3) 
Q8.6 In your current medical practice, what proportion of total patients you see on average that are 
Hispanics/ Latinos?
0 10 20 30 40 50 60 70 80 90 100
Click to write Choice 1 ()
Q8.7 PARTICIPANT DEMOGRAPHICS- PART 2
Q8.8 Are you male or female?
oMale  (1) 
o Female  (2) 
Q8.9 What is your year of birth? (YYYY)
________________________________________________________________
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Q8.10 Please indicate if you received medical training in any of the following places:
oMexico  (1) 
o Central America  (2) 
o South America  (3) 
o None of the above  (4) 
o Prefer not to answer  (5) 
Display This Question:
If Q8.10 = Central America
Q8.11 If you received medical training in Central America, indicate the country:
________________________________________________________________
Display This Question:
If Q8.10 = South America
Q8.12 If you received medical training in South America, indicate the country:
________________________________________________________________
Q9.1 
CONCLUSION
Q9.2 Thank you for participating in this questionnaire. We know your time is valuable. Your responses will 
remain anonymous and will be used to identify a baseline of knowledge and awareness of Chagas 
disease throughout the state.     In addition to the questionnaire, we are conducting additional research 
via phone interviews with practicing physicians to identify and explore additional barriers related to 
screening and diagnosing of Chagas disease in Texas. The goal is to understand the challenges that lead 
to missed Chagas diagnosis and frame recommendations to improve awareness and education among 
practicing physicians in Texas. Questionnaire responses will be kept separate and confidential if you do 
decide to provide your contact information to participate in the phone interviews.   
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Q9.3 Would you like participate in a 15-minute phone interview?
o Yes, I would like to participate.  (1) 
o No, I decline.  (2) 
Display This Question:
If Q9.3 = Yes, I would like to participate.
Q9.4 Please provide your email:
________________________________________________________________
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Appendix C: Semi-Structured Interview Scripts and Forms 
Date: _____ / ______ / _______  Time: ______________  Study ID: ___   ___   ____   ____ 
 
Semi-structured Interview Script for Physicians: Managed Care of Chagas Patients 
 
Introduction 
 
• Good morning/ afternoon. Thank you for your time. My name is Jerry Pacheco. I’m a doctoral 
candidate at the UT School of Public Health.  
• As part of my doctoral dissertation, I will focus on Chagas disease in Texas and the level of 
awareness among healthcare providers. I will be collecting primary data for my research, as part of 
my aims, I am collecting quantitative data (that is data from online questionnaires) as well as 
qualitative data—that is the data I hope to collect today through this interview.  
• We hope that through this interview, we can dive further and explore challenges and barriers that 
physicians have experienced that way we can frame recommendations for improving outreach, 
education, and resources to physicians in Texas about Chagas disease so that the disease is 
diagnosed and managed on time. 
• Thank you for agreeing to participate. 
 
Informed consent 
 Explain the risks/ benefits and confidentiality and how results will be used (refer them to form) 
• I emailed a copy of the consent. Please review and keep for your records. The risks and discomfort 
associated with participation in this study are no greater than those ordinarily encountered in daily 
life or during the performance of routine exams. The experience is expected to be informative and 
interesting and thus a generally positive experience. 
• Your decision to take part is voluntary. You may decide to stop taking part in the study at any time. 
• I would like to make am audio recording of our discussion, so that I can have an accurate record of 
the information that you provide to me. 
• This study (HSC-SPH-17-1039) has been reviewed by the Committee for the Protection of Human 
Subjects of the University of Texas Health Science Center at Houston.  
• If you have any questions refer to the Informed Consent Form I email you for the university research 
office’s contact information.. 
 
Confirm provider specialty and/ or treatment of CD patients 
 
• Can you confirm your specialty? Provider Specialty: 
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 Infectious Disease  
 Cardiology 
 Other: ____________________ 
 
 
Demographics and type of practice 
 
1. How many years of have you been in your primary specialization? _________________________________ 
2. How would you describe your current medical practice?  a.  institution, community clinic, private b. rural or urban  
3. Did you receive any medical training or practice in Mexico, Central or South America? Please 
describe: 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
Guiding Questions 
 
I will be asking questions regarding the continuum of care, which includes screening, diagnosis, treatment, 
and follow-up of care. For the purpose of my research and this interview: 
Screening: is the clinical, decision-making process or differential diagnosis to determine if further 
laboratory diagnosis are required. 
Diagnosis: the clinical and serological testing required to confirm Chagas disease. 
1. Can you describe your experience in managing the care of a Chagas disease patient? 
a. How many cases have you managed? Screened: ____ Diagnosed: ____ Treated:____ Total: ____ 
i. Were they in Texas? Mexico? Central America? South America? 
ii. When? ______________________________________________________________ 
b. How did that patient(s) come to your care? ____________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
c. Can you provide a brief summary, from your recollection, of the case study/ studies? i. Local:   Imported: ii. Acute:  Indeterminate:  Chronic: iii. Patient demographics (age, sex, Ethnicity/ race) 
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________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ ________________________________________________________________________ 
d. What resources did you review or whom did you consult with to better understand the 
process to screen, diagnose, or treat a Chagas disease patient? 
_____________________________________ ______________________________________________________________________________ ______________________________________________________________________________ 
e. What was the most important lesson(s) learned from your experience(s)? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
f. What were the most challenging aspects or barriers in delivering care to your patient with 
Chagas disease? ________________________________________________________________________ _______________________________________________________________________________ _______________________________________________________________________________ i. Screening specific: ________________________________________________________ ii. Diagnosis specific: _________________________________________________________ iii. Treatment specific: ________________________________________________________ 2. Did you ever consider a Chagas disease diagnosis prior to your first experience in managing a 
Chagas patient?  a. Why? Why not? _________________________________________________________________ 
_______________________________________________________________________________ ______________________________________________________________________________ 
b. What was your level of knowledge and skills in diagnosing patients with Chagas disease 
before your experience(s) managing your first Chagas disease patient(s)? 
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_______________________________________________________________________________ 
_______________________________________________________________________________ 
c. What was your level of knowledge and skills in diagnosing patients with Chagas disease 
after your experience(s) managing your first Chagas disease patient(s)? 
_______________________________________________________________________________ 
______________________________________________________________________________ 
d. Looking back, what are some considerations or resources that you now know of that could 
have been helpful during your first experience managing the care of a Chagas disease 
patient? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
e. Did you have sufficient education/ training to be able to screen, diagnose, and/ or treat 
Chagas disease patients? ________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
3. Do you think that Chagas disease is a bigger problem in Texas than other states in the U.S.? 
a. Why? Why not? __________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
b. Do we need to increase the level of outreach and education that we provide to physicians in 
Texas? _______________________________________________________________________________ 
_______________________________________________________________________________ 
c. How can we increase communication to physicians in Texas for them to better understand 
Chagas disease? _______________________________________________________________________ 
______________________________________________________________________________ 
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4. What proportion of Hispanic/ Latino population do you serve in your medical practice? 
_______________ 
a. What is your Spanish fluency in terms of managing Hispanic/Latino patients with Chagas 
disease? 
 ______________________________________________________________________________ 
______________________________________________________________________________ 
b. How do you handle patients with limited English fluency? ________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
5. Are there any additional comments, suggestions, or feedback you would like to share? 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
6. Lastly, are there any colleagues, within your specialty (cardiology or ID) in Texas that I may reach 
out and interview about their experiences managing the care of Chagas disease patients? a. Name: _________________________________________________________________________ b. Email: __________________________________________________________________________ c. Phone Number: __________________________________________________________________ d. Physician Specialty: _______________________________________________________________ 
Summary Recap what was discussed. 
Conclusion  
 Thank the participant for their time and remind them about confidentiality and how important this qualitative data will be in framing the results from the survey and framing recommendations. 
 
Thank you for your time. I know your time is valuable and your responses will help frame recommendations 
to address current barriers and challenges that might prevent or delay the diagnosis of Chagas disease. 
.  
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Date: _____ / ______ / _______  Time: ______________  Study ID: ___   ___   ____   ____ 
 
Semi-structured Interview Script for Physicians: Not Managed Care of Chagas Patients 
 
Introduction 
 
• Good morning/ afternoon. Thank you for your time. My name is Jerry Pacheco. I’m a doctoral 
candidate at the UT School of Public Health.  
• As part of my doctoral dissertation, I will focus on Chagas disease in Texas and the level of 
awareness among healthcare providers. I will be collecting primary data for my research, as part of 
my aims, I am collecting quantitative data (that is data from online questionnaires) as well as 
qualitative data—that is the data I hope to collect today through this interview.  
• We hope that through this interview, we can dive further and explore challenges and barriers that 
physicians have experienced that way we can frame recommendations for improving outreach, 
education, and resources to physicians in Texas about Chagas disease so that the disease is 
diagnosed and managed on time. 
• Thank you for agreeing to participate. 
 
Informed consent 
 Explain the risks/ benefits and confidentiality and how results will be used (refer them to form) 
• I emailed a copy of the consent. Please review and keep for your records. The risks and discomfort 
associated with participation in this study are no greater than those ordinarily encountered in daily 
life or during the performance of routine exams. The experience is expected to be informative and 
interesting and thus a generally positive experience. 
• Your decision to take part is voluntary. You may decide to stop taking part in the study at any time. 
• I would like to make am audio recording of our discussion, so that I can have an accurate record of 
the information that you provide to me. 
• This study (HSC-SPH-17-1039) has been reviewed by the Committee for the Protection of Human 
Subjects of the University of Texas Health Science Center at Houston.  
• If you have any questions refer to the Informed Consent Form I email you for the university research 
office’s contact information. 
 
Confirm provider specialty and/ or treatment of CD patients 
 
• Can you confirm your specialty? Provider Specialty: 
 Infectious Disease  
 Cardiology 
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 Other: ____________________ 
 
 
Demographics and type of practice 
 
4. How many years of have you been in your primary specialization? _________________________________ 
5. How would you describe your current medical practice?  a.  institution, community clinic, private, other: ________________ b. rural or urban  
6. Did you receive any medical training or practice in Mexico, Central or South America? Please 
describe: 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
Guiding Questions 
 
I will be asking questions regarding the continuum of care, which includes screening, diagnosis, treatment, 
and follow-up of care. For the purpose of my research and this interview: 
Screening: is the clinical, decision-making process or differential diagnosis to determine if further 
laboratory diagnosis are required. 
Diagnosis: the clinical and serological testing required to confirm Chagas disease. 
7. Can you confirm whether you have directly managed the care of a Chagas disease patient? 
a. Can you please describe your experience(s) with Chagas disease? __________________________ 
______________________________________________________________________________ 
______________________________________________________________________________ 
b. What resources would you use, or whom did you consult with to better understand the 
process to screen, diagnose, or treat a Chagas disease patient? 
_____________________________________ ______________________________________________________________________________ ______________________________________________________________________________ 
c. What do you think are the most challenging aspects or barriers in delivering care to a 
patient with Chagas disease in Texas? 
________________________________________________________________________ _______________________________________________________________________________ 
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_______________________________________________________________________________ i. Screening specific: ________________________________________________________ ii. Diagnosis specific: _________________________________________________________ iii. Treatment specific: ________________________________________________________ 8. Have you ever considered a Chagas disease diagnosis?  a. Why? Why not? _________________________________________________________________ 
_______________________________________________________________________________ ______________________________________________________________________________ 
b. What is your current level of knowledge and skills in screening and diagnosing patients 
with Chagas disease? 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
c. Do you have sufficient education/ training to be able to screen, diagnose, and/ or treat 
Chagas disease patients? ________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
9. Do you think that Chagas disease is a bigger problem in Texas than other states in the U.S.? 
a. Why? Why not? __________________________________________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
b. Do we need to increase the level of outreach and education that we provide to physicians in 
Texas? _______________________________________________________________________________ 
_______________________________________________________________________________ 
c. How can we increase communication to physicians in Texas for them to better understand 
Chagas disease? _______________________________________________________________________ 
______________________________________________________________________________ 
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10. What proportion of Hispanic/ Latino population do you serve in your medical practice? 
_______________ 
a. What is your Spanish fluency in terms of managing Hispanic/Latino patients with Chagas 
disease? 
 ______________________________________________________________________________ 
______________________________________________________________________________ 
b. How do you handle patients with limited English fluency? ________________________________ 
_______________________________________________________________________________ 
_______________________________________________________________________________ 
11. Are there any additional comments, suggestions, or feedback you would like to share? 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
______________________________________________________________________________________ 
12. Lastly, are there any colleagues, within your specialty (cardiology or ID) in Texas that I may reach 
out and interview about their experiences managing the care of Chagas disease patients? a. Name: _________________________________________________________________________ b. Email: __________________________________________________________________________ c. Phone Number: __________________________________________________________________ d. Physician Specialty: _______________________________________________________________ 
Summary Recap what was discussed. 
Conclusion   Thank the participant for their time and remind them about confidentiality and how important this qualitative data will be in framing the results from the survey and framing recommendations. 
 
Thank you for your time. I know your time is valuable and your responses will help frame recommendations 
to address current barriers and challenges that might prevent or delay the diagnosis of Chagas disease. 
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Appendix D: Table of ICD-9 CM and ICD-10 CM Chagas and Cardiomyopathy 
Codes 
ICD  ICD 
Code 
Code Description Total 2013 2014 2015 2016 
ICD-9  0860 Chagas with heart involvement 42 12 22 8 - 
ICD-10  B570 Acute Chagas with heart 
involvement  0 - - 0 0 
ICD-10  B572 Chronic Chagas with heart 
involvement 37 - - 10 27 
ICD-10  B571 Acute Chagas without heart 
involvement  1 - - 1 0 
ICD-9  0861 Chagas with other organ 
involvement  0 0 0 0 - 
ICD-10  B575 Chagas disease (chronic) with 
other organ involvement 0 - - 0 0 
ICD-9  0862 Chagas without mention of 
organ involvement  21 4 11 6 - 
ICD-9  4148 Other chronic ischemic heart 
disease 118,206 42,172 42,757 33,277 - 
ICD-10  I255 Ischemic cardiomyopathy  55,668 - - 10,660 45,008 
ICD-9  42291 Idiopathic myocarditis  384 127 141 116 - 
ICD-9  4254 Cardiomyopathy, includes 
idiopathic  150,207 52,970 54,302 42,935 - 
ICD-10 I425 Other restrictive cardiomyopathy 0 - - 0 0 
ICD-10 I428 Other cardiomyopathies 0 - - 0 0 
ICD-9  4258 Cardiomyopathy, excluding 
Chagas  5,666 2,092 1,956 1,618 - 
ICD-10  I429 Cardiomyopathy, unspecified 48,461 - - 9,553 38,908 
 
 Combined Chagas DX 101  
Combined Heart-Related DX 378,592 
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Appendix E: Table of Mapped ICD Counts, by County 
County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Anderson 0 0 0 978 
Andrews 0 0 0 157 
Angelina 0 0 0 1,704 
Aransas 0 0 0 366 
Archer 0 0 0 129 
Armstrong 0 0 0 10 
Atascosa 0 0 0 849 
Austin 0 0 0 609 
Bailey 0 0 0 96 
Bandera 0 0 0 417 
Bastrop 0 0 0 1,483 
Baylor 0 0 0 73 
Bee 0 0 0 521 
Bell 0 0 0 3,762 
Bexar 7 1 8 21,195 
Blanco 0 1 1 205 
Borden 0 0 0 2 
Bosque 0 1 1 168 
Bowie 0 0 0 2,066 
Brazoria 1 0 1 3,954 
Brazos 0 0 0 2,705 
Brewster 0 0 0 99 
Briscoe 0 0 0 7 
Brooks 0 0 0 136 
Brown 0 0 0 820 
Burleson 0 0 0 652 
Burnet 0 0 0 736 
Caldwell 0 0 0 777 
Calhoun 0 0 0 355 
Callahan 0 0 0 347 
Cameron 3 0 3 8,567 
Camp 0 0 0 420 
Carson 0 0 0 90 
Cass 0 0 0 705 
Castro 0 0 0 53 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Chambers 0 0 0 408 
Cherokee 0 0 0 1,153 
Childress 0 0 0 65 
Clay 0 0 0 214 
Cochran 0 0 0 50 
Coke 0 0 0 62 
Coleman 0 0 0 170 
Collin 2 0 2 7,913 
Collingsworth 0 0 0 38 
Colorado 0 0 0 561 
Comal 0 0 0 1,397 
Comanche 0 0 0 216 
Concho 0 0 0 44 
Cooke 0 0 0 586 
Coryell 0 0 0 759 
Cottle 0 0 0 24 
Crane 0 0 0 28 
Crockett 0 0 0 57 
Crosby 0 0 0 56 
Culberson 0 0 0 46 
Dallam 0 0 0 100 
Dallas 21 5 26 34,526 
Dawson 0 0 0 97 
Deaf Smith 0 0 0 149 
Delta 0 0 0 112 
Denton 7 1 8 7,218 
DeWitt 0 0 0 335 
Dickens 0 0 0 29 
Dimmit 0 0 0 223 
Donley 0 0 0 59 
Duval 0 0 0 219 
Eastland 0 0 0 337 
Ector 0 0 0 2,177 
Edwards 0 0 0 35 
Ellis 0 0 0 2,482 
El Paso 0 0 0 7,777 
Erath 0 0 0 451 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Falls 0 0 0 195 
Fannin 0 0 0 704 
Fayette 0 0 0 651 
Fisher 0 0 0 58 
Floyd 0 0 0 61 
Foard 0 0 0 28 
Fort Bend 0 0 0 6,064 
Franklin 0 0 0 131 
Freestone 0 0 0 219 
Frio 0 0 0 276 
Gaines 0 0 0 110 
Galveston 0 0 0 7,049 
Garza 0 0 0 79 
Gillespie 0 0 0 404 
Glasscock 0 0 0 7 
Goliad 0 0 0 166 
Gonzales 0 0 0 268 
Gray 0 0 0 565 
Grayson 0 0 0 2,578 
Gregg 0 0 0 2,233 
Grimes 0 0 0 833 
Guadalupe 0 0 0 1,070 
Hale 0 0 0 369 
Hall 0 0 0 63 
Hamilton 0 0 0 72 
Hansford 0 0 0 51 
Hardeman 0 0 0 92 
Hardin 0 0 0 962 
Harris 21 4 25 59,118 
Harrison 0 0 0 769 
Hartley 0 0 0 8 
Haskell 0 0 0 111 
Hays 0 0 0 2,068 
Hemphill 0 0 0 35 
Henderson 0 0 0 1,882 
Hidalgo 0 0 0 11,020 
Hill 0 0 0 447 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Hockley 0 0 0 266 
Hood 0 0 0 907 
Hopkins 0 0 0 553 
Houston 0 0 0 448 
Howard 0 0 0 951 
Hudspeth 0 0 0 46 
Hunt 0 0 0 1,624 
Hutchinson 0 0 0 351 
Irion 0 0 0 20 
Jack 0 0 0 150 
Jackson 0 0 0 271 
Jasper 0 0 0 589 
Jeff Davis 0 0 0 17 
Jefferson 0 2 2 4,664 
Jim Hogg 0 0 0 70 
Jim Wells 0 0 0 653 
Johnson 5 3 8 3,836 
Jones 0 0 0 272 
Karnes 0 0 0 179 
Kaufman 0 0 0 1,505 
Kendall 0 0 0 544 
Kenedy 0 0 0 5 
Kent 0 0 0 7 
Kerr 0 0 0 899 
Kimble 0 0 0 49 
King 0 0 0 2 
Kinney 0 0 0 50 
Kleberg 0 0 0 433 
Knox 0 0 0 66 
Lamar 0 0 0 1,416 
Lamb 0 0 0 126 
Lampasas 0 0 0 459 
La Salle 0 0 0 127 
Lavaca 0 0 0 420 
Lee 0 0 0 380 
Leon 0 0 0 502 
Liberty 0 0 0 1,846 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Limestone 0 0 0 234 
Lipscomb 0 0 0 38 
Live Oak 0 0 0 159 
Llano 0 0 0 440 
Loving 0 0 0 - 
Lubbock 0 0 0 2,781 
Lynn 0 0 0 58 
McCulloch 0 0 0 191 
McLennan 0 0 0 1,734 
McMullen 0 0 0 18 
Madison 0 0 0 344 
Marion 0 0 0 220 
Martin 0 0 0 70 
Mason 0 0 0 54 
Matagorda 0 0 0 705 
Maverick 0 0 0 1,802 
Medina 0 0 0 729 
Menard 0 0 0 35 
Midland 0 0 0 1,629 
Milam 0 0 0 444 
Mills 0 0 0 41 
Mitchell 0 0 0 116 
Montague 0 0 0 431 
Montgomery 2 0 2 7,536 
Moore 0 0 0 152 
Morris 0 0 0 263 
Motley 0 0 0 19 
Nacogdoches 0 0 0 903 
Navarro 0 0 0 855 
Newton 0 0 0 157 
Nolan 0 0 0 336 
Nueces 0 0 0 4,300 
Ochiltree 0 0 0 85 
Oldham 0 0 0 15 
Orange 0 0 0 1,586 
Palo Pinto 0 0 0 612 
Panola 0 0 0 405 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Parker 0 0 0 1,795 
Parmer 0 0 0 73 
Pecos 0 0 0 119 
Polk 0 0 0 944 
Potter 0 0 0 1,764 
Presidio 0 0 0 59 
Rains 0 0 0 258 
Randall 0 0 0 1,337 
Reagan 0 0 0 39 
Real 0 0 0 74 
Red River 0 0 0 372 
Reeves 0 0 0 123 
Refugio 0 0 0 129 
Roberts 0 0 0 13 
Robertson 0 0 0 522 
Rockwall 0 0 0 840 
Runnels 0 0 0 179 
Rusk 0 0 0 812 
Sabine 0 0 0 193 
San Augustine 0 0 0 200 
San Jacinto 0 0 0 451 
San Patricio 0 0 0 897 
San Saba 0 0 0 105 
Schleicher 0 0 0 33 
Scurry 0 0 0 177 
Shackelford 0 0 0 65 
Shelby 0 0 0 405 
Sherman 0 0 0 26 
Smith 0 0 0 4,176 
Somervell 0 0 0 92 
Starr 0 0 0 850 
Stephens 0 0 0 197 
Sterling 0 0 0 10 
Stonewall 0 0 0 25 
Sutton 0 0 0 67 
Swisher 0 0 0 119 
Tarrant 2 0 2 28,002 
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County Name Chagas, Heart 
Chagas, 
Other Chagas, Total 
Non-Chagas Heart- Related 
Total 
Taylor 0 0 0 2,711 
Terrell 0 0 0 13 
Terry 0 0 0 158 
Throckmorton 0 0 0 36 
Titus 0 0 0 337 
Tom Green 0 0 0 1,760 
Travis 2 1 3 11,941 
Trinity 0 0 0 360 
Tyler 0 0 0 360 
Upshur 0 0 0 595 
Upton 0 0 0 31 
Uvalde 0 0 0 573 
Val Verde 0 0 0 700 
Van Zandt 0 0 0 1,118 
Victoria 0 0 0 2,038 
Walker 0 0 0 1,735 
Waller 0 0 0 619 
Ward 0 0 0 123 
Washington 0 0 0 676 
Webb 0 0 0 2,365 
Wharton 0 0 0 847 
Wheeler 0 0 0 74 
Wichita 0 0 0 3,035 
Wilbarger 5 1 6 345 
Willacy 0 0 0 458 
Williamson 0 0 0 3,806 
Wilson 0 0 0 402 
Winkler 0 0 0 90 
Wise 0 0 0 1,325 
Wood 0 0 0 1,126 
Yoakum 0 0 0 54 
Young 0 0 0 366 
Zapata 0 0 0 175 
Zavala 0 0 0 279 
  78   20   98   366,575  
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Appendix F: Raw Responses for Knowledge Questions, All Questionnaires 
 
Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
Q1. How does the vector with the parasite transmit CD to 
humans?     
Infected vector penetrates the human host skin during 
bloodmeal, transmitting parasite through saliva 5 (11.6) 4 (19.1) 1 (5.3) - 
♦Through infected feces of the vector, that is deposited during 
bloodmeal, most commonly when the person rubs the infected 
feces into the bite wound while scratching the area 
23 (53.5) 6 (28.6) 15 (79.0) 2 (66.7) 
The infected vector regurgitates after bloodmeal, transmitting 
parasite to human 2 (4.7) 1 (4.8) 1 (5.3) - 
None of the above - - - - 
Not sure 4 (9.3) 4 (8.0) - - 
No response 9 (20.9)   6 (28.6) 2 (10.5) 1 (33.3) 
Q2. How do the majority of people with CD living in the U.S. 
acquire the infection?     
From drinking unpasteurized juices - - - - 
♦From exposure to vectors while residing in Mexico, Central, 
or South America 29 (67.4) 11 (52.4) 16 (84.2) 2 (66.7) 
From their mothers - - - - 
From another infected person - - - - 
Not sure 5 (11.6) 4 (19.1) 1 (5.3) - 
No response 9 (20.9) 6 (28.6) 2 (10.5) 1 (33.3) 
Q3. Total number of reported CD cases to DSHS      
Less than 5 - - - - 
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
Between 20 and 30 4 (9.3) 1 (4.0) 3 (15.8) - 
♦Between 75 and 100 7 (16.3)   4 (19.1) 3 (15.8) - 
More than 1,000 6 (14.0) 2 (9.5) 3 (15.8) 1 (33.3) 
Not sure 17 (39.5)   8 (38.1) 8 (42.1) 1 (33.3) 
No response 9 (20.9)   6 (28.6) 2 (10.5) 1 (33.3) 
Q4. Clinical course for CD     
Acute for 10-30 days following exposure to parasite, is self-
limiting in most persons within 2 months, and rarely progresses 
into the chronic phase 
3 (7.0) 2 (9.5) - 1 (33.3) 
Acute for a week following exposure to parasite. If left 
untreated, it is a chronic lifelong infection 2-4 weeks following 
exposure to parasite. 
1 (2.3) - - 1 (33.3) 
♦Acute 1-8 weeks following exposure to parasite; 
asymptomatic for years to decades in the majority of infected 
persons; but becoming symptomatic in a portion of persons 
infected with parasite 
21 (48.8) 7 (33.3) 14 (73.7) - 
None of the above - - - - 
Not sure 8 (18.6) 6 (28.6) 2 (10.5) - 
No response 14 (32.6) 10 (40.0) 3 (15.8) 1 (33.3) 
Q5. Characteristic symptoms for acute phase of CD     
Fever 1 (2.3) 1 (4.8) - - 
Swelling at the site of inoculation 5 (11.6) 1 (4.8) 4 (21.1) - 
No symptoms - - - - - 
♦All of the above 23 (53.5) 10 (47.6) 11 (57.9) 2 (66.7) 
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
Not sure 4 (9.3) 3 (14.3) 1 (5.3) - 
No response 10 (23.3) 6 (28.6) 3 (15.8) 1 (33.3) 
Q6. Proportion of patients with chronic CD that develop 
symptoms     
Less than 1% 7 (16.3) 5 (23.8) 1 (5.3) 1 (33.3) 
♦Between 20% and 40% 14 (32.6) 3 (14.3) 11 (57.9) - 
More than 50% 2 (4.7) 1 (4.8) 1 (5.3) - 
None of the above - - - - 
Not sure 10 (23.3) 6 (28.6) 3 (15.8) 1 (33.3) 
No response 10 (23.3) 6 (28.6) 3 (15.8) 1 (33.3) 
Q7. Symptoms that may develop in patients with chronic CD     
Cardiac conduction abnormalities and/ or cardiomyopathy 2 (4.7) - 1 (5.3) 1 (33.3) 
Megaesophagus and/ or megacolon - - - - 
Co-clinical manifestations 1 (2.3) - 1 (5.3) - 
♦All of the above 28 (65.1)  13 (61.9) 14 (73.7) 1 (33.3) 
Not sure 2 (4.7) 2 (9.5) - - 
No response 10 (23.3)   6 (28.6) 3 (15.8) 1 (33.3) 
Q8. Chronic CD cardiomyopathy possible manifestations     
None- can present without clinical manifestations and be 
asymptomatic - - - - 
Dyspnea on exertion, fatigue, palpitations, dizziness, syncope, 
and edema 1 (2.3) - - 1 (33.3) 
Sudden death - - - - 
♦Any of the above 30 (69.8) 13 (52.0) 16 (84.2) 1 (33.3) 
Not sure 2 (4.7) 2 (8.0) - - 
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
No response 14 (32.6) 10 (40.0) 3 (15.8) 1 (33.3) 
Q9. Request commercial lab diagnostic serology tests, initiate a 
clinical evaluation of the patient, and conduct a thorough 
history in a patient who: 
    
Has tested positive for parasite during blood donation or has a 
sibling or mother who is CD-positive 1 (2.3) - - 1 (33.3) 
Was exposed or potentially exposed to a vector in a period 
longer than 8 weeks - - - - 
Presents with onset of cardiac disease manifestations that are 
compatible with chronic CD cardiomyopathy - - - - 
♦All of the above 26 (60.5) 13 (61.9) 12 (63.2) 1 (33.3) 
Not sure 3 (7.0) 2 (9.5) 1 (5.3) - 
No response 13 (30.2) 6 (28.6) 6 (31.6) 1 (33.3) 
Q10. In patients who test positive for CD disease after blood 
donation or from a lab diagnostic, obtaining social history is 
needed to assess potential routes of exposure, including; 
    
Travel to residence in areas endemic for CD disease 1 (2.3) - - 1 (33.3) 
Previous history of blood transfusions or organ/ tissue 
transplants - - - - 
Possibility of congenital CD disease transmission - - - - 
♦All of the above 27 (62.8) 13 (61.9) 13 (68.4) 1 (33.3) 
Not sure 2 (4.7) 2 (9.5) - - 
Not response 13 (30.2) 6 (28.6) 6 (31.6) 1 (33.3) 
Q11. Which of the following best describes the method(s) for 
confirmatory diagnosis of CD?     
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
♦Seropositive results from 2 different immunoasays and/ or 
PCR performed at the CDC 17 (39.5) 5 (23.8) 11 (57.9) 1 (33.3) 
Positive serology from blood screening donations - - - - 
Detection of apolipoprotein A-1 upregulation in human serum - - - - 
All of the above 2 (4.7) 2 (9.5) - - 
Not sure 11 (25.6) 8 (38.1) 2 (10.5) 1 (33.3) 
No response 13 (30.2) 6 (28.6) 6 (31.6) 1 (33.3) 
Q12. Which of the following describes the current treatment 
options for Chagas disease?     
Benznidazole and nifurtimox are available only under current 
investigational protocol by the CDC in children up to 18 years 
of age with chronic infections, and in adults up to age 50 with 
chronic infection who have no indication of advanced 
cardiomyopathy 
10 (23.3) 2 (9.5) 7 (36.8) 1 (33.3) 
Benznidazole has been approved by the U.S. FDA for patients 
2-12 years of age and is available commercially 1 (2.3) - 1 (5.3) - 
Nifurtimox is only available by the CDC under investigational 
protocol 2 (4.7) 2 (9.5) - - 
♦Second and third choices only 4 (9.3) - 4 (21.1) - 
Not sure 13 (30.2) 11 (52.4) 1 (5.3) 1 (33.3) 
No response 13 (30.2) 6 (28.6) 6 (31.6) 1 (33.3) 
Q13. Should patients with chronic CD be treated with 
anitrypanosomal drugs?     
No, there is no evidence that antitrypanosomal treatment for 
Chronic CD can be effective 5 (11.6) 2 (9.5) 3 (15.8) - 
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Questionnaire Item 
Total 
n= 43 
(%) 
Family or 
General 
Practice 
n= 21 (%) 
Infectious 
Disease 
n= 19 
 (%) 
Cardiology 
n= 3 
 (%) 
Yes, only patients younger than 5 years of age should be 
treated for chronic CD - - - - 
♦Treatment is always recommended for patients up to age 18 
and generally recommended for patients aged 18 to 50 12 (27.9) 3 (14.3) 8 (42.1) 1 (33.3) 
Only CD patients manifesting with moderate to severe 
cardiomyopathy - - - - 
Not sure 12 (27.9) 9 (42.9) 2 (10.5) 1 (33.3) 
No response 14 (32.6) 7 (33.3) 6 (31.6) 1 (33.3) 
*Rounding 
Abbreviation: CD Disease (CD) 
♦ Denotes correct answer for the knowledge items 
** Specific totals (i.e., with not all 3 questionnaire samples contained the item, thus sub-total is listed) 
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Appendix G: Summary of Key Informant Tracking Table 
 
Study 
ID 
Date and 
Time 
Managed 
Care of 
CD 
patients 
Institution or 
Affiliation 
Current 
City Specialty 
# of 
Years in 
Specialty 
Medical 
Setting 
# of CD 
patients 
managed Sex 
2008 
7/30/28; 
11am Yes UTHouston Houston Cardiology 15 Inst. 5 M 
2104 
6/28/18, 
4:30 Yes JBSA- Lackland 
San 
Antonio Cardiology 3 Inst. 1 M 
1105 
7/2/18; 
2:30pm Yes 
Children's 
Hospital of San 
Antonio 
San 
Antonio 
Infectious 
Disease 4 Inst. 1 M 
1011 
7/9/18; 
4pm Yes 
Baylor College of 
Medicine Houston 
Infectious 
Disease 38 Inst. 2 F 
1102 
6/28/18; 
3pm Yes . Dallas 
Infectious 
Disease 5 Comm. Clin 3 M 
0001 
7/1/18; 
4pm No 
UTHealth San 
Antonio 
San 
Antonio 
Family/ 
General 
Practice 6 Inst. 0 M 
1106 
8/28/18; 
1pm Yes 
UTHealth San 
Antonio 
San 
Antonio 
Infectious 
Disease 9 Inst. 1 M 
1009 
7/6/18; 
11am Yes UTSouthwestern Dallas 
Infectious 
Disease 3 Inst. 10 F 
2010 
7/27/18; 
7:30pm Yes 
Baylor College of 
Medicine Houston Cardiology 20 Comm. Cln. 1 F 
1014 
9/14; 
11am Yes 
UTHealth San 
Antonio 
San 
Antonio 
Infectious 
Disease 10 Inst. 5 F 
1007 
7/15/18; 
8:30pm No 
Baylor College of 
Medicine Houston 
Infectious 
Disease 16 Inst. 100 F 
2015 
7/6/18; 
1pm Yes 
Baylor College of 
Medicine Houston Cardiology 12 Comm. Clin. 0 M 
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Study 
ID 
Date and 
Time 
Managed 
Care of 
CD 
patients 
Institution or 
Affiliation 
Current 
City Specialty 
# of 
Years in 
Specialty 
Medical 
Setting 
# of CD 
patients 
managed Sex 
1103 
6/28/18; 
3:45pm Yes Fort Sam Houston 
San 
Antonio 
Infectious 
Disease 12 Inst. 25 F 
 
